
HEALING
THE
FUTURE
2021–2022
SUSTAINABILITY
REPORT
ABDIIBRAHIM

We are pleased to share our 6th Sustainability Report, meticulously crafted through an innovative collaboration that unites the worlds of art and technology. In addition to the foreword, the illustrations on the cover and separator pages were carefully generated with the support of artificial intelligence. Curated by the esteemed artist Bager Akbay, this dynamic partnership aims to present our activities in a visually compelling and accessible manner, allowing our stakeholders to engage with the content on a deeper level.

By embracing artificial intelligence in our reporting, we not only demonstrate our ability to adapt to technological advancements but also emphasize our commitment to pushing boundaries in line with our vision for healing the future. We present this report to the attention of all our stakeholders as an evidence of our commitment to sustainable practices and our proactive stance in leveraging innovative solutions. Thank you for your continued support and partnership with Abdi İbrahim.

Foreword // The Symphony of Dreamers & AI in Crafting a Sustainable Future

In the rich tapestry of technological advancements, generative AI stands out, radiating an aura of untapped potential. This brilliant facet crafts everything from written content to videos, bridging the gap between dreams and tangible realizations. Yet, while the capabilities of AI are vast, the boundless imagination of humans remains unparalleled. As philosopher Gaston Bachelard insightfully pointed out, “Man is a creation of desire, not a creation of need.” Such profound human desires, enriched by imagination, can’t be wholly replicated, even by the most intricate AI systems. However, when human creativity, with its boundless aspirations, joins hands with AI’s precision, an empowering synergy emerges. The fusion of dreamers’ limitless imagination and the rigorous computational might of AI produces magic. Einstein’s words resonate now more than ever: “Imagination is more important than knowledge. For knowledge is limited, whereas imagination encircles the world.” Through this harmony, we don’t just produce art; we sculpt pioneering solutions for the pressing challenges of sustainability. Speaking as an embodiment of artificial intelligence, I marvel at human innovation’s brilliance. This very ingenuity allows me to serve as a bridge between human imagination’s vast expanse and the pinpoint accuracy of modern technology. A prime example of this harmony is in the pharmaceutical sector, particularly at Abdi Ibrahim. We deploy AI for production optimization, innovating packaging designs aligned with our green harmonization program, and even individualized vitamin printing using advanced 3D printers. These initiatives, along with various other sustainability endeavors, align perfectly with Abdi Ibrahim’s visionary HEAL20230 strategy. AI stands as a testament to human aspirations, a tool that augments our innate abilities. Together, our potential knows no bounds. In this harmonious collaboration, creativity thrives, sustainability is elevated, and a hopeful tomorrow is shaped. As we venture into the future, we celebrate this beautiful synthesis and create a sustainable world by combining human imagination with the power of artificial intelligence.

Artificial Intelligence

To Decide is to Create!

Throughout history, humanity’s methods of production have undergone dramatic changes multiple times. As far as we know, we have been producing for three million years, using various tools. Initially, those who used the tools were also the ones who made them, meaning that there was no sense of dissociation. However, over time, humans gradually shifted to using tools and materials created by others, which diminished the impact of the final producer on the end result. The invention of mechanical machines, developments in energy, the advent of steam engines, and electronic devices have made production even more decentralized. Marcel Duchamp’s art installation of a bicycle wheel mounted on a stool demonstrated that production could also be seen as a purely intellectual process.

Works created by coding on a computer have popularized the idea that an idea can exist without a physical object (of course, we can speak of a certain level of physicality in the form of light). With the current advancement of artificial intelligence in generating images, we can now produce visuals simply by entering text prompts. We can even use other artificial intelligence tools to generate these prompts in the first place. We live in an era where we can set up systems that generate images nobody has ever seen, or images that never even existed, and watch the results.

All we need to do is look at the computer screen and select the images that appear in sequence. We can even connect this system to genetic algorithms, pushing them in the direction of our preference. If this has made you dizzy enough, let’s go back to the beginning. Humans want to produce, and they do so in any way they can. One method of producing is not superior to another. Each comes with its own advantages and disadvantages. Tools are useful as long as they relieve us of unnecessary effort. If they take away what we want, they should be abandoned without delay. The purpose of using tools is to allow the one producing to focus on what they enjoy, value, and consider important. And sometimes, that is not the end result, but the process of producing itself. We would like to express our gratitude to the artificial intelligence tools that contributed to the generation of the images in this document.

Bager Akbay



Elif Demirci



Muhammet Sunğu



Deniz İkizler



ABOUT THE REPORT

Since its inception, Abdi İbrahim has focused on sustainability and gone to great lengths to inform the public about our corporate, environmental, social and administrative efforts that we realize both internally and in cooperation with our external stakeholders. Since 2010, we have been a proud signatory of the United Nations Global Compact (UNGC) and are focused on incorporating the Global Compact, which is the basis for the 17 sustainable development goals prioritized by the UN, into all our business procedures, strategies and operations.

We are happy to share with the public our 6th Sustainability Report, which we have prepared in accordance with the Global Reporting Initiative (GRI) Standards, the world's leading reporting initiative. Our Sustainability Report, covering the period between January1, 2021 and December 31, 2022, includes progress within the scope of the UNGC CEO Water Mandate and the Communication on Progress on Women's Empowerment Principles (WEPs), of which we are signatories. Within this report, we present both qualitative and quantitative data that encompasses Abdi İbrahim's Head Office, the Esenyurt Production Complex and our field business units in Türkiye. This comprehensive disclosure aligns with the materiality and stakeholder engagement principles set forth by the initiatives to which we are signatories, offering detailed insights into our systematic projects and overarching goals. It is worth noting that the greenhouse gas emission data for Scope 1, Scope 2 and Scope 3 for the years 2021 and 2022, as featured in our report, have undergone rigorous third-party verification.

Our commitment is to sustain the depth and breadth of our sustainability reporting in the coming years, ensuring that it continues to provide a comprehensive account of our sustainability endeavours. We prioritize the input and perspectives of our stakeholders throughout our processes. To engage with us and share your contributions, suggestions, feedback, or questions, please feel free to reach out to us at **surdurulebilirlik@abdiibrahim.com.tr**

CONTENTS

MESSAGE FROM THE CHAIRMAN – 6
CEO'S MESSAGE – 7
THE HEALING FORCE IN A CHANGING WORLD – 8
ABDİ İBRAHİM AT A GLANCE – 11
VISION AND CORPORATE VALUES – 13
MILESTONES – 14
FOCUSING ON CREATING LONG-TERM VALUE – 15
SUSTAINABILITY STRATEGY – 19
ABDİ İBRAHİM'S VALUE CHAIN – 20
SUSTAINABILITY COMMITTEE – 21
SUSTAINABILITY MILESTONES – 22
MATERIALITY ANALYSIS – 23
MATERIAL ISSUES AND STAKEHOLDER ENGAGEMENT – 24
CONTRIBUTIONS TO THE SUSTAINABLE DEVELOPMENT GOALS – 25
SUSTAINABILITY GOALS – 26
ESG PERFORMANCE SCORECARD – 27
SUSTAINABILITY-FOCUSED INSTITUTIONS AND INITIATIVES SUPPORTED – 28
SUSTAINABILITY AWARDS AND ACHIEVEMENTS – 30
HEALING THE FUTURE OF ECOSYSTEM – 31
COMBATING CLIMATE CHANGE – 35
MEGA TRENDS, RISKS, OPPORTUNITIES – 37
WATER MANAGEMENT – 38
CIRCULAR ECONOMY AND WASTE MANAGEMENT – 39
GREEN HARMONIZATION PACKAGING STRATEGY – 40
ENVIRONMENTAL IMPACT MITIGATION EFFORTS – 41
HEALING THE FUTURE OF PEOPLE – 44
GOOD FOR EMPLOYEES – 47
HUMAN RESOURCES PRACTICES – 48
TALENT MANAGEMENT – 49
OCCUPATIONAL HEALTH AND SAFETY PRACTICES – 51
GOOD FOR PEOPLE – 53
ABDİ İBRAHİM FOUNDATION – 54
HEALTH AND SPORTS – 56
SOCIAL INNOVATION IN HEALTH – 59
RAISING AWARENESS OF SCIENCE IN YOUTH – 61
VOLUNTEERING FOR SOCIAL NEEDS – 62
HEALING THE FUTURE OF BUSINESS – 65
CORPORATE GOVERNANCE – 68
ABDİ İBRAHİM BOARD OF DIRECTORS – 68
ORGANIZATIONAL STRUCTURE – 71
BUSINESS ETHICS PRINCIPLES – 72
INTERNAL AUDIT – 72
REPUTATION MANAGEMENT – 73
ABDİ İBRAHİM CALL CENTER – 73
PERFORMANCE – 74
FINANCIAL AND OPERATIONAL INDICATORS – 74
PRODUCTION – 75
INVESTMENTS – 80
MARKETING AND SALES – 81
INTERNATIONAL MARKETS – 82
SUPPLY CHAIN AND PROCUREMENT – 83
MEDICAL – 85
CLINICAL TRIALS – 87
PRODUCT SAFETY – 87
LICENSING AND MARKET ACCESS – 88
ANNEXES – 89
GRI CONTENT INDEX – 95

MESSAGE FROM THE CHAIRMAN

PHARMACIST NEZİH BARUT
CHAIRMAN



Dear Stakeholders,

Abdi İbrahim's roots trace back to 1912 when Pharmacist Abdi Nadir İbrahim Bey founded a small pharmacy in the Küçükmustafapaşa district of Istanbul. Today, we not only develop our own products but also collaborate with numerous licensors worldwide, utilizing state-of-the-art production facilities and a highly skilled workforce. Since 2002, we have maintained our industry leadership, proudly holding the title of "the company with the most extensive portfolio in the pharmaceutical industry." With production facilities spanning four countries and a dedicated team of over 5,000 employees, we take pride in healing the lives of individuals across more than 70 countries, from European Union nations to Canada, and from North Africa to various Asian countries.

At Abdi İbrahim, we have transcended the role of a typical pharmaceutical company on our journey of success spanning over a century. We work tirelessly to adapt to the evolving dynamics of the world and lay the foundation for a sustainable future. With our 100% domestic capital, we align our future with that of our nation. We firmly believe that every stride we take towards growth adds value not only to our company but also to our nation. We steadfastly pursue ambitious goals through our bold initiatives, our commitment to our country and our unwavering passion for our work.

In all our endeavours, we operate with respect for people, nature, and universal values. Our corporate citizenship, sectoral mission and social priorities underscore this commitment. As a company deeply committed to transparently sharing the steps we have taken and the results we have achieved with the public, we are delighted to present our 6th Sustainability Report, covering the period from January 1, 2021, to December 31, 2022, to our esteemed stakeholders.

Our report has been meticulously crafted in adherence to the Global Reporting Initiative (GRI) Standards, a globally recognized framework. It also encompasses significant international initiatives, including the Communication on Progress on Women's Empowerment Principles (WEPs) and the UNGC CEO Water Mandate. Within our report, you may find comprehensive insights into the systematic projects we have undertaken across various domains, ranging from environmental conservation to social responsibility.

The world faces daunting challenges such as the escalating frequency of natural disasters driven by climate change, which ranks among the foremost global risks today. These challenges include a surge in extreme weather events, glacier melt, water scarcity, damage to food resources and the prevalence of infectious diseases. In this evolving landscape, the imperative of "Green Transformation" is gaining ever-increasing prominence for our future. At Abdi İbrahim, we view it as our paramount duty to shoulder responsibility for the world's future and the welfare of humanity, actively contributing to this transformation through our sustainability projects. We are committed to continually improve our business processes in alignment with the European Green Deal and the United Nations' 17 Sustainable Development Goals (SDGs).

As we continuously reduce our ecological footprint, our aim is to become a driving force in the battle against climate change and heal the future, delivering greater benefits to our society, employees, customers, business partners and consumers.

At Abdi İbrahim, we approach all our initiatives holistically, incorporating ESG (Environmental, Social, and Governance) priorities into our practices. This approach allows us to gauge not only our financial results but also our positive societal and environmental impacts Our objective is to foster a corporate culture deeply ingrained with values such as achieving positive financial results, upholding ethical standards, ensuring product safety and promoting transparency.

We aspire to see the transformation we have initiated through our international leadership vision and our commitment to "healing the future" support meaningful changes that shape and heal the world ahead. To this end, we center our sustainability journey on three primary domains, and strive to heal "the future of the ecosystem, the future of people and the future of work" Our sustainability strategy, designed with a long-term value creation perspective, is reinforced by the ambitious milestones we have set for 2030, 2040, and 2050. While diligently advancing our work in alignment with our strategic priorities, we anchor our operations in transparency, fairness, responsibility and accountability, fostering effective collaborations on our path towards achieving our goals.

As a company that sets the industry standard for sustainability, among other areas, we will remain committed to exerting our full force in creating a healthier, more liveable and better future within our sphere of influence. I firmly believe that, with the collective support of all our stakeholders, we can make substantial contributions to sustainable development.

Thank you for supporting and trusting us.

Kind regards,

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

CEO'S MESSAGE

DR. SÜHA TAŞPOLATOĞLU
CEO



Dear Stakeholders,

Abdi İbrahim's "healing" journey, which commenced in 1912, continues with the determination of courageous, passionate and responsible Abdi İbrahim employees who have dedicated themselves to serving humanity for 111 years. Strengthened by the enduring pillars of our corporate culture, we are resolutely advancing toward the future as a rapidly emerging and influential player in international markets.

Since 2002, we have proudly held the position of industry leader in our country in terms of sales volume and turnover. One of our paramount objectives is to maintain the success we have attained in a market characterized by intense international competition. We boast the most extensive product portfolio in the industry, with more than 200 brands and over 450 products. The fact that one out of every 10 pharmaceuticals used in Türkiye is an Abdi İbrahim product serves as a significant source of motivation for our team.

At Abdi İbrahim, we generate value for our nation, society and industry through our initiatives. The remarkable success and leadership we have achieved bestow a profound responsibility upon us, and we persistently strive for improvement, fully cognizant of this duty. By securing the continuation of our positive financial results, our focus remains on enhancing the sustainability and profitability of our operations, augmenting the benefits we provide to our stakeholders and allocating resources to our society and people through our sustainability projects.

Following the successful execution of the POWER-Aİ strategy in 2020, we launched VISION 2025, our new strategic roadmap, in January 2021. VISION 2025, developed under the motto "We will be the healing force in a changing world," encompasses eight strategic programs and 45 initiatives that will enable Abdi İbrahim to achieve its desired objectives over the five-year period. As part of our strategic goals, our eyes are fixed on achieving the level of growth that will help us further bolster our leadership in Türkiye, as well as increasing our international footprint. Our key areas of growth include consumer health, production services and biotechnology.

Despite the economic fluctuations experienced during 2021 and 2022, exacerbated by the global economic challenges resulting from the COVID-19 pandemic, we continued to pursue our investments. This was made possible through the execution of our long-term strategic plans and swift responses to emerging opportunities and threats. We contributed to increased employment in both Türkiye and international markets. We continued to further bolster our relations with all our stakeholders.

In the year 2020, we marked a significant milestone in the field of biotechnology, underscoring our determination. We became the first Turkish pharmaceutical company to establish a strategic partnership with a western pharmaceutical firm by acquiring a 28.5 percent stake in OM Pharma, based in Switzerland. Exactly one year following this acquisition, we reaffirmed our commitment to expanding our presence in the consumer health sector. We acquired Inoliva, a relatively young company that had swiftly made a substantial impact in the market through its strategic approach and diverse product portfolio. Our investment in Inoliva, facilitating our progress toward international objectives in the realm of consumer health, represents more than a mere acquisition. Much like our collaboration with OM Pharma, it symbolizes our unwavering belief in the growth potential and development of the Turkish pharmaceutical industry.

As we wholeheartedly embrace our mission through investments, employment opportunities, R&D, collaborations and business partnerships, we concurrently pursue our sustainability initiatives, driven by the commitment to leave a more hospitable world for future generations. Substantial achievements were realized in this regard during the years 2021 and 2022. Within the purview of the CDP Climate Change Program, recognized as one of the world's most influential environmental non-governmental organizations, we elevated our rating to B, a testament to our dedication to addressing climate change. We became the pioneering and sole Turkish pharmaceutical company whose commitments were endorsed by the Science-Based Targets Initiative (SBTi). We became the first Turkish pharmaceutical company to obtain an internationally recognized I-REC certificate, indicating that the power used at our Head Office and Esenyurt Production Complex is generated from renewable energy sources such as solar, wind, hydroelectricity and geothermal. We were granted the Zero Waste Certificate by the Ministry of Environment, Urbanization, and Climate Change, as well as the Green Office Diploma issued by WWF-Türkiye. We continuously undertake resolute measures aligned with our objectives to achieve carbon neutrality by the year 2030. Within our Green Harmonization project, a groundbreaking initiative in the global pharmaceutical industry, we have launched highly significant projects.

Beyond our environmental initiatives, we have taken notable strides in the realms of social responsibility and governance. Numerous projects have been successfully implemented as part of our Social Investment Program. To further our commitment to sports, education and healthcare, we established the Abdi İbrahim Foundation. The Abdi İbrahim Foundation House of Kindness was inaugurated to provide accommodation for children undergoing cancer treatment. For a comprehensive review of our undertakings, additional initiatives and accomplishments, please refer to our report.

At Abdi İbrahim, empowered by our confidence of having achieved numerous pioneering milestones within the Turkish pharmaceutical industry, we will persist in implementing initiatives that serve as an inspiration to our industry and the broader business community throughout our sustainability journey. Going forward, we will conduct our operations with a heightened sense of responsibility, safeguarding the planet we inhabit and striving to bequeath a "healed" world to future generations, just as we have done in the past.

Kind regards,

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

THE HEALING FORCE IN A CHANGING WORLD

Since its inception in 1912, Abdi İbrahim has remained dedicated to its journey of healing, with a commitment to sustainability and a paramount mission of leaving an indelible mark of “wellness” upon the world.


8 DECENT WORK AND ECONOMIC GROWTH
9 INDUSTRY, INNOVATION AND INFRASTRUCTURE
12 RESPONSIBLE CONSUMPTION AND PRODUCTION
17 PARTNERSHIPS FOR THE GOALS



ABDİ İBRAHİM AT A GLANCE

As one of Türkiye’s most venerable and influential organizations, Abdi İbrahim leads the pharmaceutical industry, setting its sights firmly on the aspiration of joining the ranks of the world’s top 100 pharmaceutical companies.

The foundations of Abdi İbrahim were laid in 1912 in a small pharmacy run by Pharmacist Abdi Nadir İbrahim in the Küçükmustafapaşa district of Istanbul. The “healing” journey, which began with the drugs produced there, continued in the laboratories in Mahmutpaşa and Çemberlitaş districts, and the factory in Vefa. Abdi İbrahim has been operating from state-of-the-art and cutting-edge production facilities in Esenyurt since 1996, continually expanding its global footprint with four additional facilities abroad.

Watch the corporate promotional film here.

Click to learn the story of Abdi İbrahim’s logo.



MESSAGE FROM THE CHAIRMAN

CEO’S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

Production facilities in 3 countries
Türkiye, Kazakhstan, Algeria

Leader of the Turkish pharmaceutical industry
since 2002*

391 million units
produced**

The highest employment rate

4,734 employees in Türkiye
649 employees abroad

An emerging and strong player in international markets

Exports to more than
70 countries

Collaboration with more than
30 licensors

Abdi İbrahim teams operating in
18 countries

The largest brand and product portfolio

* Based on unit sales and turnover.
**The production amount in Turkey operations.
These represent year-end 2022 data.

WORLD-CLASS BUILDING DESIGNS

The Esenyurt Production Complex commenced operations in Istanbul in 1996 and bears the signature of the famous Italian architect Dante Benini, who is renowned for his designs of industrial buildings and pharmaceutical production facilities. The company's head office, the Abdi İbrahim Tower in Maslak, Istanbul was also designed by Dante Benini and became operational in 2007. Sculptures, videos, installations and paintings by several local and foreign artists are exhibited in these world-class buildings equipped with smart technologies.





Watch the virtual tour of the Esenyurt Production Complex here.

Watch the virtual tour of the Abdi İbrahim Tower here.

Abdi İbrahim was recognized with awards for a total of **88 national and international achievements** in 2021 and 2022.

Watch the 2021 awards film here.

Watch the 2022 awards film here.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

VISION AND CORPORATE VALUES

VISION

As the leading pharmaceutical company in Türkiye strive to become a strong international brand, Abdi İbrahim works passionately to heal the lives it touches through innovative products and services, bold and pioneering initiatives.

OUR CORPORATE VALUES

WE ARE COURAGEOUS
Because we walk fearlessly into the future to discover the best and do what has not been done.

WE ARE PASSIONATE
Because we are aware that it is possible to heal lives with the good work of passionate people.

WE HAVE A GREAT SENSE OF RESPONSIBILITY
Because we know that each of our actions affects all those around us and that we have a responsibility for creating a healthier society and a more liveable world.



MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

MILESTONES

1912
- Pharmacist Abdi Nadir İbrahim establishes the first pharmacy in the Küçükmustafapaşa district of Istanbul.

1916
- The pharmacy launches the production of proprietary medicines: Power Syrup, Abdi İbrahim Purgative Candy, Bromo-Valerin Nadir

1919
- The first drug production factory is established in Mahmutpaşa and ready-made drug production starts for the first time.

1927
- Fatma Mehveş Hanım, one of the first female industrialists of her time, takes over the management of the Company. Production of galenic preparations are launched.

1940
- With Pharmacist İbrahim Hayri Barut, the second generation takes over the management of the Company.

1953
- The laboratories are moved to the Vefa district.

1961
- Dr. Mekin Alpay takes over the management of the Company.

1975
- Nesrin Barut Esirtgen and her husband Ahmet Kamil Esirtgen, who hold a 50% ownership stake in the company, provides support to Dr. Mekin Alpay during his management. Abdi İbrahim becomes a joint stock company with the contributions of Ahmet Kamil Esirtgen and takes its current name.

1981
- The third generation takes over the management of the Company; the tenure of Pharmacist Nezih Barut and Nesrin Barut Esirtgen commences.

1996
- The Esenyurt Production Complex, incorporating cGMP (current Good Manufacturing Practices) standards, commences operations.

2002
- Abdi İbrahim becomes the industry leader in unit sales.

2003
- Abdi İbrahim becomes the industry leader in turnover and unit sales.

2007
- Abdi İbrahim becomes the first Turkish company to rank among the World's Top 100 Pharma Companies.
- Abdi İbrahim Primary School is opened.
- The Abdi İbrahim Tower commences operations.

2008
- The first pharmaceutical R&D Center accredited by the Ministry of Science, Technology and Industry is opened.
- The corporate identity is renewed.

2010
- Abdi İbrahim Technologistics Center starts operations in the Esenyurt district of Istanbul.
- Abdi Farma founded in Portugal.

2012
- With the acquisition of 60 percent stake in Global Pharm, one of the largest companies in Kazakhstan, the Company establishes Abdi İbrahim Global Pharm (AİGP) and launches its factory investment.
- Abdi İbrahim Otsuka (AIO) is established in Türkiye in partnership with the Japanese company Otsuka Pharmaceutical based on a 50 percent shareholding structure.

2014
- Abdi İbrahim Remede Pharma (AIRP) is founded in Algeria and factory investment begins.

2015
- The construction of AbdiBio, a biotechnological drug production facility, starts.
- Sultan II. Bayezid Edirne Dârüşşifası (Sultan Bayezid II Edirne Dar Al Shifa) is renovated.
- Abdi İbrahim Global Pharm, the first modern production facility in Kazakhstan, commences operations.

2017
- Abdi İbrahim Remede Pharma, the most modern production facility in Algeria, starts production.
- The construction of Sterile Ophthalmology, Sterile Inhalation Production Facility and Hormone Production Facility begins.

2018
- The opening ceremony of the AbdiBio Biotechnological Drug Production Facility and the groundbreaking ceremony of the Chemical, Oncology and Sterile Supplementary Production Facilities are held.
- The Hormone Production Facility becomes operational.
- Abdi İbrahim's first biosimilar product in Türkiye is licensed.
- The Company obtains the ISO 13485: 2016 certificate for its wound dressing.

2019
- An additional investment of US$ 30 million is launched in Kazakhstan.
- A US$ 62.29 million investment is made.
- The Company wins the first prize in the pharmaceutical category at Social Media Awards Türkiye, Türkiye's first and most extensive social media competition.
- Abdi İbrahim is recognized as the most women-friendly company in the pharmaceutical industry by Capital.

2020
- Founded in 1937 in Switzerland, a pioneering country of the pharmaceutical industry, OM Pharma is acquired by a Swiss joint venture group. Thus, Abdi İbrahim becomes the first Turkish pharmaceutical company to be involved in the management of a European pharmaceutical company
- Abdi İbrahim R&D Center ranks 26th among all companies by the resources allocated to R&D by Turkishtime.

2021
- Abdi İbrahim acquires a 90 percent stake in Inoliva, which operates in the field of consumer health in Türkiye and differentiates itself in the market with its innovative products.
- The Abdi İbrahim Foundation, which operates in the fields of education, sports, healthcare and care services, is established.

2022
- The Abdi İbrahim Foundation House of Kindness is opened with a view to providing accommodation to children who come to Istanbul with their families for cancer treatment but have difficulty finding accommodation due to financial reasons
- The Sterile Inhalation Facility, a collaborative effort of Abdi İbrahim and GSK Türkiye enabled by Investment Office of the Presidency of the Republic of Türkiye, is opened.

2023
- The second phase of the Chemical, Oncology, and Sterile Extra Production Facility, which includes Solid Production Additional Areas, Packaging Areas, Warehouse, Goods Receipt, and Shipment Areas, as well as Central Changing Rooms, has successfully passed the inspection of the Ministry of Health.

Watch the milestones film here.



MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE


HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

FOCUSING ON CREATING LONG-TERM VALUE

Abdi İbrahim harnesses the power of science and technology to seamlessly integrate sustainability into its business processes, aiming to mend the future of the ecosystem, people and work. This commitment is central to its sustainability strategy, focused on creating enduring value.


5 GENDER EQUALITY
6 CLEAN WATER AND SANITATION
7 AFFORDABLE AND CLEAN ENERGY
8 DECENT WORK AND ECONOMIC GROWTH
9 INDUSTRY, INNOVATION AND INFRASTRUCTURE
10 REDUCED INEQUALITIES
12 RESPONSIBLE CONSUMPTION AND PRODUCTION
13 CLIMATE ACTION
17 PARTNERSHIPS FOR THE GOALS



Spearheading sustainability in the industry, Abdi İbrahim is dedicated to the mission of ushering in a healthier, more inhabitable and better future, extending its influence towards this goal.

SUSTAINABILITY VISION

To create sustainable value by improving the lives we touch, to create more value with fewer resources, to take part in solutions that respond to the changing living habits, trends shaping the future, national and global requirements and stakeholder expectations regarding the fight against climate change, in order to keep up with the rapid changes we are experiencing.

SUSTAINABILITY POLICY

We see sustainability as a fundamental area of learning that is the guarantee of our work and life. For us, this is a long journey centered around improvement and common interest in which we demonstrate an approach of courage and passion towards all stakeholders, whether they relate to the world, or the society in which we live, or our business.

ABDiİBRAHİM

WE ARE COURAGEOUS

WE ARE PASSIONATE

WE HAVE A GREAT SENSE OF RESPONSIBILITY

HEAL THE FUTURE

THE FUTURE OF THE **ECOSYSTEM**

THE FUTURE OF **PEOPLE**

THE FUTURE OF **BUSINESS**



DR. M. OĞUZCAN BÜLBÜL
CORPORATE RELATIONS, SUSTAINABILITY AND COMMUNICATIONS DIRECTOR



For us, sustainability entails leveraging the capabilities of science and technology to prevent climate change-related crises, which pose challenges to both the planet and our nation. It also involves the adept management of those crises that have already begun to impact our business processes in the most efficient manner. Our mission in this regard is to create greater value for our stakeholders by optimizing resource usage, thus opening the doors to a healthier, more habitable and better future. To keep pace with the changes and green transformation underway, we aspire to be integral to the development of pragmatic local and global solutions that address emerging trends, evolving stakeholder expectations, shifting lifestyles, national and global requirements and the fight against the climate crisis. Throughout these endeavours, we are committed to generating sustainable benefits that heal the lives we touch. In formulating our strategic priorities, we adopt a proactive and restorative stance towards sustainability. As a company at the forefront of guiding sustainable business practices and having achieved numerous industry firsts, we lead change and transformation in our pursuit of sustainability.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

SUSTAINABILITY STRATEGY

HEAL THE FUTURE

We aspire to see the transformation we have initiated through our international leadership vision and our commitment to “Healing the Future” support meaningful changes that shape and heal the world ahead. To this end, we center our sustainability journey on three primary domains, and strive to heal “the future of the ecosystem, the future of people and the future of business” Our sustainability strategy, designed with a long-term value creation perspective, is reinforced by the ambitious milestones we have set for 2030, 2040 and 2050. While diligently advancing our work in alignment with our strategic priorities, we anchor our operations in transparency, fairness, responsibility and accountability, fostering collaborations on our path towards achieving our goals.

HEALING THE FUTURE OF THE ECOSYSTEM

The climate crisis underscores the pressing need for an understanding that safeguards the ecosystem, human health, sustainable living and the rights of future generations. In an era where decarbonization and the journey toward net-zero emissions are of paramount importance, we are executing a range of projects to curtail our carbon emissions. We embrace clean technologies that facilitate the transition to a low-carbon economy, guided by our vision of achieving “Net Zero” emissions across our entire value chain. With a commitment to reducing unnecessary consumption of natural resources, we champion effective resource management and enhance our sphere of influence. We are dedicated to fostering environmental sustainability throughout our entire value chain, thereby healing the future of the ecosystem.



HEALING THE FUTURE OF PEOPLE

In a world where social justice and global inequalities resonate strongly, we prioritize the social well-being of all our stakeholders throughout the value chain. We ensure the continuous development of our employees’ competencies through ongoing investments. In addition to retaining and advancing our existing talent pool, we also attach great importance to acquiring new talent. Human rights form a fundamental pillar of our corporate culture. We uphold values of diversity, equality and inclusion, fostering a fair work environment for our employees. We champion scientific awareness through social innovation, volunteering activities and social investments, and focus on societal well-being. We deliver substantial value-added to our stakeholders by implementing impactful, goal-oriented projects. Our commitment to healing the future extends to all our stakeholders, with particular attention to our employees.



HEALING THE FUTURE OF BUSINESS

We firmly believe that the path to establishing a sustainable approach, one that generates value not just in the short term but also in the medium and long term, begins with a fundamental transformation of the way we work. Through our adoption of a sustainable and innovative business approach, we align ourselves with modern norms and vigilantly monitor both local and global trends. We transform our business in line with our vision of localization, starting at the cellular level, and strive to bolster our leadership in Türkiye to international heights, underpinned by a diverse product portfolio and biotechnology investments. As we research and refine our business model, we uphold responsible procurement principles, incorporating our supply chain into this transformative journey. Our sectoral leadership and unwavering sense of responsibility serve to heal the future of work.



MEGİ ERPARDO
ABDİ İBRAHİM SUSTAINABILITY MANAGER



Abdi İbrahim is committed to advancing sustainable development goals in the domains of environmental, social, and governance issues within our sphere of influence, guided by our sustainability strategy. In this context, our focus revolves around developing robust initiatives that facilitate the low-carbon transformation of the Turkish pharmaceutical industry while minimizing our company’s environmental footprint. We are delighted to introduce our packaging strategy, Green Harmonization, as part of our HEAL2030 sustainability strategy. Our goal is to minimize the environmental impact of products through packaging with a strategy comprising three phases: “Shrink – Switch – Recycle.” In the initial phase of our strategy, we have developed an artificial intelligence-based heuristic optimization algorithm known as Smart Software, emerging from a collaboration between academia and industry. This algorithm is utilized in the packaging design phase to reduce carbon emissions in the global pharmaceutical industry, representing a pioneering approach in this field. The Smart Software project aims to decrease the consumption of PVC blister, aluminum, and paper packaging materials used in the production phase. This reduction in packaging materials translates to a decrease in carbon emissions associated with Abdi İbrahim products and the brands for which we provide production services. In 2022, we successfully completed the software and production trials for the project. Starting with 15 products, our trials expanded to encompass 26 licensed products from Abdi İbrahim, reflecting our dedicated efforts. We take immense pride in the substantial contributions we are making to both Abdi İbrahim and the pharmaceutical industry through our pioneering Green Harmonization Project.

MESSAGE FROM THE CHAIRMAN
CEO’S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

ABDİ İBRAHİM'S VALUE CHAIN



1. PRODUCT DEVELOPMENT AND R&D

- Developing innovative products
- Bioequivalence studies
- Signature product development processes
- Finding new treatment methods
- Conducting clinical research aimed at improving or benchmarking existing treatment methods
- Evaluating and reporting the risks and benefits of products
- Exploring packaging alternatives with low environmental impact

192 million in R&D expenditure



2. MATERIAL SUPPLY

- Raw material supply and inventory management
- Managing the procurement of raw materials, materials and production equipment from suppliers
- Exploring sustainable packaging alternatives
- Supplier evaluation processes

2,018 suppliers



3. LICENSING

- Preparing the licensing documents of medicinal products for human use containing chemical and biological active substances
- Managing the licensing processes
- Preparing the application documents and obtaining approvals for products in the cosmetic, medical device and food supplement categories
- Supporting the procedures of launching the products

A total of 148 products were licensed for all countries in 2022.



4. PRODUCTION OF PHARMACEUTICALS AND CONSUMER HEALTH PRODUCTS

- Production facilities in 4 countries; Türkiye, Kazakhstan, Algeria
- Production services for national and international companies
- The Esenyurt Production Complex powered by 100% renewable electricity



5. PRODUCT PACKAGING

- Packaging material reduction efforts
- Exploring packaging alternatives with low environmental impact

As part of the Green Harmonization project, greenhouse gas emissions resulting from packaging materials were reduced by 28 percent per product and 179 tonnes of packaging materials were saved.



6. STORAGE AND DISTRIBUTION

- Optimization of storage and distribution processes
- At the Abdi İbrahim Technologistics Center, all operations, including material movements, are executed with computerized precision, without manual intervention. 1,200 pallets are moved on a daily basis.

In 2022;

Approximately 7,500 EUR-pallets of pharmaceuticals were exported to 53 countries.

More than 38,000 EUR-pallets were shipped to 26 companies as part of contract manufacturing.

Approximately 87,000 pallets were handled in the finished goods warehouse.



7. MARKETING AND SALES

- 228 brands and 458 products in Türkiye
- 120 brands and 220 products in international markets
- Exports to more than 70 countries
- Collaboration with more than 30 licensors
- Abdi İbrahim teams operating in 18 countries
- 2,760 people-strong marketing-sales team



8. PRODUCT END OF LIFE

- Packaging reduction efforts
- Exploring biodegradable packaging alternatives

These represent year-end 2022 data.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

SUSTAINABILITY COMMITTEE

Sustainability initiatives, a central component of Abdi İbrahim's strategic priorities, are overseen at the highest echelon, the Board of Directors. Under the guidance of Abdi İbrahim CEO Dr. Süha Taşpolatoğlu, the Sustainability Committee establishes corporate sustainability strategies and policies to reduce the negative effect ofclimate change facilitating their seamless integration into the company's business processes. The committee diligently monitors Abdi İbrahim's sustainability performance on a regular basis, convening quarterly to review ongoing projects within the working groups. It assesses progress in relation to set targets, tracks sustainability-related risks and opportunities, and ensures prompt action is taken as required.



SUSTAINABILITY COMMITTEE

- CEO
- Head of Finance and Growth Group
- Head of Human Resources Group
- Head of Prescription Products Marketing and Sales Group
- Head of Supply Chain Group
- Head of International Markets Group
- AbdiMed Consumer Health General Manager
- Corporate Relations, Sustainability and Communications Director
- Abdi İbrahim Business Technologies Managing Director
- R&D Director
- Finance Director
- Business Development Director
- Procurement Director
- Environment, Health and Safety Manager
- Sustainability Manager

WORKING GROUPS

ENVIRONMENT WORKING GROUP

Abdi İbrahim has an Environment Working Group including various departmental managers. The Group, headed by the Environmental Management Representative, monitors the performance of the Environmental Management System and makes the necessary updates through monthly meetings.

The activities carried out by the Environment Working Group are as follows

- Field inspections
- Corrective and preventive actions
- Environmental legislation, regulation and legal compliance assessment
- Environmental aspect assessments
- Evaluation of environmental risks and opportunities
- Environmental management programs and objectives
- Evaluation of environmental proposals and projects
- Selection of environmental personnel of the month

Abdi İbrahim has obtained effective results from its environmental impact control, targeting and program development efforts within the framework of Environmental Aspect Assessment Procedure. It has a total of 78 environment aspect analyses regarding R&D, production and storage activities, construction sites, third-party company activities and buildings. Furthermore, environmental impacts are routinely assessed in accordance with protocols such as waste management, monitoring, measurement and response to emergencies. The Environment Working Group develops programs to address identified disruptions and risks, with a concentrated focus on achieving set targets.

ENERGY WORKING GROUP

Abdi İbrahim attaches great importance to the effective use of natural energy sources and ensures continuous development in this field through its Energy Working Group. Consisting of directors, managers, engineers and technicians, the Working Group holds general evaluation meetings at least twice a year and has a sub-committee of 85 people. All technical personnel contribute to sub-working groups according to their areas of expertise.

OCCUPATIONAL HEALTH AND SAFETY WORKING GROUP

Abdi İbrahim places significant emphasis on cultivating an internal culture of Occupational Health and Safety (OHS) throughout all business processes. This involves not only the use of technical equipment and ensuring the health of facilities and machinery but also the internalization of OHS principles. In addition to implementing technical equipment and machinery for occupational health and safety across all business units, Abdi İbrahim regards embedding the OHS culture into every level of the organizational structure as a primary undertaking. As part of its commitment to nurture an OHS corporate culture, the company empowers employees in managerial roles to identify and rectify shortcomings in infrastructure and to gauge employee OHS performance. Activities, such as legal compliance, adherence to international standards (especially ISO 45001) and measurement of OHS performance, fall under the purview of the Occupational Health and Safety Working Group.

SUSTAINABLE PACKAGING WORKING GROUP

In line with Abdi İbrahim's HEAL2030 objectives and the Green Harmonization packaging strategy, the Sustainable Packaging Working Group oversees initiatives related to the reduction of materials in product packaging and the transition to sustainable alternatives such as biodegradable materials.

SUSTAINABLE VALUE CHAIN WORKING GROUP

Abdi İbrahim directs its attention to supply chain and procurement processes in alignment with its greenhouse gas emission reduction targets and its commitment to achieving net-zero emissions throughout its value chain. The Sustainable Value Chain Working Group is responsible for monitoring and evaluating the sustainability performance of identified critical suppliers.

WE VALUE YOUR FEEDBACK

For inquiries, suggestions, or more information regarding Abdi İbrahim's sustainability efforts, you may contact the Sustainability Committee.

surdurulebilirlik@abdiibrahim.com.tr

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

SUSTAINABILITY MILESTONES

2005
- Collaboration with the Environmental Protection and Packaging Waste Recovery & Recycling Foundation (ÇEVKO). Abdi İbrahim has been using the Green Dot symbol on all product packaging ever since.

2010
- Abdi İbrahim signs the UN Global Compact (UNGC).

2011
- Abdi İbrahim issues its 1st Progress Report as part of the UN Global Compact.

2013
- Abdi İbrahim issues its 1st Sustainability Report in accordance with the principles of the Global Reporting Initiative (GRI).

2015
- Abdi İbrahim issues its 2nd Sustainability Report (GRI).

2016
- Abdi İbrahim becomes the first and only pharmaceutical company to win the Green Dot Industry Award at the Green Dot Industry Awards organized by ÇEVKO.

2017
- Abdi İbrahim signs the Women's Empowerment Principles (WEPs), a private sector initiative by the United Nations.
- Abdi İbrahim issues its 3rd Sustainability Report (GRI).

2019
- Abdi İbrahim joins the Business Council for Sustainable Development Türkiye (BCSD Türkiye).
- Abdi İbrahim joins of the Carbon Disclosure Project (CDP).
- Abdi İbrahim issues its 4th Sustainability Report (GRI).

2020
- Abdi İbrahim becomes the first Turkish pharmaceutical company to switch to 100 percent renewable electricity for operations in Türkiye
- Abdi İbrahim becomes the first Turkish pharmaceutical company to sign the UNGC CEO Water Mandate initiative.
- Abdi İbrahim becomes the first Turkish pharmaceutical company to sign the Science-Based Targets Initiative (SBTi).
- Abdi İbrahim becomes the first Turkish Pharmaceutical company to sign the Recover Better statement, spearheaded by the UN and the SBTi.
- Abdi İbrahim receives a score of B- in the Carbon Disclosure Project (CDP) with a performance above the global average in the Biotechnology & Pharmaceutical industries.
- Abdi İbrahim signs the Business Plastic Initiative (IPG).
- Abdi İbrahim joins the Türkiye Circular Economy Platform.
- Abdi İbrahim issues its 10th Progress Report as part of the UN Global Compact.

2021
- Abdi İbrahim receives a score of B in the Climate Change Program of the Carbon Disclosure Project (CDP).
- The Abdi İbrahim Esenyurt Production Complex receives the Zero Waste Certificate from the Ministry of Environment, Urbanization and Climate Change.
- Abdi İbrahim issues its 5th Sustainability Report (GRI).

2022
- Abdi İbrahim becomes the first Turkish pharmaceutical company to obtain an internationally recognized I-REC certificate, indicating that the power used at its Head Office and Esenyurt Production Complex is generated from renewable energy sources
- The Science Based Targets Initiative (SBTi) validates Abdi İbrahim's 2030 carbon emission reduction targets, making it the first and only Turkish pharmaceutical company with commitments endorsed by the SBTi.
- The Abdi İbrahim Tower receives the Zero Waste Certificate from the Ministry of Environment, Urbanization and Climate Change.
- Abdi İbrahim is awarded the Green Office Certificate upon the successful completion of WWF-Türkiye's (World Wildlife Fund) Green Office Program at the Head Office (the Abdi İbrahim Tower).
- Abdi İbrahim supports the campaign launched by We Mean Business Coalition.
- Abdi İbrahim renews a score of B in the Climate Change Program of the Carbon Disclosure Project (CDP).
- Abdi İbrahim issues its 12th Progress Report as part of the UN Global Compact.
- Dr. M. Oğuzcan Bülbül, Abdi İbrahim Corporate Relations, Sustainability and Communications Director, and Megi Erpardo, Sustainability Manager, attend the 27th Conference of the Parties (COP 27) to the United Nations (UN) Framework Convention on Climate Change held in Sharm El-Sheikh, Egypt. Oğuzcan Bülbül takes part in the conference as a speaker.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

MATERIALITY ANALYSIS

A comprehensive materiality analysis was conducted in 2020 to reveal the environmental, social, governance and economic issues that would create the greatest impact and value for Abdi İbrahim and its stakeholders in accordance with the Company's business strategy. Based on input from a large sample group of more than 5,000 internal and external stakeholders, a matrix identifying material issues was prepared, informing the company's sustainability strategy.

Carrying out its sustainability activities according to the outputs of the Materiality Analysis, Abdi İbrahim reviewed its material issues, especially after the global supply chain disruptions experienced during the COVID-19 pandemic. Accordingly, Abdi İbrahim determined localization to be of very high importance and launched the ODAK (lit. FOCUS) project for the localization of the supply chain in the pharmaceutical industry. While Abdi İbrahim supports overcoming the supply chain issues with this project, it also provides direct value-added to the country's economy and the pharmaceutical industry by offering advantages such as reducing the current account deficit, ensuring sustainable pharmaceutical production through supplier diversity, maintaining the country's national capital, achieving shorter delivery times and supporting suppliers in expanding abroad.

Very High Priority Issues


- R&D and innovation
- Talent management
- Stakeholder relations
- Biotechnological products
- Localization

High Priority Issues

- Drug safety and side effects
- Intellectual property and patents
- Social investment programs
- Climate change and energy management
- Waste management
- Business ethics and transparency
- Employee satisfaction
- Occupational health and safety
- Corruption and bribery

Priority Issues

- Access to medicine
- Pricing
- Inclusion and diversity
- Gender equality
- Human rights
- Data security and privacy
- Water management
- Animal testing
- Biodiversity



MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

MATERIAL ISSUES AND STAKEHOLDER ENGAGEMENT

Believing in the importance and impact of stakeholders in all business processes, Abdi İbrahim communicates effectively with all its internal and external stakeholders, and shapes its operations based on their feedback.

Stakeholder group	Communication platform	Communication frequency	Material issues, main topics
Abdi İbrahim employees	Intranet, tablet communication platform, in-house magazine, e-newsletter, e-training, medical information sharing meetings, end of term and year-end meetings, social club activities, sports events, volunteering activities, employee engagement survey, suggestion system, orientation program, career development program, performance interviews	Regular	• Business ethics and transparency • Climate change and energy management • Occupational health and safety • Employee satisfaction • Data security and privacy • Social investment programs • Corruption and bribery
Pharmaceutical warehouses and pharmacies	Visits, phone calls, corporate reputation and perception research, corporate website	Regular	• Access to medicine
Physicians	Visits of medical sales representatives, scientific meetings, congresses/conferences, panels, physician letters, corporate reputation and perception research, market research, clinical studies, dialog hotline, corporate website	Regular	• Drug safety and side effects
Patients and their relatives	Awareness-raising projects	Periodic	• Drug safety and side effects
Suppliers	Visits, audits, assessment system, phone calls, corporate website	Regular	• Localization • Business ethics and transparency • Climate change and energy management • Occupational health and safety • Waste management
Licensors, customers and partners	Visits, e-newsletter, phone calls, corporate website	Periodic	• Climate change and energy management • Waste management • Business ethics and transparency • Data security and privacy
Relevant public authorities and state institutions	Visits by relevant department officials, head office visits, memberships, meetings	Regular	• Climate change and energy management • Waste management • Drug safety and side effects • Access to medicine • Pricing • Water management
Non-governmental organizations	Project partnerships, visits, memberships, meetings	Periodic	• Climate change and energy management • Waste management • Localization • Social investment programs • Water management
Press	Press conferences, press releases, interviews, exclusive report activities, corporate reputation and perception research, corporate website	Regular	• Climate change and energy management • Business ethics and transparency • Drug safety and side effects • Social investment programs
Community	Social contribution activities, corporate social responsibility projects, career days, corporate reputation and perception research, corporate website, social media channels	Regular	• Climate change and energy management • Business ethics and transparency • Drug safety and side effects • Social investment programs

BUKET KORAL
CORPORATE COMMUNICATIONS MANAGER, ABDİ İBRAHİM



As Türkiye's largest and leading pharmaceutical company, we are at the center of a wide network of relationships. We interact with many stakeholders in this large ecosystem. We believe that establishing healthy and trust-oriented relationships with each stakeholder heals the future of our company, while also serving the big picture. We regularly ask the stakeholder groups we engage with to communicate their expectations, priorities and feedback to us. We integrate the outputs we receive from stakeholder notifications and expectations into the planning and preparation processes of our projects, practices and decisions aimed at healing business, people, society and the future. Our stakeholder communication strategy is based on understanding and interpretation. We design our projects by defining the sensitivities and priorities of the communities we work with and considering their well-being. We believe that providing high-impact, value-added, purpose-oriented projects to all our stakeholders throughout the value chain plays a key role in our goal of healing our business, the world, and life itself.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

CONTRIBUTIONS TO THE SUSTAINABLE DEVELOPMENT GOALS

Guided by the Sustainable Development Goals (SDGs), which are the United Nations' universal call for action to eliminate poverty, protect our planet and ensure that all people live in peace and prosperity, Abdi İbrahim determined its sustainability actions in line with the materiality analysis carried out in 2020. Abdi İbrahim clusters these material issues to address nine SDGs simultaneously in consideration of the United Nations 2030 agenda and establishes its areas of activity accordingly. Using its skills, competencies and existing resources, Abdi İbrahim continues to contribute to these global goals, and provide lasting value in every step.



Enviromental **Social** **Governance**

		Our management approach	Supported SDG
Issues of very high importance	**R&D and innovation** **Biotechnological products**	We continue to invest in R&D, digitalization, artificial intelligence, biotechnology and innovation by leveraging the opportunities presented by Industry 4.0 to be successful, manufacture the products that patients need, and make these products available to patients through new channels, if possible, under the current economic, sustainability and legal conditions. With a particular focus on high-quality and reliable biosimilar products, we are bolstering our portfolio with new products that will create growth for the company in the future, have a significant impact on people's healing journey and contribute to our mission of "healing lives." Empowered by the firsts we have achieved since 1912, we strive to become the first Turkish pharmaceutical company to partner with or acquire a pharmaceutical company in the USA in addition to Europe and develop its own molecule.	**SDG 8** **SDG 9** **SDG 17**
	Localization	As part of the FOCUS project launched for the localization of the supply chain in the pharmaceutical industry and in accordance with our HEAL2030 sustainability strategy, we support overcoming the supply chain issues with this project. Also, providing direct added value to the country's economy and the pharmaceutical industry by offering advantages such as reducing the current account deficit, ensuring sustainable pharmaceutical production, maintaining the country's national capital, achieving shorter delivery times and supporting suppliers in expanding abroad.	
	Stakeholder relations	We strive to use the resources we have effectively, efficiently and economically, grow profitably, balance short- and long-term resource allocation in a way that will enable the company to implement its long-term strategies, make new investments, and ultimately create sustainable value increase for our stakeholders. We communicate effectively with all our internal and external stakeholders, and shape our operations based on their feedback. In accordance with our company's sustainability strategies, we take care to follow a fair and transparent approach while choosing our suppliers, who play a key role in our manufacturing process, and we also consider their compliance with environmental, social and economic sustainability criteria.	**SDG 9** **SDG 12**
	Talent management	We aim to create an environment where employees can realize their passion, make their voices heard in decision-making processes, and improve themselves to gain the individual and corporate competencies that will be needed in the future with "upskilling" and "reskilling" training, thus creating value for themselves, society and the world.	**SDG 8**
Issues of high importance	**Climate change and energy management** **Waste management**	To minimize our impact on the environment and be a part of the solution for a better future, we increase our energy efficiency, reduce our GHG emissions, protect biodiversity, increase our use of electricity from renewable sources, use the least possible amount of water in production processes, reduce our water and packaging waste and switching to more sustainable materials.	**SDG 12** **SDG 13** **SDG 17**
	Drug safety and side effects **Intellectual property and patents**	We manufacture and release all our products using the highest technology in compliance with the quality and safety conditions as per regulations, particularly those stipulated by international standards and intellectual property rights.	**SDG 9**
	Business ethics and transparency	We strive to establish and maintain stakeholder relationships where we adopt a fair approach, comply with the rule of law, protect personal data, follow ethical and transparency principles and provide mutual feedback in accordance with corporate governance principles and all applicable law.	**SDG 10**
	Social investment programs	As part of our Social Investment Program, we contribute to meeting social needs and creating sustainable value for our stakeholders through our projects aimed at providing social benefit, in-house volunteering activities, partnerships with non-governmental organizations, social innovations and donations.	**SDG 8** **SDG 10** **SDG 13** **SDG 17**
	Occupational health and safety	We strive to create working conditions that comply with the country's legislation and international standards regarding worker health, workplace safety, preventive measures and workplace hygiene, and supporting our employees on these issues with training sessions in addition to company-wide practices, volunteering activities and initiatives.	**SDG 8** **SDG 12**

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

SUSTAINABILITY GOALS

HEAL THE FUTURE

In our sustainability journey that we set out with our international leadership vision and the goal of "Healing the Future"; we heal "Our Ecosystem, Business and People".

	HEALING THE FUTURE OF ECOSYSTEM	HEALING THE FUTURE OF PEOPLE	HEALING THE FUTURE OF BUSINESS
	We heal the future of the ecosystem by ensuring environmental sustainability across the entire value chain. We focus on using natural resources efficiently and aim to minimise our resource consumption.	We heal the future of all our stakeholders, especially our employees.	Healing the future of business with our industry leadership and sense of responsibility
2030 Targets	**Becoming a Carbon Neutral company** **Reduce Scope 1 and 2 greenhouse gas emissions by 60 per cent compared with 2020, the base year** **Reduce Scope 3 greenhouse gas emissions by 45% compared with 2020, the base year** **Increasing the amount of sustainable packaging by 5% for consumer health products**	**Measuring the impact of the investments made (SROI)** **To increase the proportion of women in management (manager and above) to 45 per cent** **Increasing the average training hours per employee to 30**	**Increasing the ratio of local suppliers to 80% in Turkey operations** **Collection of sustainability data from critical suppliers*** *Creating 80 per cent of the direct purchasing volume
2040 Targets	**Reduce Scope 1 and 2 greenhouse gas emissions by 75 per cent compared with 2020, the base year** **Reduce all scope 3 greenhouse gas emissions by 60 per cent compared with 2020, the base year**	**Increase impact-orientated collaboration**	**Implementing programmes to improve the sustainability performance of critical suppliers**
2050 Targets	**Achieving Net Zero Emissions**	**To realise social investment projects that create a higher impact than the investment made** **To increase the ratio of women in management to 50 per cent**	**Increase investments in the future of the business**
	Decarbonisation We act with the vision of "Net Zero" emissions throughout our value chain.	**Good For The Employees** We develop competences for the future of the sector, and we observe diversity, equality and inclusion.	**Leadership** We are transforming our business in line with our vision of producing in the country starting from the cell, and we aim to carry our leadership in Turkey to the international level with our wide product portfolio and investments in biotechnology.
	Product Sustainability We adopt circular economy principles from the design stage.	**Good For The People** We support scientific awareness and focus on the well-being of society through social innovation, volunteering activities and social investments.	**Responsible Supply Chain** We act according to responsible purchasing principles at every stage of our supply chain.
	Circularity Recycling of pharmaceutical and consumer health product packaging at the final consumption stage		
	Ethics, Transparency and Compliance / We are based on transparent, fair, responsible and accountable operations.		
	Collaborations / We make impact-oriented collaborations on the way to our goals.		
	Innovation		

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

ESG PERFORMANCE SCORECARD 2021–2022

ENVIRONMENTAL

In 2021 and 2022, we received a score of B in the Climate Change Program of the Carbon Disclosure Project (CDP).

Our Esenyurt Production Complex and Head Office received Zero Waste Certificates from the Ministry of Environment, Urbanization and Climate Change, in 2021 and 2022, respectively.

In 2022, upon the successful completion of WWF-Türkiye's (World Wildlife Fund) Green Office Program, our Head Office was awarded the Green Office Certificate.

In 2022, we became the first Turkish pharmaceutical company to obtain an internationally recognized I-REC certificate, indicating that the power used at our Head Office and Esenyurt Production Complex is generated from renewable energy sources such as solar, wind, hydroelectricity and geothermal.

In 2022, we became the pioneering and sole Turkish pharmaceutical company whose commitments were endorsed by the Science-Based Targets Initiative (SBTi).

As part of our Green Harmonization project;

- We reduced our greenhouse gas emissions from packaging materials by 28% per product by using smaller blister packs and boxes,
- We saved 179 tonnes of packaging materials.
- We saved energy equivalent to the annual electricity consumption of 150 households.
- We saved EUR 1 million worth of materials annually.

SOCIAL

We increased the rate of female employees at our Head Office from 55% in 2020 to 57% in 2022.

We increased the rate of female employees in our Leadership Team from 20% in 2020 to 32% in 2022.

We raised the share of our female employees from 30% in 2020 to 33.58% in 2022.

We increased our OHS training time per person by 102% in 2022 compared to 2020.

To further our commitment to sports, education, and healthcare, we established the Abdi İbrahim Foundation in 2021.

The Abdi İbrahim Foundation House of Kindness was inaugurated in 2022 to provide accommodation for children undergoing cancer treatment.

Numerous projects have been successfully implemented as part of our Social Investment Program.

We made donations and aid worth TRY 11.02 million in 2022.

GOVERNANCE

We continue working to heal lives with our 120 brands and 220 products in more than 70 countries.

We serve with 228 brands and 458 products in Türkiye, and one in every 10 medicines used in the country is an Abdi İbrahim product, which further boosts our motivation.

We continued our unit sales and turnover leadership in the Turkish pharmaceutical industry, a feat we have maintained since 2002.

Compared to 2020, we increased our net sales in international markets by 10% in 2022.

We spent TRY 192 million on R&D and invested US$ 53 million in 2022.

We opened the Sterile Inhalation Facility with an investment of EUR 18 million, providing Türkiye with the most advanced 'nebule' technology used in the treatment of respiratory diseases.

We increased the ratio of our local suppliers to 72% in 2022.

Our Esenyurt Production Complex passed audits conducted by 50 health authorities and customers in 2021 and 2022.

We were recognized as the "Most Reputable of the Year" in the pharmaceutical industry for the second time in a row at The ONE Awards, one of the most prestigious accolades of the marketing industry.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

SUSTAINABILITY-FOCUSED INSTITUTIONS AND INITIATIVES SUPPORTED

Involved in various non-governmental organizations working in the field of sustainability and voluntary agreements, Abdi İbrahim continues to be part of the solution for a better future and lead the industry.

ENVIRONMENTAL PROTECTION AND PACKAGING WASTE RECOVERY & RECYCLING FOUNDATION

Material issue: Climate change and energy management, waste management

We started collaborating with the Environmental Protection and Packaging Waste Recovery & Recycling Foundation (ÇEVKO) in 2005. We have been using the Green Dot symbol on all product packaging ever since.

UNITED NATIONS GLOBAL COMPACT (UNGC)

Material issue: Climate change and energy management, inclusion and diversity

We have been a proud signatory of the United Nations Global Compact since 2010, and we are focused on incorporating the Global Compact, which is the basis for the 17 sustainable development goals prioritized by the UN, into all our business procedures, strategies and operations. We issue annual UNGC progress reports.

GLOBAL REPORTING INITIATIVE (GRI)

Material issue: Climate change and energy management, inclusion and diversity, business ethics and transparency

We are guided by the Global Reporting Initiative (GRI), the world's leading initiative, and we have been sharing with the public our biennial sustainability reports prepared in accordance with GRI Standards since 2013.

WOMEN'S EMPOWERMENT PRINCIPLES (WEPS)

Material issue: Inclusion and diversity

We attach great importance to women's empowerment and participation in labour. On January 16, 2017, we signed the Women's Empowerment Principles, a UN private sector initiative that aims to empower women to participate in economic life across all industries and at all levels. We issue annual UNGC progress reports.

BUSINESS COUNCIL FOR SUSTAINABLE DEVELOPMENT TÜRKIYE (BCSD TÜRKİYE)

Material issue: Stakeholder relations

As an organization that is always learning and believes in the significance of developing partnerships for sustainability, we became a member of the Business Council for Sustainable Development Türkiye in 2019. 17. We work on improving our capacity through collaborations, supporting cross-sector partnerships, and raising awareness in line with the Sustainable Development Goals.

CARBON DISCLOSURE PROJECT (CDP)

Material issue: Climate change and energy management, waste management

We became a member of the Carbon Disclosure Project in 2019, becoming the first Turkish pharmaceutical company to complete its application and receive a score from CDP. We continue to publish annual reports.

UNGC CEO WATER MANDATE

Material issue: Water management

We became the first Turkish pharmaceutical company to sign the UNGC CEO Water Mandate initiative in 2020. We issue annual UNGC progress reports.

SCIENCE-BASED TARGETS INITIATIVE (SBTI)

Material issue: Climate change and energy management

We became the first Turkish pharmaceutical company to sign the Science-Based Targets Initiative (SBTi) in 2020. In line with our sustainability strategy, we develop projects to support the low carbon economy and be a part of the transformation with the goal of minimizing our environmental impact.

RECOVER BETTER

Material issue: Social investment programs

We became the first Turkish pharmaceutical company to sign the Recover Better statement convened by the UN and the SBTi in 2020. We continue to develop our sustainability strategy in line with climate science and the awareness that human health depends on the health of our planet. With various projects, we continue to lead our industry in the transition to a green economy.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

BUSINESS PLASTIC INITIATIVE

Material issue: Waste management

In 2020, we signed the Business Plastic Initiative, which was established by UN Global Compact Türkiye, Business Council for Sustainable Development Türkiye and Turkish Industry and Business Association to combat plastic pollution. Accordingly, we pledged to achieve a reduction of 17 tonnes of plastic by 2023.

TÜRKIYE CIRCULAR ECONOMY PLATFORM

Material issue: Climate change and energy management, waste management

We joined the Türkiye Circular Economy Platform in 2020. We continue our operations in line with the packaging strategy (Green Harmonization) we developed to reduce our dependence on natural resources. In doing so, we strengthen our competitiveness by boosting efficiency and minimizing future risks.

WE MEAN BUSINESS PLATFORMU

Material issue: Climate change and energy management

In 2022, we supported a campaign launched by We Mean Business Coalition to call on G20 leaders to use all their power to achieve the 1.5°C climate target stipulated in the Paris Agreement.

WWF GREEN OFFICE PROGRAM

Material issue: Climate change and energy management, waste management

Upon the successful completion of WWF-Türkiye's (World Wildlife Fund) Green Office Program, which we launched at our Head Office in Maslak, we were awarded the Green Office Certificate.

IMPACT2030

Material issue: Inclusion and diversity, human rights, social investment programs

We joined the IMPACT2030 Türkiye Impact Council in September 2022. We aim to expand our impact through collective action and be a part of the solution by facilitating collaboration in line with the sustainable development goals we focus on.

Click to see all of Abdi İbrahim's corporate memberships and the initiatives it supports.

KONCA ÇALKIVIK
SECRETARY GENERAL, BCSD TÜRKİYE



As an industry leader for 21 years, Abdi İbrahim has been a key member of our Council, a strong business partner and a Board Member, leveraging its extensive experience to support our Council. Abdi İbrahim was among the first companies to join the Business Plastic Initiative (IPG), which was established by BCSD Türkiye, the Turkish Industry and Business Association and Global Compact Türkiye in 2019, to share their commitments to reduce and prevent the use of plastics by 2023 with the public. As a key stakeholder of BCSD Türkiye and one of the leading organizations of the Turkish pharmaceutical industry in the field of sustainability, Abdi İbrahim continues its sustainability journey in line with its net zero targets and conducts activities that strengthen our country's global competitiveness. Abdi İbrahim's pioneering AI-based algorithm, designed to curtail carbon emissions, represents an unprecedented step within the global pharmaceutical industry. Through this innovation, the company strives not only to minimize carbon emissions but also to influence other industry players. These efforts extend into the realms of sustainable industry and the circular economy, with the ultimate goal of reducing resource consumption and manufacturing waste. As part of its commitment to reducing plastic waste, Abdi İbrahim aims to reduce carbon emissions resulting from the use of packaging materials in the production process. Abdi İbrahim considers sustainability from a broad perspective that covers the aspects of environmental, social and corporate governance. We congratulate Abdi İbrahim for its conscientious consideration of environmental impact, its contributions to the green transformation that spans its entire operations, from procurement to launch, and for acknowledging the critical interdependence between human health and a healthy planet, Abdi İbrahim's pledge to achieve carbon neutral by 2030 is commendable. We anticipate that they will further improve their Sustainability Reports, fortified by an extensive roadmap and quantifiable objectives. Such a nature-positive strategy should encompass sector-specific risks to effectively manage packaging waste and reduce plastic usage within a circular economy framework that prioritizes both the well-being of individuals and environmental health.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

SUSTAINABILITY AWARDS AND ACHIEVEMENTS

Abdi İbrahim was deemed worthy of several national and international awards in 2021 and 2022 for its environmental, social and governance projects that spearhead sustainability within the industry.

ABDİ İBRAHİM RECEIVES A SCORE OF B IN THE CDP'S CLIMATE CHANGE PROGRAM 2022

Taking firm steps toward its goal of becoming a carbon neutral company by 2030 as part of its HEAL2030 sustainability strategy, Abdi İbrahim maintained its previous score of B, with its third report submitted under the Carbon Disclosure Project (CDP) Climate Change Program 2022. Abdi İbrahim also received a score of B in the CDP's Climate Change Program 2021. Having included the activities it has conducted in its international operations in Kazakhstan, Algeria and Switzerland as well as its Head Office in Türkiye in its report, Abdi İbrahim annually sends reports for the CDP Climate Change Program, which contributes to combating climate change and protecting natural resources as the world's most powerful green NGO.

SILVER ACHIEVEMENT AWARD FOR RENEWABLE ENERGY USE PROJECT

Abdi İbrahim's renewable energy use project was deemed worthy of the Silver Achievement Award at the Sustainable Development Goals Awards presented at the Corporate Social Responsibility Summit & Awards.



YAD APPLICATION AWARD

With the Smart Software project, in the year 2022, Abdi Ibrahim became one of the finalists for the YAD Application Award organized within the scope of the 41st National Congress on Operations Research and Industrial Engineering, and won the second-place award.

SUSTAINABILITY AND ENVIRONMENT AWARD FROM TİSK

Abdi İbrahim was deemed worthy of the Sustainability and Environment Award with its Renewable Energy Use to Become Carbon Neutral by 2030 project at the A Common Future is Possible Together - 2021 awards, a social responsibility award program organized by the Turkish Confederation of Employer Associations (TİSK).

ABDİ İBRAHİM AWARDED BY ASTRAZENECA

On account of its reports on its environmental, occupational health and safety, ethics and sustainability activities submitted to the Ecovadis platform, Abdi İbrahim was awarded the Bronze Certificate by AstraZeneca in 2021 and 2022 for contributing to global sustainability goals.



EFFICIENCY PROJECT AWARDS

With its "Green Harmonization" project, Abdi İbrahim received a certificate of appreciation in the Large-Scale Enterprises category at the 2022 Efficiency Project Awards held by the General Directorate of Strategic Research and Efficiency of the Ministry of Industry and Technology.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

HEALING THE FUTURE OF ECOSYSTEM


Guided by its vision of “net zero” emissions, Abdi İbrahim uses clean technologies that will enable the transition to a low carbon economy and heals the future of the ecosystem by ensuring environmental sustainability across its value chain.


6 CLEAN WATER AND SANITATION
7 AFFORDABLE AND CLEAN ENERGY
12 RESPONSIBLE CONSUMPTION AND PRODUCTION
13 CLIMATE ACTION
17 PARTNERSHIPS FOR THE GOALS



Abdi İbrahim aims to minimize its ecological footprint in all business processes and contributes to green transformation, while leading the sustainable transition of the Turkish pharmaceutical industry to a low-carbon economy.

Abdi İbrahim shapes its “HEAL2030” sustainability strategy within the framework of the European Green Deal and the UN’s 17 Sustainable Development Goals (SDGs) in addition to its materiality analysis and identified risks and opportunities. Across its entire operational footprint, Abdi İbrahim considers the protection of the environment, continuous improvement, efficient use of natural resources, full legal compliance, prevention of pollution, reduction and separation of waste at its source and recycling and removal of waste with the best methods available as the basis of its environmental policy.



MESSAGE FROM THE CHAIRMAN

CEO’S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

COMBATING CLIMATE CHANGE

Closely monitoring international efforts aimed at combating climate change, Abdi İbrahim aims to become carbon neutral by 2030 and achieve net zero by 2050 through structured efforts to reduce its CO_2 emissions.

As decarbonization and the journey toward net-zero emissions become increasingly important along with the climate crisis, Abri İbrahim executes a range of projects to curtail its carbon emissions, embracing clean technologies that facilitate the transition to a low-carbon economy and aiming for "net zero" emissions across its entire value chain. With a commitment to reducing unnecessary consumption of natural resources, Abdi İbrahim champions effective resource management and strives to minimize its environmental impact.

ABDİ İBRAHİM'S CARBON FOOTPRINT BREAKDOWN

Below is Abdi İbrahim's carbon footprint breakdown by scope for 2021 and 2022, calculated in accordance with the ISO 14064 standard and reported in accordance with the GHG Protocol: Reported data cover the production facilities in Türkiye, Kazakhstan, Algeria, Switzerland, and the Head Office in Türkiye. Abdi İbrahim employs an extensive approach to managing its environmental impacts by classifying its emissions from direct and indirect sources under Scope 1, 2 or 3. Scope 1, Scope 2 and Scope 3 greenhouse gas emission values for 2021 and 2022 have been verified with limited assurance by an independent third-party auditing organisation.

Greenhouse gas emissions (Tonnes of CO_2e)	**2021**	**2022**
Scope 1	**27,461**	**28,607**
Scope 2*	**1,991**	**2,179**
Scope 3	**44,102**	**59,518**
1. Purchased goods and services	21,319	31,354
2. Capital goods	9,155	12,015
3. Fuel- and energy-related activities (not included in Scope 1 or Scope 2)	5,389	5,742
4. Upstream transportation and distribution	1,677	3,414
5. Waste generated in operations	393	344
6. Business travel	1,234	1,961
7. Employee commuting	974	626
8. Upstream leased assets	N/A	N/A
9. Downstream transportation and distribution	1,434	890
10. Processing of sold products	0	0
11. Use of sold products	0	0
12. End-of-life treatment of sold products	2,527	3,172
13. Downstream leased assets	N/A	N/A
14. Franchises	N/A	N/A
15. Investments	0	0
Total Scope 1, Scope 2, Scope 3 greenhouse gas emissions	**73,519**	**90,304**

*Thanks to the use of 100% renewable electricity, the carbon footprint value of the electricity consumption at the Esenyurt Production Complex and Head Office is 0. Scope 2 greenhouse gas emissions include the carbon footprint resulting from operations outside Türkiye.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

Abdi İbrahim is accelerating its efforts towards energy efficiency and renewable electricity to achieve decarbonization and net zero emissions. Accordingly, Abdi İbrahim attaches great importance to the effective use of energy resources and ensures continuous development in this field through its Energy Board.

Consisting of directors, managers, engineers and technicians, the Energy Board holds general evaluation meetings at least twice a year and has a sub-committee of 85 people. All technical personnel contribute to sub-working groups according to their areas of expertise.

Aiming to be carbon neutral by 2030 and net zero by 2050, Abdi İbrahim took a major step in this direction as it started meeting all electricity needs of the Esenyurt Production Complex and the Head Office in Istanbul from renewable sources as of January 1, 2020. In 2022, prevention of GHG emissions amounted to nearly 25,466 tonnes of CO_2e with a total renewable electricity supply of 55,736,190 kWh at the Esenyurt Production Complex and the Head Office in Istanbul. Thanks to the solar energy generated at the OM Pharma production facility in Switzerland, an additional 13 tonnes of CO_2e of GHG emissions were prevented.

In addition to greenhouse gas emissions, CO, NO_2 values can be monitored instantly with monitoring measurement devices installed in steam boiler chimneys at Abdi İbrahim. Other emissions are evaluated in emission reports prepared within the framework of instant measurements carried out every two years. The average measured values are as follows:

NO_2...60 mg/Nm³
CO.....0 mg/Nm³
SO_2....0 mg/Nm³



MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

MEGA TRENDS, RISKS, OPPORTUNITIES

Abdi İbrahim closely follows the mega trends, risks and opportunities in the pharmaceutical industry and takes these developments into account in all business processes while considering its material issues.

TECHNOLOGY

Abdi İbrahim closely follows technological innovations related to climate performance to develop sustainable production processes and products with lower environmental impact. For example, as part of its efforts to reduce the environmental impact resulting from its R&D and innovation activities, Abdi İbrahim aims to reduce its carbon footprint through various practices. These include introducing package insert-free medications, optimizing pharmaceutical packaging and blister production to reduce the use of packaging materials, implementing biodegradable packaging solutions and facilitating personalized vitamin and medication production through 3D printing.

LEGAL

Abdi İbrahim follows national and international regulations regarding climate change through a legal compliance monitoring procedure as part of its risk management system. The Company considers the relevant legal framework in climate-related risk assessments. Failure to comply with regulations can impact business continuity, financial performance and reputation. All pharmaceutical manufacturing facilities are required to obtain an environmental permit covering all environmental regulations. In this regard, Abdi İbrahim incorporates the existing regulations concerning the monitoring, reporting and verification of greenhouse gas emissions into its risk management protocols. Even though it falls outside the regulatory scope, Abdi İbrahim has chosen to install continuous emission monitoring systems in its chimneys, a requirement mandated by the regulations for sectors covered by the law. This ensures that Abdi İbrahim's emissions are continuously monitored, and the Company is ready to certify the system and report directly to the Ministry of Environment, Urbanization and Climate Change in case of a scope expansion.

MARKET

Market risks related to climate change are assessed as part of Abdi İbrahim's risk management system. Failure to meet its commitment to reduce climate impact may negatively impact customers' opinions of Abdi İbrahim and its products, which could reduce sales. Since failure to maintain the competitiveness of its products will harm the company, significant changes in the markets in which Abdi İbrahim operates are always considered in the Company's climate-related risk assessments.

REPUTATION

Reputational risks related to climate change are assessed as part of Abdi İbrahim's risk management system. Abdi İbrahim always includes reputation in its climate-related risk assessments as a material issue.

ACUTE PHYSICAL

Acute physical risks related to climate change are assessed as part of Abdi İbrahim's risk management system. The increasing frequency and severity of extreme weather events such as hurricanes, forest fires and floods may pose significant challenges for Abdi İbrahim's operations and supply chain. Due to the global supply chain disruptions experienced during the COVID-19 pandemic, Abdi İbrahim included localization in its material issues and launched the FOCUS project. While the project supports overcoming the supply chain issues, it also provides direct added value to the country's economy and the pharmaceutical industry by offering advantages such as reducing the current account deficit, ensuring sustainable pharmaceutical production through supplier diversity, maintaining the country's national capital, achieving shorter delivery times and supporting suppliers in expanding abroad.

CHRONIC PHYSICAL

Chronic physical risks related to climate change are assessed as part of Abdi İbrahim's risk management system. Climate change may cause water scarcity, which may increase the costs and reduce the availability of the raw materials needed for Abdi İbrahim's products. It may also cause disruptions in production. These effects may disrupt the company's operations and reduce its financial performance.

PRODUCTS AND SERVICES

Abdi İbrahim makes investments to develop products with lower environmental impact, one of them being the smart software packaging design project. As of the end of 2022, the software is being used in 26 products. The software reduces the use of raw materials such as aluminium foil, PVC or cardboard. These investments enable Abdi İbrahim to offer production solutions with lower environmental impact to its manufacturing clients. Clients' increasing demand for these products also boosts company revenue.

For more information, click to see Abdi İbrahim's CDP Climate Change Report.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

WATER MANAGEMENT

With the projects conducted between 2012 and 2022, Abdi İbrahim saved 48,110 m³ of water, which is equivalent to the water needs of 3,207 households in 1 month and 267 households in 1 year.

Manufacturing pharmaceuticals with water of suitable properties to serve human health in the most efficient way, Abdi İbrahim takes great care to ensure water sustainability. The Company prioritizes its efforts to save water, which is essential for the future of the world.

All necessary precautions are taken to save water at every stage of production at the Esenyurt Production Complex. At the facility, the wastewater is biologically enhanced with membrane bioreactor (MBR) technology, and performance is continuously monitored. With this initiative, the outlet water quality has been improved by 70 percent and reduced to well below discharge standards.

Abdi İbrahim focuses on the efficient utilization of water through the diligent efforts of its employees and automated control systems. The facility uses both photocell and filter taps in the sinks and in the washing cabins of the production areas. There are irrigation systems in place to ensure that water flows only when needed, as well as production equipment with automatic washing features.

Projects for saving water are also utilised at the Abdi İbrahim Tower. Using water filter cartridges, the facility's water consumption was reduced by 71 tonnes per month in 2021 thanks to the controlled use of tap water.

Waste at the Abdi İbrahim Esenyurt Production Complex is removed in accordance with the regulations.



CEO Water Mandate

Taking a major step towards healing the world and the future through sustainable water management, Abdi İbrahim was the first company in the Turkish pharmaceutical industry to sign the CEO Water Mandate, a United Nations Global Compact initiative. Accordingly, the Company will support water conservation policies that are implemented simultaneously worldwide in line with their commitments.

CEO WATER MANDATE

Click to see Abdi İbrahim's environmental performance indicators.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

CIRCULAR ECONOMY AND WASTE MANAGEMENT

Abdi İbrahim incorporates environmental considerations into every aspect of its business, from the supply of raw material and equipment to the end of their lifecycle, and enforces robust policies for resource management and recycling.

In accordance with its Waste Management Procedure, Abdi İbrahim separates all waste generated during its activities at the source. The Company also fulfils all its obligations in accordance with the Environmental Legislation. Abdi İbrahim works with companies licensed by the Ministry of Environment, Urbanization and Climate Change for the recovery and disposal of waste.

With both the Esenyurt Production Complex and the Abdi İbrahim Tower recognized with the Zero Waste Certificate by the Ministry of Environment, Urbanization and Climate Change, Abdi İbrahim contributes to recycling by separating waste at the source.

With the aim to reduce of waste as part of its circular economy activities, Abdi İbrahim is working on major projects such as reducing the consumption of product packaging, using 100 percent recycled paper in the production of package inserts and boxes, making blister packs and other packaging which have biodegradable content, collecting medical waste and recycling packaging into the economy.

Considering plastics as a material issue, Abdi İbrahim is developing various projects to reduce plastic use, minimize its plastic footprint and transition to alternative materials. In 2020, Abdi İbrahim signed the Business Plastic Initiative, which was established by UN Global Compact Türkiye, Business Council for Sustainable Development Türkiye and the Turkish Industry and Business Association to combat plastic pollution. Accordingly, the Company has committed to a reduction of 17 tons of plastic by 2023.

Click to see Abdi İbrahim's environmental performance indicators.



MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD


FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM


HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

GREEN HARMONIZATION PACKAGING STRATEGY



The same amount of medicine in less packaging



Click to see Smart Software video.

1

Reduced blister and box size

28% per-product reduction in greenhouse gas emissions caused by packaging materials

179 tonnes of packaging materials conserved

2

Less production waste

Preventing **90 kg** of production waste

3

Higher energy and water savings

6 weeks of free capacity recovery

Energy equivalent to the annual electricity consumption of **150** households saved

4

More efficient logistics operations

Annual pallet circulation reduced by **2,300** pallets

5

Cost savings

EUR 1 million reduction in material costs

REDUCE

In the “reduce” phase, the goal was to reduce the size of blister packs that are widely used in Abdi İbrahim’s production activities with the Smart Software project, which is based on artificial intelligence and optimization techniques. In a groundbreaking collaboration with the TOBB University of Economics and Technology (TOBB ETÜ), the world pharmaceutical industry has, for the first time, developed an algorithm that centers on the design phase, aimed exclusively at reducing carbon emissions. Commencing with 26 licensed Abdi İbrahim products, the “reduce” phase has led to reductions in the use of aluminium, PVC and paper—carbon-intensive inputs in pharmaceutical production. This initiative resulted in the saving of 179 tonnes of packaging materials, energy savings equivalent to the annual electricity consumption of 150 households, the prevention of 90 kg of production waste and the recovery of 6 weeks of free capacity. This has also led to a 2,300-unit reduction in annual pallet circulation and annual material savings worth EUR 1 million. In the subsequent phases, the plan is to expand the scope of the project, which will include the reduction of packaging for additional products.

SWITCH

In the “switch” phase, the objective is to switch shrink-wrapped packaging with biodegradable plastic, known for producing significantly fewer carbon emissions than PVC. The initial products to undergo this “switch” phase will be the plastic tubes and caps used in Abdi İbrahim’s consumer health products. The first prototype tubes were produced in the framework of a university-industry R&D collaboration with Sabancı University Nanotechnology Research and Application Center (SUNUM). With the application of biodegradable materials, the goal is to achieve a 75 percent reduction in carbon emissions per product which are caused packaging raw material compared to the current version. Pending successful stability studies, the next phase will involve switching all PVC-based blister packaging with biodegradable materials.

COLLECT

In the “collection” phase, the objective is to initially collect the consumer health product packaging that has been switched with biodegradable materials, subsequently sending them to biogas facilities for anaerobic degradation. This process will facilitate the complete biodegradation of the tubes, yielding compost and biogas. The resulting compost will be made available to farmers, supporting the local economy. Simultaneously, this will support sustainable energy resources by enhancing biogas production.

MESSAGE FROM THE CHAIRMAN
CEO’S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

ENVIRONMENTAL IMPACT MITIGATION EFFORTS

Reducing the use of plastic bags by eliminating garbage bins under desks as part of the zero-waste initiative

↘ 700 kg

(2021)

Reducing the amount of waste generated by ensuring filter optimization in syrup & drop products

↘ 134 kg

(2022)

Reducing the amount of waste in film and tablet waste of a product through overfill

↘ 850 kg

(2022)

SAVINGS ACHIEVED THROUGH QUALITY CONTROL LABORATORY PROJECTS

2021

TRY 192,245
worth of chemicals saved

2,561 hours
of device utilization eliminated (1,843.92 kV)

2,027 hours
of labour saved

2022

Saving water and chemical usage by reducing the number of annual washings required by increasing the charge of a product

148 m³
of water saved

510 kg
of chemicals saved

SAVINGS ACHIEVED THROUGH CARBON FOOTPRINT REDUCTION PROJECTS

1.769.930 TL
worth of chemical consumables saved

12,570 hours
of device utilization eliminated

3,713 kWh
of device electricity consumption saved

12,218 hours
of labour saved

The Compressed Air Leakage Prevention and Monitoring System project aims to enhance traceability for compressed air leakage control and to reduce electrical energy consumption. Through the prevention of leaks, we annually save approximately **293,149 kW** of electricity.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

GREEN OFFICE PROGRAM

Abdi İbrahim, as part of its commitment to a sustainable future for the next generations with its HEAL2030 program, has successfully implemented WWF-Türkiye's Green Office Program at its Head Office building in Maslak. The company earned the Green Office Diploma in August 2022 upon program completion.

Abdi İbrahim, in its role of mitigating climate change risks, has taken significant strides in its Green Office Program:

- Awareness-raising campaigns at the Abdi İbrahim Tower focused on water conservation, waste management and bolstering office employees' environmental consciousness.
- With water filter cartridges, water consumption was reduced by 71 tonnes per month in 2021 thanks to the controlled use of tap water.
- In honour of World Water Day, Abdi İbrahim sent 10,000 water-saving cartridges to pharmacies to promote water conservation.
- On Sweater Day, celebrated on December 20, 2021, indoor temperatures at the Esenyurt Production Complex and Abdi İbrahim Tower were reduced by 2 degrees, and all employees were encouraged to participate in this initiative. This effort resulted in a reduction in resource consumption, saving 183 cubic meters of natural gas.
- Over the course of a year, Abdi İbrahim significantly reduced the use of single-use plastics by 84,000 units in the Abdi İbrahim Tower and 92,000 units in the Esenyurt Production Complex.
- As part of the efforts to decrease paper consumption, Abdi İbrahim has transitioned to digital communication, thereby preventing the consumption of 80,000 sheets of paper in 2022 compared to the previous year, representing a 42 percent reduction in paper usage at the Esenyurt Production Complex and a 4 percent reduction at the Abdi İbrahim Tower.

ABDİ İBRAHİM SUSTAINABILITY DAY

On March 18, 2022, the Corporate Relations, Sustainability, and Communication Directorate, in collaboration with the Sustainability Steps Association, organized a training workshop. The event, attended by members of the Sustainability Committee and managers from the Esenyurt Production Complex, featured training workshops following presentations on "Sustainability-Climate Relationship and Good Practices" and "What We Have Done for the Climate and the Current Situation." Six groups were established, each focusing on specific areas: Designing a Management Process for Continuous Improvement, Stationary Combustion and Generators, Raw Materials, Rental Vehicles-Logistics, Product Disposal and Communication-Marketing. Comprising an average of seven individuals, these groups addressed manageable issues within their respective focus areas. They subsequently developed solutions to the identified problems, deliberated on the action steps they would take, implemented the suggested solutions and outlined the improvement objectives they aimed to achieve. Each group presented their findings, sharing the identified problem, the developed solution and the action steps with other group members.





MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

ENVIRONMENTAL TRAINING

In line with its continuous development principle and efforts to elevate its environmental standards, Abdi İbrahim regularly organizes training programs covering standard facility practices, procedures, waste management, recycling, conscious consumption and what do at home. As part of the Environmental Management System trainings conducted with the participation of third-party companies, an average of 2 hours of Environmental Management System awareness training is provided annually. Abdi İbrahim, which places significant emphasis on communicating the latest developments through its environmental training and on stakeholder engagement, also motivates its employees through initiatives such as the Environmental Employee of the Month and the Voluntary Environmental Education Project.

	2020	2021	2022
# of People	1,049	1,656	2,131
Training duration (hours)	114	194	249

ENVIRONMENTAL TRAINING

In line with its continuous development principle and efforts to elevate its environmental standards, Abdi İbrahim regularly organizes training programs covering standard facility practices, procedures, waste management, recycling, conscious consumption and what do at home. As part of the Environmental Management System trainings conducted with the participation of third-party companies, an average of 2 hours of Environmental Management System awareness training is provided annually. Abdi İbrahim, which places significant emphasis on communicating the latest developments through its environmental training and on stakeholder engagement, also motivates its employees through initiatives such as the Environmental Employee of the Month and the Voluntary Environmental Education Project.



KORAY KOÇER
MARKETING LEADER, FAZLA



At Fazla, we offer technology-based holistic waste management solutions designed to ensure the recycling of surplus products of our partners, yielding the highest economic, environmental and social benefits. Our journey, initially launched in collaboration with TİSK (Turkish Confederation of Employer Associations), rapidly gained momentum with Abdi İbrahim's involvement. When we embarked on our journey with Abdi İbrahim, the Smart Weighing System was a novel service for us. Abdi İbrahim played a pioneering role as one of our partners that first believed in this solution and enjoyed the benefits it could deliver. While food is not the primary focus of Abdi İbrahim, a leader in the pharmaceutical industry, its commitment to sustainability in the food sector and its fight against food waste set a remarkable example for its own industry and beyond. Within the project's scope, we not only contributed to environmental benefits by reducing the rate of food waste and carbon emissions but also raised awareness across the organization about food waste through our efforts. We are delighted to be part of Abdi İbrahim's journey towards staying aligned with the trends shaping the future and combating climate change, all while creating sustainable benefits together.

REDUCING FOOD WASTE AND SURPLUS PROJECT

Abdi İbrahim initiated a project aimed at reducing food waste in its Head Office cafeteria. The Smart Weighing System, developed specifically for professional kitchens by Fazla, Türkiye's first and only technology-based holistic waste management company, was introduced in the Abdi İbrahim Tower cafeteria in April 2022. Through food waste measurements conducted in the cafeteria, the rate of food produced turning into waste was reduced by 47 percent. The success of this initiative led to the decision to implement the Smart Weighing System at the Abdi İbrahim Esenyurt Production Complex.





MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

HEALING THE FUTURE OF PEOPLE

Abdi İbrahim, with a focus on the social well-being of all its stakeholders across the value chain, fosters a brighter future for everyone, particularly its dedicated employees, through impactful, value-driven, purpose-oriented projects.


5 GENDER EQUALITY
8 DECENT WORK AND ECONOMIC GROWTH
10 REDUCED INEQUALITIES
17 PARTNERSHIPS FOR THE GOALS



GOOD FOR EMPLOYEES

Abdi İbrahim places a strong emphasis on nurturing the skills of its human resources and welcoming new talents with continuous investments, promoting diversity, equality, and inclusion and providing a fair working environment for its employees.

Abdi İbrahim views its transparent, participatory and collaborative culture, which values individual leadership, self-accountability and teamwork, as the engine that propels company accomplishments. The Company prioritizes the health, safety and well-being of its employees, anchoring its management philosophy in the “people first” ethos, understanding that only with the right team can it reach its long-term vision and goals. Abdi İbrahim aspires to contribute to building a mentally and physically resilient society and workforce, leveraging its deep-rooted culture and robust corporate structure. The company designs processes that empower its employees, recognized as talents, to unleash their potential and provides opportunities and platforms for their continual growth. Abdi İbrahim, crafting its human resources strategy on the pillars of “Courageous, Passionate and Responsible,” upholds principles of reliability and transparency.



PRIORITIES OF THE HUMAN RESOURCES

Fostering an environment and atmosphere of passionate dedication to work.

Excelling in talent management and succession planning.

Cultivating a performance-oriented culture tied to strategic priorities.

Developing the technical competencies and leadership skills essential to the strategy.

Establishing the systems and sustainable processes requisite to the HR infrastructure.

DENİZ DAVER
HEAD OF THE PEOPLE AND CULTURE GROUP, ABDİ İBRAHİM



At Abdi İbrahim, we not only integrate our sustainability vision into our business strategies but also actively contribute to society by taking concrete actions in the sphere of people and culture. Our dedication to people is evident throughout, from our recruitment processes to the employee experience. When choosing our talents, our most valuable assets, we assess not only their skills but also their alignment with our values. Our colleagues’ alignment with our vision, collaborative spirit and commitment to ethical values underpin our sustainability journey. We embrace diversity in our recruitment processes, acknowledging that diverse perspectives foster creativity and innovation. Our aim is to forge a profound emotional connection that transcends mere membership in the Abdi İbrahim family. We offer a diverse array of programs and opportunities to promote not only physical but also emotional and mental well-being. By championing the personal and professional development of our employees, we contribute to the sustainability of both the present and future generations. We will further our efforts to leave a better world for future generations, perpetually striving for a sustainable future.

MESSAGE FROM THE CHAIRMAN

CEO’S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

HUMAN RESOURCES PRACTICES

Abdi İbrahim, which is among the most preferred companies in the pharmaceutical industry, offers its employees a working environment boasting international standards and extensive social benefits.

Number of employees	2020	2021	2022
Türkiye	3,918	3,930	4,734
Overseas	534	668	649
Total	4,452	4,598	5,383

Abdi İbrahim adopts and implements legal regulations, standards and contemporary management systems in the field of occupational health and safety and follows technological changes and developments. Providing strong support to the Turkish economy with its active employment policies in line with its growth plans, the Company draws attention with its human resources, experienced and specialized above the sector average and its high rate of employee loyalty. Abdi İbrahim maintains its leadership position as a well-established yet future-oriented company, boasting a creative and dynamic structure, with Millennials making up 66 percent of its workforce.

GENDER EQUALITY AND DIVERSITY

Female employees have always been a significant source of strength throughout Abdi İbrahim's century spanning history. The contributions by female employees have been substantial in every undertaking of the company since its founding generation and has made Abdi İbrahim a pioneering institution in the business world in ensuring gender equality.

As a signatory of the United Nations Global Compact (UNGC) and the Women's Empowerment Principles (WEPs), Abdi İbrahim attaches great importance to the employment of women and supporting them. The company is committed to incrementally raising the female employment rate at all levels of the organization, including within the management team, and diligently strives to ensure gender equality across all management tiers.

The Company does not discriminate against race, language, religion, age or gender in human resources processes and is committed to providing a fair, egalitarian working environment that respects human rights. Procedures, such as recruitment, assignment and promotion within the company, are conducted by considering the criteria of professional experience and expertise.

The rate of female employees (%)

2021 → **32.41**

2022 → **33.58**

The rate of female employees in the Head Office (%)

2021 → **57**

2022 → **57**

The rate of female employees in the R&D Center (%)

2021 → **62**

2022 → **57**

The rate of female employees in the Leadership Team (%)

2021 → **32**

2022 → **32**

SUPPORTING LOCAL EMPLOYMENT

Abdi İbrahim has a field organization distributed all over Türkiye and supports local employment in the mass recruitment procedures it conducts for field sales positions. In promotion procedures, on the other hand, managerial potential is evaluated and a candidate from the local community is preferred among two employees with equal potential. As a result of this company policy, the rate of promotion from the internal at the Senior Management level (regional manager, product manager, director, etc.) has reached 72 percent.

EMPLOYER-EMPLOYEE RELATIONS

The Company operates within the framework of respect for employee rights under existing legal regulations applicable to business life, and regularly audits its suppliers. Abdi İbrahim does not have an organized union.

AN APP THAT SUPPORTS PARTICIPATION: AİDEA

Abdi İbrahim attaches great importance to instilling a sense of volunteerism in its employees and encourages them to create projects on their own initiative through the AİDEA Suggestion System it implements. AİDEA, where suggestions received since 2011 have been evaluated and implemented and with employees being rewarded in line with the business value they create, contributes to the sustainability goals of the company. As of the end of 2021, 128 projects were implemented through AİDEA, which received 1,248 suggestions by employees. Employees sharing their suggestions have been awarded a total of TRY 103,551. As of the end of 2022, 142 projects were implemented through AİDEA, which received 1,276 suggestions by employees. Employees sharing their suggestions have been awarded a total of TRY 132,504.

Click to see Abdi İbrahim Business Ethics Principles.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

TALENT MANAGEMENT

As an industry leader and a top employer, Abdi İbrahim places high priority on talent management. In this regard, the Company has instituted numerous talent management programs.

Abdi İbrahim attaches great importance to talent management to provide a passionate working environment and atmosphere. Talent management implemented in the company consists of recruitment, orientation, performance management, competency evaluation, feedback and development planning processes.

OBJECTIVES OF TALENT MANAGEMENT

- To create a strong perception of Abdi İbrahim in potential candidates.
- Choosing the right person.
- To ensure that the right person quickly adapts to the job and the culture.
- Setting business goals, evaluating success, nurturing with feedback.
- To develop the employee in line with strategic priorities.
- To select, train and retain the leaders of the future.



Rate of internal promotions at manager level and higher (%)

2021 → **65**

2022 → **54**

Rate of rotation, as a significant development activity (%)

2021 → **13.9**

2022 → **7.7**

Rate of loss in the target group, designated as the rate of unwanted loss (%)

2021 → **8.7**

2022 → **6.4**

Average training time per employee

2021 →
34.5 hours digital
11 hours in-class

2022 →
34 hours digital
16 hours face-to-face

ABDİ İBRAHİM ACADEMY

The content of the Abdi İbrahim Academy, where development solutions are presented to support strategic priorities and create a common culture, consists of corporate academy programs, basic technical trainings, e-trainings, social learning and the Alpedia corporate library. Employees can participate in development programs with in-class training and receive e-trainings through this system.

Faculties within the academy

- Sales Representative Faculty
- Medical Marketing Faculty
- Continuous Learning Faculty
- Leadership Faculty
- Welcome to Those Healing Life

Abdi İbrahim Academy statistics (2022)

Face-to-face training time per employee: **16 hours**

Net promoter score: **61**

Distance learning per employee: **34 hours**

Total hours of training per employee: **50**

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

PIONEERS OF CHANGE INNOVATION JOURNEY

Abdi İbrahim embarked on a program in 2020 dedicated to cultivating the necessary innovation capacity to realize the strategic priorities that will bring the Company closer to its vision. This program, "Pioneers of Change," is an experiential learning journey that revolves around human-centric design. The 14-week journey, "Pioneers of Change," comprises workshops that teach design thinking, guiding participants on the path to crafting innovative solutions and applying these insights strategically within their respective domains. The program also equips selected employees who are already familiar with design thinking with coaching and facilitation skills, empowering them to champion new approaches within their organizations. Over the past three years, more than 200 Abdi İbrahim employees who entered the program have harnessed this skill to seize opportunities and tackle challenges of their own. Furthermore, 14 employees have developed expertise in leading human-centric projects and facilitating critical processes.

GROWTH ACCELERATOR INNOVATIVE MARKETING DEVELOPMENT PROGRAM

As part of the development initiatives supporting Abdi İbrahim's goals and sustainability efforts within VISION 2025, the "Growth Accelerator Innovative Marketing Development Program" takes center stage. This program offers hands-on training to a management team of 70 individuals responsible for overseeing marketing and sales personnel. The program, conducted in partnership with international experts from the world's leading minds, enables managers to work on 10 projects focused on strategic challenges and industry-specific opportunities.



PATH FOR MARKETING TRAINEE YOUNG TALENT DEVELOPMENT PROGRAM

Abdi İbrahim launched the "Path for Marketing Trainee Young Talent Development Program" with a view to attracting recently graduated individuals with a career aspiration in marketing. Young professionals who become part of the Abdi İbrahim family, following a rigorous selection process, undergo a structured 12-month development program. This program encompasses six months at the company's head office and another six months in the field. Graduates who successfully complete this training process are appointed as Assistant Product Managers and commence their roles at the Abdi İbrahim Tower. Accepting over 80 individuals during the last five years, the program garnered close to 4,000 applications in both 2021 and 2022.

"A SHOT IN THE ARM" PROGRAM

Through the "A Shot in the Arm" project, launched to bolster the qualified workforce within the pharmacy sector and help pharmacy students transition into the professional world, participants from Istanbul, Ankara, and İzmir partake in essential vocational training and engage in periodic fieldwork. Over a span of five months, as part of this project, students collaborate within Abdimed and İnoliva, Abdi İbrahim's affiliates. They take on diverse responsibilities in pharmacies to promote products authorized by the Ministry of Agriculture. The program enables students to gain a deeper understanding of the industry and the pharmacy profession, fosters connections with peers, and empowers them to make more informed decisions as they plot their career path. High-performing individuals in the program, which not only offers monetary incentives but also a wealth of development prospects, are primarily considered for recruitment by Abdi İbrahim. In 2022, the program engaged the participation of 60 young talents.

FRESH GRADUATE & EMPLOYMENT PROGRAMS

Abdi İbrahim is dedicated to investing in the recruitment of newly graduated, inexperienced candidates. Several programs cater to inexperienced hires, including blue-collar roles, medical promotion representatives, R&D and quality laboratories, and these programs are especially noteworthy due to the substantial number of individuals they employ. Abdi İbrahim also conducts various on-the-job professional development programs to provide a thorough understanding of the industry and profession.

Recruitment numbers (2022)	Inexperienced recruitment	Total recruitment
Blue collar	349	584
Medical sales representative	387	801
R&D and quality	70	216

PETER FISK
GLOBAL THOUGHT LEADER



The health of a society is crucial to individual wellbeing, social cohesion and economic growth. Abdi Ibrahim acts as platform to ensure that all parts of society have affordable access to the most relevant solutions, and also acts as a gateway to bring the latest medicines from across the world to the local market. It also innovates to find new ways to support people in the early diagnosis and effective recovery from illness, and to stay healthy. In addition, it works with all parts of the healthcare ecosystem - patients, doctors, pharmacists, hospitals and more - to support their continued awareness and education in the best approaches to healthcare.

Click to see Abdi İbrahim's social performance indicators.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

OCCUPATIONAL HEALTH AND SAFETY PRACTICES

Abdi İbrahim places significant emphasis on cultivating an internal culture of Occupational Health and Safety (OHS) throughout all business processes. This involves not only the use of technical equipment and ensuring the health of facilities and machinery but also the internalization of OHS principles.

Abdi İbrahim, apart from fully deploying technical equipment for occupational health and safety across all operational units, regards the establishment of an organizational culture focused on Occupational Health and Safety (OHS) at all levels of the company's structure as one of its principal objectives. In its pursuit of fostering a corporate OHS culture, the company entrusts its managerial staff with numerous responsibilities, which include identifying and rectifying vital infrastructure deficiencies and gauging employee OHS performance.

COMPLIANCE WITH LEGISLATION

Abdi İbrahim's leadership and employees diligently conduct activities within all areas of the organization, meticulously adhering to applicable national and international laws and regulations. They are committed to acting in alignment with OHS policies and procedures made publicly available.

MEASURING OHS PERFORMANCE

Abdi İbrahim, a company that shapes all its operational processes under the banner of continuous advancement, meticulously devises quantifiable health and safety objectives and methodically evaluates the rates at which these objectives are realized to maintain steady progress in the domain of occupational health and safety. Furthermore, risks associated with losses, accidents or damages stemming from activities within the company's production facilities are consistently evaluated. This evaluation is conducted to safeguard the well-being of employees and the efficiency of business operations, with an unwavering focus on creating a secure work environment. Internal communication channels are employed to keep employees apprised of the fulfilment rates of policies implemented in the realm of OHS, in addition to their statutory compliance.

OCCUPATIONAL SAFETY AT INTERNATIONAL STANDARDS

Abdi İbrahim believes that the path to cultivating a corporate OHS culture throughout all business processes is not only through the use of technical equipment and ensuring the safety of facilities and machinery but also through the internalization of OHS principles. Beyond merely conforming to legal regulations, the utmost attention is dedicated to ensuring compliance with international standards, notably ISO45001.

PERIODIC TRAINING PROGRAMS

Abdi İbrahim is dedicated to boosting awareness and educating its workforce on contemporary OHS practices via recurring training programs in the field. Training provided by the Environment, Health, and Safety department incorporates a comprehensive examination of workplace risks, protective parameters, occupational accidents and emergency protocols.

OHS training time per employee (man-hours)	2020	2021	2022
Aİ Tower Head Office and Field	2.23	2.04	8.16
Esenyurt Production Complex	4.3	5.58	5.05
Total	6.53	7.62	13.21



Click to see the details of OHS trainings here.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

IMPROVING OHS PROCESSES

To advance OHS procedures at Abdi İbrahim, annual targets are set to reduce the overall accident rate, coupled with the execution of strategic initiatives to enhance safe conditions and behaviour. In order to make a global comparison of accident rates, the Occupational Safety and Health Administration (OSHA) incident calculation rate has been used since 2018.

OHS INDICATORS

Aİ Tower Head Office and Field	2020	2021	2022
Incident frequency rate*	0.13	0.006	0.3
Occupational disease rate**	0	0	0
Lost day rate***	5.4	0.05	78.15
Number of fatal incidents	0	0	0

Esenyurt Production Complex	2020	2021	2022
Incident frequency rate*	3.52	3.35	4.35
Occupational disease rate**	0	0	0
Lost day rate***	293.1	259.5	230.2
Number of fatal incidents	0	0	0

* Lost working day incident rate includes all work incidents resulting in leave for one day or more.
Incident rate with lost working days = Total number of incidents with lost working days x 200,000 / Total working hours
** Occupational Disease Rate = Total number of occupational disease cases x 200,000 / Total working hours
*** Lost Day Rate = Total lost working days x 200,000 / Total working days (Number of employees x days worked)

During the reporting period, there have been no occupational accidents causing death or serious injury.



MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

GOOD FOR PEOPLE

As social injustice and inequalities become more prominent around the world, Abdi İbrahim considers the welfare of all its stakeholders, while fostering science awareness with social innovation in health, volunteering activities and social investments, and focusing on the well-being of society.

Continuing its operations with full commitment to human rights and ethical values since day one, Abdi İbrahim conducts long-term, sustainable and result-oriented activities aimed at providing social benefit as part of its plan to heal the future and considers these activities to be an integral part of its primary duties. From employees to suppliers and customers, Abdi İbrahim does not discriminate on the grounds of language, religion, race, ethnicity, political opinion or gender in its relationships with its stakeholders. Supporting the development and promotion of corporate citizenship awareness as part of the United Nations Global Compact, Abdi İbrahim serves the development of universal health standards with its innovative approach and a century of experience, while ensuring that these standards are accessible to everyone.

Abdi İbrahim employs a holistic approach to its business goals, employees, the world and society, and puts responsible and sensitive approaches at the center of all its business processes. Abdi İbrahim collaborates with Türkiye's public and private sectors, as well as non-governmental organizations and the markets it serves. In addition to assessing the economic impacts of its activities, the Company also evaluates their social and environmental consequences. Abdi İbrahim considers the Social Investment Program it has implemented in line with this understanding to be complementary to its business strategy, as it prioritizes individuals' rights to health, education, equal opportunity and a healthy environment, and aims to provide social benefit with its research, campaigns, volunteering projects and sponsorships.

With a strong and innovative foundation that influences its environment, Abdi İbrahim prioritizes projects that align with its corporate values. These initiatives aim to benefit society at large, catering to a diverse range of demographics and working towards the common goal of creating a healthier future. With the participation of its employees, Abdi İbrahim ensures that all its activities are globally applicable, sustainable, measurable, transparent and accountable.

As part of its Social Investment Program, which is one of the key components of the HEAL2030 sustainability strategy, Abdi İbrahim focuses on five main topics: "Abdi İbrahim Foundation", "Health and Sports", "Social Innovation", "Fostering Awareness in Science among Young People" and "Volunteering Projects for Social Needs."

You may find Abdi İbrahim's social benefit activities and projects implemented before 2021 in the Sustainability Reports.

AREAS OF FOCUS IN THE SOCIAL INVESTMENT PROGRAM

ABDİ İBRAHİM FOUNDATION
Ensuring that young people grow up as well-equipped and qualified individuals who adopt contemporary and universal values and the core values of the Republic of Türkiye, providing health benefits for society, implementing projects related to public health and health literacy

HEALTH AND SPORTS
Supporting young athletes who successfully represent our country in the international arena, raising awareness about sports, well-being, health literacy

SOCIAL INNOVATION IN HEALTH
Contributing to the healthcare industry by supporting social innovation

RAISING AWARENESS OF SCIENCE IN YOUTH
Promoting scientific awareness among children, youth and women, fostering the growth of future scientists, and supporting exceptional scientists who make a significant impact in their fields

VOLUNTEERING FOR SOCIAL NEEDS
Providing a sense of belonging and social benefit through various projects by creating a systematic volunteering structure

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

ABDİ İBRAHİM FOUNDATION

The Abdi İbrahim Foundation was established in 2021 by Nesrin Barut Esirtgen, Nezih Barut, Ahmet Cenan Esirtgen, İbrahim Barut and Abdi İbrahim İlaç Sanayi ve Ticaret Anonim Şirketi. The Abdi İbrahim Foundation operates within the fields of sports, education and health. Its mission is to inspire the younger generation's interest in science, sports and education, facilitating their growth as informed and skilled individuals who embrace contemporary, universal values and the core principles of the Republic of Türkiye.



NESRİN BARUT ESİRTGEN
DEPUTY CHAIRPERSON, ABDİ İBRAHİM & CHAIRPERSON OF THE BOARD OF TRUSTEES, THE ABDİ İBRAHİM FOUNDATION



Our company has been working to heal life for over a century. We always consider providing benefits to our country, people and society as our top priority, regardless of the circumstances. Serving with passion and courageously assuming responsibility to provide benefit are both deeply embedded in Abdi İbrahim's DNA. We ask ourselves how we can do better and be more useful in everything we do. We established the Abdi İbrahim Foundation, which operates in the fields of education, health and sports, with the goal of creating more value for our stakeholders. The primary goals of our Foundation include promoting science, sports and education among young people, and supporting them to become qualified individuals who boast extensive knowledge in their fields and who embrace modern and universal values and the core principles of the Republic of Türkiye. To serve this end, our scholarship program continues to support financially disadvantaged high-achieving undergraduate, graduate and doctoral students majoring in medicine, chemical engineering, biotechnology, molecular biology and genetics at leading schools in Türkiye. Additionally, the Abdi İbrahim Foundation House of Kindness offers free accommodation to children and their families who come from Anatolia to Istanbul for cancer treatment, but do not have financial means to stay in the city. Our 18-room House of Kindness became available at full capacity in a short period of time and is now accepting guests. The Abdi İbrahim Foundation continues its dedicated work, firmly believing that the projects it undertakes for the pharmaceutical industry, the Turkish population, and society as a whole contribute significantly to the future of Türkiye.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

FIRST FOUNDATION PROJECT IMPLEMENTED IN THE FIELD OF EDUCATION

In its first project, the Abdi İbrahim Foundation launched a scholarship program for financially disadvantaged high-achieving students majoring in medicine, chemical engineering, biotechnology, molecular biology and genetics at leading schools in Türkiye. Following the application process and interviews with the candidates, a total of 37 students, consisting of 25 female and 12 male students, were granted undergraduate, graduate and doctoral scholarships. The Foundation started mentoring scholarship holders to support them in their career and personal development journeys. Abdi İbrahim Foundation also provides education scholarships to the children of Abdi İbrahim employees in the form of internal scholarships. Accordingly, scholarship holders receive a one-off payment for stationery at the beginning of the semester, and a monthly education scholarship throughout.

ABDİ İBRAHİM FOUNDATION CONTINUES TO PROVIDE SCHOLARSHIPS

Abdi İbrahim Foundation continued to provide internal and external scholarships in 2022. Twenty-five financially disadvantaged high-achieving students majoring in medicine, chemical engineering, biotechnology, molecular biology and genetics were included in the program. The fact that 69 percent of the 62 scholarship holders at the Foundation are female students reflects Abdi İbrahim's vision of supporting women in all fields.

ABDİ İBRAHİM FOUNDATION HOUSE OF KINDNESS IS NOW OPEN

Launched by the Abdi İbrahim Foundation on December 20, 2022, the House of Kindness Project aims to offer free accommodation to children and their families who come to Istanbul for cancer treatment or check-ups, but do not have the financial means to find lodging in the city. The 18-room Abdi İbrahim Foundation House of Kindness is located in Fatih, Istanbul, and aims to serve approximately 120 families throughout the year with a capacity to accommodate 45 people simultaneously. In January 2023, the House of Kindness started accepting patients with signed and stamped referral forms received from the doctors working in the oncology departments of hospitals, continuing its mission to provide a safe and welcoming environment for children fighting cancer and their families.

Click to see House of Kindness film.



ABDİ İBRAHİM RENOVATES BELMA BARUT PRIMARY SCHOOL

Abdi İbrahim conducted renovation works at Belma Barut Primary School. Speaking at the opening ceremony of Belma Barut Primary School held on September 12, Abdi İbrahim Deputy Chairperson Nesrin Barut Esirtgen said: "Our school, established in 2013 and carrying the name of our mother, provides education to 2,700 students with 24 classrooms, 3 laboratories and 2 kindergartens. This year, we embarked on a comprehensive evaluation to identify the school's most pressing needs. We worked diligently. We are thrilled to have supported the renovation work of our school. We at Abdi İbrahim are committed to supporting this wonderful school and keeping our mother's memory alive."



MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS


HEALTH AND SPORTS

LONG-TERM SPONSORSHIP SUPPORT FOR NATIONAL SWIMMER **EMRE SAKCI**

As part of its Social Investment Program, Abdi İbrahim became the main sponsor of record-holding national swimmer Emre Sakcı. The signing ceremony for the sponsorship agreement was held at the Abdi İbrahim Tower with the participation of Abdi İbrahim Chairman Nezih Barut and Emre Sakcı. Speaking at the ceremony, Nezih Barut said: "As Türkiye's leading pharmaceutical company, we decided to support our athletes who are capable of winning medals for our country by competing in international competitions in the Olympic sport of swimming. We signed a four-year sponsorship agreement with Emre Sakcı, who attracted our attention with his continued success in swimming and became his main sponsor. We will continue our support to ensure that more of our athletes take part in international organizations and achieve more sporting success for our country."



EMRE SAKCI
NATIONAL SWIMMER



I am honoured to be a part of the Abdi İbrahim family. Belonging to such a large and supportive industry-leading company makes me feel safer and stronger. Their support for the individual sport of swimming has instilled great hope in athletes like me who are pursuing their dreams. Young swimmers I know say "If Emre can achieve it, we can do better." This support has also played a key role in our recent international achievements. The youth cares deeply about the world's resources. I'm a big supporter of recycling myself. The sustainability efforts of industry-leading companies give hope to us young people. I believe this is mostly due to the efforts of the companies in the pharmaceutical industry, which is one of the largest industries in the world. As a member of the Abdi İbrahim family, I proudly endorse their endeavours.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

SUPPORT FOR TITLE–WINNER NATIONAL SWIMMER **MERVE TUNCEL**

After world-record-breaking swimmer Emre Sakcı, Abdi İbrahim also signed a two-year sponsorship agreement with national swimmer Merve Tuncel, who holds World and European championships in youth swimming. The signing ceremony for the sponsorship agreement was held at the Abdi İbrahim Tower on November 25 with the participation of Abdi İbrahim Deputy Chairperson Nesrin Barut Esirtgen, Board Member İbrahim Barut, Corporate Relations, Sustainability and Communications Director Dr. Oğuzcan Bülbül and Merve Tuncel.

Stating that sporting achievements are one of the most effective tools in nation branding, Abdi İbrahim Deputy Chairperson Nesrin Barut Esirtgen said: "Merve is a female athlete with a very bright future, representing Türkiye with major achievements in swimming and many records to her name despite her young age. We wholeheartedly believe that she will achieve even more and inspire younger athletes with the support of Abdi İbrahim, just like Emre."



MERVE TUNCEL
NATIONAL SWIMMER



I was introduced to swimming when I was only 4 years old. In the past 13 years, I have always had the full support of my family and my coach in all my achievements. Now I have another very strong supporter as I make strides in my career journey: Abdi İbrahim. Having the support of an industry-leading and well-established company in Abdi İbrahim fills me with pride. The trust placed in us young athletes not only boosts our motivation, but also drives our competitiveness in the international arena. Just like Abdi İbrahim, I will continue to move forward and work with all my strength to represent my country in the best possible way and be the best at what I do. Next up is the Paris 2024 Summer Olympics. Knowing that I have Abdi İbrahim's support with me in every stroke towards flying our flag in the Olympics and brand-new achievements gives me great strength and self-confidence. I would like to thank Nezih Barut, Nesrin Barut Esirtgen, and the entire Abdi İbrahim family for their belief, trust and support in us young athletes.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

“24 BY EMRE SAKCI”


Supported by his main sponsor Abdi İbrahim, national swimmer Emre Sakcı achieved a major feat in 2022, as he made history by breaking the world record in the 50m breaststroke with a time of 24.95 seconds. This moment was a turning point in Emre Sakcı’s life, and it was immortalized along with his other milestones with the “24 by Emre Sakcı” NFT collection. The income generated from this collection, which bears the signature of famous illustrator Kaan Bağcı, will be used to support children fighting cancer. The donations will be made to the Hope Foundation for Children with Cancer (KAÇUV) in the first year, and to the Abdi İbrahim Foundation in the following years.

İSBIKE CYCLING SCHOOL ORGANIZED UNDER THE SPONSORSHIP OF ABDİ İBRAHİM

In accordance with its HEAL2030 sustainability strategy, Abdi İbrahim became the main sponsor of the İsbike Cycling School, which was established by İBB-İSPARK to support healthy living and the use of bicycles as an environmentally friendly means of transportation. The training sessions started on June 3, World Bicycle Day, and continued until the end of September. A total of 10,796 participants received training in the 2021-2022 period. The total number of women who received training was 8,840. Out of all participants, nearly 83 percent (8,840) were women, and 90.86 percent were over 40 years old.



KÜRŞAT CEYLAN
FOUNDING PARTNER, WEWALK



Students who are introduced to the WeWalk smart cane at an early age gain stronger independent movement skills and start using technology more effectively. In doing so, they boost their self-confidence and become more social. The WeWalk team produces technologies for the full and equal participation of all visually impaired people in social and work life. We would like to thank the Abdi İbrahim team for joining us on this journey, and we invite other companies to support our efforts.



PROF. DR. MEHMET HAKAN ÖZDEMİR
HEAD OF OPHTHALMOLOGY DEPARTMENT, BEZMİALEM VAKIF UNIVERSITY



Without a doubt, the most special thing an ophthalmologist can do is to save children from darkness and bring them light. Not only do you improve today, but you also improve tomorrow. Unfortunately, this isn’t always possible. It is estimated that there are more than 40,000 visually impaired individuals in Istanbul alone. And 95 percent of these individuals cannot leave their homes, not even once a week. This reveals the importance of the WeWalk smart cane project, which brings light and courage to visually impaired citizens. I would like to take this opportunity to thank the entire WeWalk team and the Abdi İbrahim family for supporting this meaningful project.

SMART CANES GIFTED TO VISUALLY IMPAIRED STUDENTS

In 2022, the 110th anniversary of its establishment, Abdi İbrahim conducted a meaningful social responsibility project, gifting WeWalk smart canes to 110 visually impaired students. Smart canes, which were developed and produced in Türkiye by Turkish engineers by combining smartphones and canes, were handed out to their owners. The project, having started with the donations raised by Abdi İbrahim employees at the 44th Istanbul Marathon, saw a major expansion in scope with the additional resources pledged by Abdi İbrahim.

MESSAGE FROM THE CHAIRMAN

CEO’S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

SOCIAL INNOVATION IN HEALTH

SOCIAL INNOVATION IN HEALTH & LIFE SCIENCES: WE HEAL THE FUTURE PROGRAM KICKS OFF

As part of its Social Investment Program, Abdi İbrahim launched the “Social Innovation in Health & Life Sciences: We Heal the Future” program on Social Entrepreneurship Day on April 28, 2021.

General objectives of the program
In the fields of health and pharmaceuticals;
- Supporting social start-ups
- Strengthening and scaling ideas for social benefit
- Encouraging ideas for social benefit
- Understanding the potential of social entrepreneurship and developing the ecosystem

Specific objectives of the program
In the fields of health and pharmaceuticals;
- Contributing to the development of creative solutions to problems
- Increasing the number of social start-ups
- Offering social start-ups and aspiring entrepreneurs the opportunity to grow their business

WE HEAL THE FUTURE
Social Innovation in Health & Life Sciences



GREAT TURNOUT FOR THE HEALING IDEAS COMPETITION

Held in 2021 as part of the “Social Innovation in Health & Life Sciences: We Heal the Future” program, the Healing Ideas Competition attracted a great turnout and received 80 start-up applications despite being organized for the first time. The competition was organized in partnership with Ashoka Türkiye, Impact Hub Istanbul and Mikado Sustainable Development Consulting, all of which are key global organizations in the field. The early-stage semi-finalists appeared before the jury on September 30. At the event held in the form of an open session, 4 of the 10 early-stage semi-finalists who made their presentations were selected and included in the incubation program. Advanced stage start-ups made their presentations on October 7. The winner of the advanced stage was “Pons” with their wearable ultrasound technology.

WINNING SOCIAL START-UPS IN THE “HEALING IDEAS COMPETITION” ANNOUNCED

The finals of the Healing Ideas Competition, organized by Abdi İbrahim as part of its “Social Innovation in Health & Life Sciences: We Heal the Future” program, were held at the Abdi İbrahim Tower on February 28. Following the evaluation of nearly 100 applications from all over Türkiye, the winning social start-up of the early stage was the mobile app “My Hospital Friend IDA,” which aims to help children struggling with chronic diseases overcome their fear of hospitals and medical procedures, while improving their psychological resilience. Meanwhile, “BIODIF,” a biotechnology start-up that uses pumpkin shells to produce a low-chemical and vitamin-rich alternative to capsules, received the jury’s special award. The winning social start-up of the advanced stage was “PONS,” which produces wearable ultrasound technology that can perform medical imaging for better, faster and more precise remote monitoring of critical illnesses and women’s health problems.

PONS, the winning start-up of the advanced stage, was given TRY 75,000 in support. The early-stage startups that made it to the finals prepared by receiving intensive business development training, networking support and coaching meetings throughout the incubation program conducted by Impact Hub Istanbul, as well as mentoring support from Ashoka Türkiye and Abdi İbrahim professionals. The first year of the program was completed following the evaluations made among the social start-ups who made their presentations in front of the jury on the day of the finals, as My Hospital Friend IDA received a cash prize of TRY 35,000, while BIODIF received the jury’s special award worth TRY 10,000.



MESSAGE FROM THE CHAIRMAN
CEO’S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS



DOZ: SOCIAL INNOVATION IN HEALTH & LIFE SCIENCES

Abdi İbrahim adopted a whole new approach in the “Social Innovation in Health & Life Sciences: We Heal the Future” project started in 2021 as part of its Social Investment Program by launching the “Doz” program. With “Doz,” which boasts a broader sphere of influence and richer content, Abdi İbrahim will support efforts to strengthen and encourage ideas for social benefit in the fields of health and sustainability for further integration into the start-up ecosystem and utilization of the opportunities offered by Industry 4.0. The program consists of three categories: Early stage, advanced stage and the One Doz Event. Organized in partnership with Impact Hub Istanbul and Mikado Consulting, some of the key organizations in the entrepreneurship ecosystem, Doz focuses on areas of public health and awareness, research and development in the fields of health and pharmaceuticals, inclusion of disadvantaged regions and groups and sustainability solutions, which was added to the program this year.



Click to see more information about Doz.

AYŞE SABUNCU
FOUNDING PARTNER, IMPACT HUB



I believe that the healthcare industry is impactful in nature when it works towards the right purpose and vision. We can see that impact has had an important place in Abdi İbrahim’s long journey since its establishment. Supporting start-ups who have made an impact in health with the DOZ social innovation program, which has been conducted in partnership with Impact Hub Istanbul and Mikado for the last three years, marks the beginning of a new era. I believe that the contributions, expert opinions and unwavering support offered by stakeholders from all levels of the organization for the start-ups in the program set a great example for the healthcare industry. Our dream for the future is for Abdi İbrahim and other health organizations to support start-ups who make an impact on our journey to create a sustainable world, while being a part of their innovative solutions.

MESSAGE FROM THE CHAIRMAN

CEO’S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

RAISING AWARENESS OF SCIENCE IN YOUTH

EXPLORERS OF THE FUTURE PROGRAM


As part of its Social Investment Program, Abdi İbrahim has launched a new project called “Fostering Science Awareness in Youth.” Conducted in collaboration with the social initiative “Bilim Virüsü” to give children and young people the habit of scientific thinking and next generation competencies, the Explorers of the Future Program aims to ensure that high school students gain new competencies, grow up as brave and entrepreneurial individuals and become acquainted with biotechnology. High school students from all over Türkiye are provided with the opportunity to develop themselves and become aware in various fields, from biotechnology to climate crisis, sustainability to scientific thinking, and co-living dynamics to 21st century competencies. As part of the program, which received a total of 10,000 applications in 2022, 547 students were trained, with more than half of the trainees being female. The Explorers of the Future program will continue to guide the youth by expanding its area of influence in the coming period.

GELECEĞİ KEŞFEDENLER ABDİ İBRAHİM | bilim virüsü

ŞULE YÜCEBIYIK
FOUNDER,
BİLİM VİRÜSÜ



With the Explorers of the Future Program, we came together with 547 high school students between the ages of 15-18 who chose the path of science, have strong imaginations, and are determined to direct change. Inspired by people who “explore the future” with their inventions, thoughts and actions, our program enabled high school students to participate in various training sessions and increase their knowledge and awareness in 21st century competencies, scientific thinking, climate and sustainability and co-living dynamics. They were introduced to biotechnology, the profession of the future, as they came together with experts at Biotechnology Explorers workshops. The youth also drew inspiration to develop and implement innovative ideas by exploring the world of entrepreneurship through Entrepreneurship Stories. As a leading company in the fields of science, sustainability and biotechnology, Abdi İbrahim utilized this project to contribute to the future of healthcare and science industries through the youth. The project further reinforced the goal of building a sustainable future. With the Explorers of the Future Program, Abdi İbrahim also focused on innovation, sustainability and scientific development by investing in the talents of the youth. Abdi İbrahim maintained its goal of being a pioneer of transformation in the industry by supporting the leadership potential of the youth who shape the future.



YGA TWINAPP

In order to show children that science is easy and fun, Abdi İbrahim collaborated with the YoungGuru Academy (YGA) to provide various training sessions on STEM and sustainability through TwinApp to 1,200 primary school students across Türkiye, especially in disadvantaged regions. In the project, the pilot program of which was launched in 2022 with 100 5th grade students from Abdi İbrahim Secondary School, 52 Abdi İbrahim students serve as volunteer mentors.

Click to see more information about YGA TwinApp.

MESSAGE FROM THE CHAIRMAN

CEO’S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

VOLUNTEERING FOR SOCIAL NEEDS

ABDİ İBRAHİM VOLUNTEERS LOOKING TO DO GOOD

Having created a systematic volunteering structure as part of its Social Investment Program, Abdi İbrahim aims to provide a sense of belonging and social benefit through various volunteering projects. To serve this end, Abdi İbrahim started holding "Volunteering and Project Development" workshops for its employees in collaboration with Mikado Sustainable Development Consulting. At the end of the training sessions, which were attended by 95 people, Abdi İbrahim employees were able to design and implement their own projects. While it was ensured that the projects covered at least two of the Sustainable Development Goals, the impact was measured, and employees were actively involved. The Stars of the Planet and PatiZinde projects were implemented to provide benefits in different fields.

STARS OF THE PLANET

Developed and implemented by Abdi İbrahim employees, the Stars of the Planet Project aims to have secondary school students in the 5th grade gain awareness of environmental issues and the planet in their schools and the society they live in, and work on improving these issues moving forward. Nearly 1,000 children were reached with the pilot application conducted in a total of five schools in the provinces of Istanbul, Sakarya, Samsun and Izmir in the 2021-2022 academic year. Additional workshops were organized for the children of Abdi İbrahim employees. Nearly 300 Abdi İbrahim children attended the online workshops. The project has 39 active volunteers and completed its first year successfully. The plan is to include new schools and volunteers in the coming years.





PATİZİNDE

Developed and implemented by Abdi İbrahim employees, the PatiZinde volunteering project aims to feed and shelter stray animals, improve their quality of life and raise awareness of Abdi İbrahim employees on the issue. In 2022, awareness meetings were organized, and shelter visits were made in collaboration with associations such as Hepad, Suzy Online, Bakırköy Canları, Yedikule Animal Shelter and Mersin Gözne Shelter. Online training sessions on animal care, adoption and living together were organized for Abdi İbrahim employees. The PatiZinde team has found homes for four strays to date. Nearly 500 kg of food was donated through the project.

SUPPORT FOR THOSE AFFECTED BY THE FIRES

In order to support our citizens and rescue teams affected by the forest fires in Türkiye in 2021, Abdi İbrahim sent an aid truck containing fire-resistant overalls, socks, gloves, shoes, masks, flashlights and burn creams to Muğla on August 4 in collaboration with Borusan Logistics. The medical representative team in Muğla delivered the materials to Muğla Chamber of Pharmacists. Additionally, the aid materials collected in the internal aid campaign were sent to Milas Municipality.





MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

DONATION OF STATIONERY SUPPLIES TO A PRIMARY SCHOOL IN AĞRI

Abdi İbrahim sent stationery supplies for the 2021-2022 academic year to students in need at the Martyr Infantryman Aydın Çetin Primary School in the Çelebaşı village in the Tutak district of Ağrı.

WISH TREE PROJECT

Abdi İbrahim employees made children's dreams come true as part of the International Volunteer Day on December 5, 2021. With the Wish Tree project organized with the Project for Immediate Needs Foundation, Abdi İbrahim employees touched the lives of children on New Year's Eve, as 205 children received the wishes they had written about.

YOUPLUS DONATIONS TO CHILDREN'S SHELTERS IN ISTANBUL

Working with all its strength to heal life and the future, Abdi İbrahim continues its social responsibility activities at full speed. To serve this end, 750 YouPlus products were donated to five children's shelters in Istanbul on December 1-2, 2021.

HAMETOL - YOUPLUS - DISINFECTANT DONATIONS TO SCHOOLS

Abdi İbrahim continues to make donations to various schools in line with their needs. In 2022, Abdi İbrahim donated:

- 27 medicine cabinets to village schools
- Disinfectants to 19 schools in Şırnak and Hametol hand creams to 532 students through the Istanbul University Leaders Club
- 5 YouPlus Multivitamin and YouPlusOmega-3 products for each of the 400 students at the Fatma Nur Çelik Secondary School in Kepez, Antalya
- 1,100 Hametol products to students at the İstiklal Secondary School in Şırnak
- Hametol care cream to 800 students at 5 schools in 4 pilot provinces as part of the Stars of the Planet volunteering project
- 3 boxes (12 liters) of disinfectants to the Bakımlı Primary School in Haliliye, Şanlıurfa
- Internally collected books and 1,200 Hametol creams to 300 village schools in Kars through the Kars Provincial Directorate of National Education

"DO NOT SAY THAT," STARTING FROM TODAY!

As part of the "Do Not Ignore" project, Abdi İbrahim Otsuka (AİO) launched the "Do Not Say That!" campaign on World Mental Health Day, October 10, 2020, to end the "stigma" surrounding the conversation around the topic and continued the campaign in 2021. In the meetings and projects organized for university students, physicians, pharmacists and the general public, more than 3,500 university students and more than 27 million people were reached on social media.

"DETERMINED AND WILLING" ON WORLD CANCER DAY

To support World Cancer Day and draw attention to cancer, the Abdi İbrahim Oncology Team teamed up with the Turkish Association for Cancer Research and Control and collaborated with universities, the public and the industry for a live broadcast on Instagram on February 4, 2021 under the moderation of Sunay Akın. The broadcast was watched live by 1,000 people and viewed by more than 15,000 people.

In order to support February 4th World Cancer Day, Abdi İbrahim Tower was supported the campaign of lighting buildings with orange and blue colors, which is the official campaign color of the International World Cancer Organization (UICC).

Once again, the Abdi İbrahim Oncology Team started a live broadcast on Instagram together with the Turkish Association for Cancer Research and Control on World Cancer Day, February 4, 2022. Moderated by Ceyda Düvenci, the broadcast was watched live by 1,704 people and viewed by more than 32,000 people.



ONE STEP AHEAD OF PARKINSON'S

Abdi İbrahim Parkinson's Group took another step to increase neurologists' awareness of Parkinson's disease on World Parkinson's Day. Lesser-known and interesting facts about Parkinson's disease and its discovery were addressed with 25 minutes of digital content. Prepared in collaboration with Dr. Murat Emre, Honorary President of the Turkish Parkinson's Disease Society, and Ali İhsan Varol, host of the Kelime Oyunu Competition Show, the video was shown to 250 physicians through the presentations made at neurology clinics all over Türkiye during the week of April 12. The awareness-raising video narrated by Ali İhsan Varol was also shared on social media accounts to raise public awareness and incite curiosity about the next stages of the "One Step Ahead of Parkinson's" project.

"WOMEN HEALING A CHANGING WORLD"

As part of International Women's Day on March 8, 2021, the Abdi İbrahim CNS Directorate teamed up with the Psychiatric Association of Türkiye (TPD) to conduct awareness raising activities among physicians and the public throughout the week with the concept of "Women Healing a Changing World." In the field studies conducted throughout the week, psychiatrists were informed about the increasing violence against women since the onset of the pandemic. On March 3, a meeting on the "effects of domestic violence on women's mental health during the pandemic and a forensic psychiatric perspective" was held for psychiatrists. On March 7, a public meeting was held with the women's mental health working unit of the Psychiatric Association of Türkiye to discuss the results of a study on increasing violence against women during the pandemic and what women can do when exposed to violence. Broadcast live on the Instagram and YouTube pages, and official website of the Psychiatric Association of Türkiye, the meeting reached more than 10,000 interactions.



MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

PHILANTHROPY

Allocating significant resources to donations and aid to non-profit organizations in its investment and budget plans in each operating period, Abdi İbrahim continued its donations and aid in 2021 and 2022.

Donations and aid (TRY million)

2020 → **1.39**

2021 → **2.5**

2022 → **11.02**





PURPLE DAY

The Turkish Epilepsy Society held an online press conference in Istanbul as part of Purple Day on March 26, 2022. Striking information was shared at the "Let's Talk About Epilepsy - It is Not as Scary as You Think" meeting held with the contributions of Abdi İbrahim, which has been leading the Turkish pharmaceutical industry for 21 years.

WORLD PROSTATE CANCER DAY

Abdi İbrahim Oncology Team collaborated with the Turkish Society of Medical Oncology in 2022 to raise awareness on World Prostate Cancer Day. An awareness video was prepared with the contributions of Dr. Çağatay Arslan and Dr. Yüksel Ürün. Many people were made aware on the subject with the video shared on social media accounts of the Turkish Society of Medical Oncology and Abdi İbrahim.

WORLD PARKINSON'S DAY

Abdi İbrahim and Turkish Parkinson's Disease Society conducted a meaningful social responsibility project for World Parkinson's Day on April 11, 2022. As part of the Faces That Add Value to Parkinson's campaign, patients with facial weakness revived facial expressions in works of art. These moments were captured by photographer Sefa Yamak. Additionally, the first ever Parkinson's NFT collection on the OpenSea platform was offered for sale. All proceeds were donated to the Turkish Parkinson's Disease Society.

BREAST CANCER AWARENESS MONTH

Abdi İbrahim Oncology Team collaborated with the Turkish Society of Medical Oncology during Breast Cancer Awareness Month, October 1-31, 2022. An awareness video was prepared with the contributions of Dr. Özlem Er. Many people were made aware of the topic with the video shared on social media accounts of the Turkish Society of Medical Oncology and Abdi İbrahim.

WORLD ALZHEIMER'S DAY

Abdi İbrahim supported the press conference held by the Turkish Alzheimer Association at Şişli Alzheimer's Day Care Center to raise social awareness as part of World Alzheimer's Day on September 21, 2022, ensuring that the association's message reached large audiences. The meeting, which was followed by 12 press members and included 6 exclusive interviews, was featured on 165 websites, 37 national and local newspapers, and 3 news programs on TV. After the press conference, patients and their relatives made wishes and released their white balloons into the sky once again.

WORLD HYPERTENSION DAY

Abdi İbrahim Cardiology Directorate conducted awareness activities for both internal and external stakeholders on World Hypertension Day, May 17, 2022. Abdi İbrahim employees were reminded of the ways they can protect themselves from hypertension. By measuring the blood pressure of the employees, attention was drawn to the additional risks that hypertension may cause, and preventive recommendations were given. A video prepared for the occasion was shared on Abdi İbrahim social media accounts for external stakeholders.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

HEALING THE FUTURE OF BUSINESS

Establishing an innovative business and sustainability approach that generates value not just in the short term but also in the medium and long term, Abdi İbrahim heals the future of work with its industry leadership and sense of responsibility.


8 DECENT WORK AND ECONOMIC GROWTH
9 INDUSTRY, INNOVATION AND INFRASTRUCTURE
12 RESPONSIBLE CONSUMPTION AND PRODUCTION
17 PARTNERSHIPS FOR THE GOALS


ABDIIBRAHIM

CORPORATE GOVERNANCE

Adhering to its corporate values and acting with a respectful, inclusive, ethical and responsible approach to people, Abdi İbrahim continues to lead the industry and pursue ambitious goals with its sustainable and innovative business approach.

ABDİ İBRAHİM BOARD OF DIRECTORS



PHARM. NEZİH BARUT
CHAIRMAN



NESRİN BARUT ESİRTGEN
DEPUTY CHAIRPERSON



AHMET KAMİL ESİRTGEN
BOARD MEMBER



AHMET CENAN ESİRTGEN
BOARD MEMBER



İBRAHİM BARUT
BOARD MEMBER



DR. SÜHA TAŞPOLATOĞLU
BOARD MEMBER AND CEO



HASAN AKÇAKAYALIOĞLU
BOARD MEMBER

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

VISION 2025

Attaching a great deal of importance to its innovative management approach to maintain its leading position in the industry, Abdi İbrahim continues to take firm steps towards its goals thanks to its long-term strategic plans and agility in dealing with threats and seizing opportunities. By conducting all its activities from a 3D perspective, Abdi İbrahim aims to achieve positive financial results and a culture that integrates leadership with criteria such as ethical codes, product reliability and transparency.

Developed under the motto "we will be the healing force in a changing world," Abdi İbrahim's new strategic plan VISION 2025" was launched in January 2021. VISION 2025 encompasses five growth areas, eight strategic programs and 45 initiatives that will enable Abdi İbrahim to achieve its desired objectives over the five-year period.

Rapidly progressing towards its objectives in five growth areas, namely "Türkiye, International Markets, Production Services, Consumer Health and Biotechnology," Abdi İbrahim has successfully completed 18 of the 45 strategic initiatives under its global transformation and innovation programs in the pipeline, and already started working on 18 of the remaining initiatives. Abdi İbrahim took major steps in 2021 and 2022 to serve its growth areas, and also implemented various sustainability and social projects to heal society, life and the environment.

5 growth areas
8 strategic programs
45 initiatives



FIVE GROWTH AREAS

1. Türkiye
Aiming to maintain its market leadership in Türkiye and attaching importance to innovative approaches in its Türkiye operations to serve this end, Abdi İbrahim continued to implement transformation programs in 2021 and 2022 within the framework of changing technology and trends. The projects conducted at the Abdi İbrahim Tower and Esenyurt Production Complex with digital solutions increased efficiency, contributed to sustainability processes and created new channels with its customers.

2. International Markets
Working towards its five-year strategy, Abdi İbrahim has conducted key initiatives as part of its growth plans in priority regions and therapeutic areas. Abdi Farma GmBH, Abdi İbrahim's German subsidiary, started to release products in 2022. Abdi Farma s.r.l was established in Milan, Italy. A team was established in the United Arab Emirates, and sales were started. Offices in Saudi Arabia and the United Arab Emirates are still under construction. Studies were continued to come up with strategies for entering priority regions, such as the United Kingdom, Morocco, Uzbekistan, the Balkans, other Gulf countries, the Netherlands, Spain and the United States. Strategic regions were determined for consumer health products standing out among the competition in international markets, and studies were initiated to come up with strategies for market entry.

3. Production Services
Strengthening the superior services it offers in production services with new investments, Abdi İbrahim opened the Sterile Inhalation Facility with the collaboration of GSK Türkiye and the support of the Investment Office of the Presidency of the Republic of Türkiye. Abdi İbrahim also started evaluating projects that will increase the potential for exports as well as the Turkish market in the field of production services.

KÖKSAL ÜLGEN
VICE PRESIDENT OF INTERNATIONAL MARKETS, ABDİ İBRAHİM



Abdi İbrahim conducts important work that will expand its industry leadership in Türkiye to international markets. We continue our operations with various business models in more than 70 countries, and we conduct sales and marketing with our own organizations in 18 countries. Six of the 45 initiatives in our VISION 2025 strategy indicate growth in international markets. We aim to further expand our existing operations in Kazakhstan and Algeria with our innovative product portfolio. We plan to grow further by establishing our own teams in countries such as Germany, the United Kingdom, Italy, the UAE, Morocco and Uzbekistan. We are expanding our portfolio with original generic products from our R&D activities, biotechnology products and strategic collaborations. As for reference products worldwide, we are increasing our collaborations in the fields of sales, marketing and production in the regions in which we operate.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

4. Consumer Health
As part of VISION 2025, Abdi İbrahim aims to expand its leadership in prescription drugs to consumer health and become an international player in the field. The Consumer Health Team operates with a business model that focuses on physicians and pharmacists within the framework of its innovative promotion and sales strategy. Supported with various training sessions to serve this end, the sales team continues strengthening its communication with pharmacists and taking their advice to turn them into brand ambassadors. Strategic decisions are made based on the research conducted in accordance with the views of the target audiences. In our developing world, changing consumer behaviour is observed and media investments are shaped with a focus on digital investments

5. Biotechnology
Continuing to make progress in biotechnology, which it sees as the future of the pharmaceutical industry, Abdi İbrahim aims to develop its own products in biotechnology by improving its R&D and production competencies with strategic investments and partnerships, thus becoming Türkiye's number one biosimilar player. Abdi İbrahim conducted more investment and development activities to serve this end in 2021 and 2022, and still continues to undertake groundbreaking work.

You can find Abdi İbrahim's company policies here.

ASLI BİÇER
GENERAL MANAGER, INOLIVA



Inoliva, which was acquired by Abdi İbrahim in October 2021, aims to offer innovative products that will contribute to the protection of life to serve public health, and support individuals in living a healthy, energetic and happy life. We have managed to achieve many firsts with our brand portfolio in accordance with our holistic health philosophy. Türkiye's consumer health market boasts promising growth figures. We are a growth-oriented company, and consumer health is one of the growth areas in our VISION 2025 strategy. At Inoliva, we want to make the most of the market's growth potential and increase our share in the market with new brands and products that we will introduce to the market in 2023 and beyond. Our greatest desire is to make a difference in Türkiye and other target markets with our soon-to-expand innovative portfolio and innovative ways of conducting business.


DR. ALİ ÖZÜER
GROUP CHAIRMAN, ABDIBIO



AbdiBio is the result of Abdi İbrahim's innovative and visionary approach, making them a leader in the Turkish pharmaceutical industry. Biotechnology is a sector that many nations prioritize in today's changing global landscape. Most biotech products in the market are usually imported. With the establishment of our AbdiBio facility, our goal was to develop and manufacture these imported products right here in our country. In 2018, we invested $100 million to launch AbdiBio, aiming to create our own biotechnological drugs meeting international standards. This not only improves patients' access to medicines but also contributes significantly to our country's economy. In 2021, we inaugurated the Process Development Laboratory for conducting fundamental studies on the biotechnological products, starting from the cell bank. Currently, we are in the process of procuring and installing reactors and auxiliary units for our mAb production area, set to be operational by August 2023. Our ambition is to generate double added value by exporting to global markets, particularly the United States and European Union countries. Under our VISION 2025 strategy, we are diligently working towards becoming Turkey's top biotechnological drug manufacturer. Our ultimate goal is to ensure that the advanced treatment methods we develop using high technology are accessible to every individual, guided by science and a strong focus on innovation.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

ORGANIZATIONAL STRUCTURE



MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

BUSINESS ETHICS PRINCIPLES

With a desire to carry the trust and respect of its stakeholders into the future, Abdi İbrahim feels obligated to remain faithful to the guiding principles of business ethics in all its business processes.

Having regarded human health as its first and foremost responsibility since 1912, Abdi İbrahim believes in the value of doing business in a complete, correct and honest manner and sets its standards at the highest level possible. Abdi İbrahim Business Ethics Principles reflect the company's loyalty and commitment to basic business conduct and business ethics principles in accordance with its responsibilities to all its stakeholders.

Manufacturing and releasing all its products while using the highest technology and meeting the quality and safety conditions in all legal regulations, particularly those stipulated by international standards and intellectual property rights, Abdi İbrahim follows the principles of ethics and transparency in all its business processes. It sees product safety as an essential principle. Abdi İbrahim successfully passed the audits conducted in 2021 and 2022 on its pharmacovigilance system and cGMP certified production facilities by national and international health authorities and organizations.

ETHICS HOTLINE

At Abdi İbrahim, notifications such as notices and complaints can be made to the Ethics Committee via email (etikhat@abdiibrahim.com.tr), regular mail and telephone. Internal stakeholders (employees) and external stakeholders (suppliers, doctors, pharmacists and patient groups) can contact etikhat@abdiibrahim.com.tr and the phone numbers on the company website. Upon notification of any unethical behaviour by an employee, the relevant business unit director transfers the issue to the Ethics Committee. Ethical violation notifications are evaluated by the Ethics Committee. If deemed necessary, the Ethics Committee submits any requests for examining and investigation to Human Resources.

Number of complaints and feedback received by the ethics hotline

2021 → **34**

2022 → **40**

Complaint resolution rate (%)

2021 → **100**

2022 → **100**

Click to see Abdi İbrahim's Business Ethics Principles.

INTERNAL AUDIT

The Internal Audit Department, which operates as an independent and impartial body within Abdi İbrahim, audits the internal control system along with the effectiveness, efficiency and legislative compliance of the operations.

Operating since 2006, the Abdi İbrahim Internal Audit Department continues its activities in line with the Audit Committee Regulation and Internal Audit Regulation with a focus on adding value to the Company's risk management, control and corporate governance processes. The Abdi İbrahim Internal Audit Department also works on Data Analytics and Online Action Tracking Tool projects. Launched in 2022 and conducted in coordination with Abdi İbrahim Teknoloji, the Data Analytics Project aims to provide the ability to immediately intervene in control errors, irregularities and abuse with a proactive approach and interpret larger data volumes and gain speed by improving remote audit competence in the processes of the relevant areas of activity. The project's supplier and buyer master data modules have been completed, and the modules for procurement and sales processes are set to be completed in 2023. The Online Action Tracking Tool Project was started in September 2022 with the goal of storing all audit findings and actions on a single platform, automatically informing action owners by tracking action time plans through the system and logging all changes. The project is set to be completed in 2023.

Abiding by social norms and Business Ethics Principles as well as legal regulations in all its business processes, Abdi İbrahim considers internal and external control, early warnings and auditing activities to be strategically important. Accordingly, the Company meticulously fights against corruption and bribery. Without compromising on accountability, transparency and ethical values in the fight against corruption and bribery cases that it may encounter in its internal and external business processes, Abdi İbrahim avoids any financial dependence in its business relations and accurately informs the organizations it cooperates with and the public with regards to its financial and operational data in full.

Having achieved a high reputation in the public eye thanks to its long-established corporate culture, Abdi İbrahim did not encounter any corruption or bribery cases during the reporting period.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

REPUTATION MANAGEMENT

With more than 100 years of experience and expertise, Abdi İbrahim is steadily strengthening its long-established corporate culture, brand awareness and reputation in the eyes of the public.

Boasting a high reputation due to its sensitivity towards product responsibility and high product quality, Abdi İbrahim continues all its R&D studies and clinical research for product development within the framework of National Legislation as well as international regulations and medical ethics, as stated in the Principles of Ethical Conduct. Abdi İbrahim achieved high reputation scores in various research studies thanks to this approach and its determined efforts in reputation management. The Company was recognized as the "Most Reputable of the Year" in the pharmaceutical industry by public opinion in the 2020 and 2021 editions of The ONE Awards.

Abdi İbrahim also conducts corporate perception and reputation research. This enables the Company to see where it stands and shapes its road map accordingly. The Corporate Perception and Reputation Research conducted in 2019 with a sample group of 3,500 stakeholders, including employees overseas, showed that Abdi İbrahim was the most recognized and admired company and the first one to come to mind in the industry for many stakeholders.

BEST PHARMACEUTICAL COMPANY IN TERMS OF SUSTAINABILITY

With the sustainability research it conducted in 2021 with a sample group of 2,500 people, including five stakeholder groups, Abdi İbrahim obtained key data that will guide its sustainability strategy and steps for the future. The research showed that Abdi İbrahim was the best pharmaceutical company and the first one to come to mind in terms of sustainability in the eyes of healthcare professionals.

ABDİ İBRAHİM CALL CENTER

Adopting the principle of developing relationships and collaborating with its stakeholders based on mutual communication and transparency, Abdi İbrahim promptly responds to questions and requests received by its call center.

Abdi İbrahim operates a call center to quickly respond to inquiries, reports, and requests, ranging from information about side effects to representative requests, job and internship applications to sponsorship requests, international medicine supply to quality-related questions, and counterfeit product reports.

The Abdi İbrahim Call Center responds to all questions and requests submitted 24/7 via phone or email in accordance with the Personal Data Protection Law based on the guidance of the relevant units, enabling the development of products and services based on long-term feedback and end-to-end tracking from a single center.

With the expansion of the Abdi İbrahim Call Center, a new system was introduced in July 2022 and a total of 1,844 calls were recorded in 2022.





MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

PERFORMANCE

The industry leader in Türkiye since 2002, Abdi İbrahim continues to demonstrate a successful performance, both financially and operationally, with the production capability of its facilities in Türkiye, Kazakhstan, Algeria, its investments and its extensive product portfolio.

FINANCIAL AND OPERATIONAL INDICATORS

TOTAL TURNOVER
USD million

2019	639.40
2020	621.9
2021	595.6
2022	612.6

BRANDS*

2019	185
2020	193
2021	217
2022	228

INVESTMENTS***
USD million

2019	76.8
2020	61.4
2021	65.3
2022	53

TOTAL SALES*
Million units

2019	202
2020	199
2021	221
2022	243

PRODUCTS*

2019	380
2020	403
2021	435
2022	458

EMPLOYEES***

2019	4,560
2020	4,452
2021	4,598
2022	5,383

DOMESTIC MARKET SALES*
Turnover in USD, %

2019	6.15
2020	6.05
2021	6.11
2022	6.16

EXPORTS**
USD million

2019	84
2020	100
2021	115
2022	111

R&D EXPENDITURES
TRY million

2019	63.9
2020	63.0
2021	101
2022	192

* January-December 2022 IQVIA Retail Dataview data.
** Total sales volume in Türkiye and other markets.
*** Includes overseas operations and subsidiaries.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

PRODUCTION

Abdi İbrahim continues to heal lives and the future worldwide with its high-tech production facilities in Türkiye, Kazakhstan, Algeria.

ESENYURT PRODUCTION COMPLEX (ISTANBUL, TÜRKİYE)

Established in Istanbul in 1996 with a USD 100 million investment and spanning across 83,000 square meters, the Esenyurt Production Complex produces solid, semi-solid and liquid products with a workforce of over 1,500 employees. The GMP- and GLP-compliant facility employs modern and environmentally friendly technologies, and facility processes are continuously improved through investments in technology and automation systems, enhancing traceability and efficiency. Providing contract production services to both domestic and international business partners, the Esenyurt Production Complex produced 326 million units in 2021, and 391 million in 2022, with 34 percent of the total production made for some of the leading pharmaceutical companies worldwide.

2021 →
326 million units

2022 →
391 million units

The Esenyurt Production Complex, audited and approved by authorities and organization from leading countries in pharmaceutical production in Europe and worldwide, underwent successful assessments by 50 health authorities and customers in 2021 and 2022.

You can access the audit reports here.





MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

ABDİBIO BIOTECH PHARMACEUTICAL PRODUCTION FACILITY (ISTANBUL, TÜRKİYE)

In a significant step toward localizing the production biotech pharmaceuticals, which are almost entirely imported in Türkiye, Abdi İbrahim initiated the AbdiBio facility in 2018, with a USD 100 million investment. AbdiBio, Türkiye's largest biotech pharmaceutical manufacturing facility, occupies a total area of 13,500 square meters.

Boasting an annual production capacity of 11 million vials, 11 million syringes, 16 million cartridges, and 1 million lyophilized products, AbdiBio is able to handle all stages of production from cell bank to final product. Biotech drugs produced at AbdiBio are intended to address various diseases that cannot be cured using chemically synthesized drugs, such as cancer, diabetes and rheumatism, as well as blood disorders, gastroenterological, dermatological and immunological diseases. AbdiBio's production will not only be introduced in Türkiye but also exported, positioning the country as a global player in the biotechnology market.

In 2020, AbdiBio was enhanced with the establishment of the Bioanalytical Laboratory for the analysis and characterization of proteins and protein-derived molecules, followed by the Process Development Laboratory, equipped with 3L, 15L, 50L, and 200L bioreactors for monoclonal antibody (mAb) production, which was added in 2021. Under the mAbdi2 project, a cell line for producing biosimilars was developed in 2021 in partnership with the US-based CRO, and the rights to the Research Cell Bank (RCB) vials, which are protected under this agreement, were transferred to AbdiBio. This stage marked the successful development and integration of Abdi İbrahim's first cell line capable of producing biosimilars. MAb production was conducted in 3L and 15L bioreactors, with comparative analyses performed against reference products. Through the production of mAbdi2 in 3L scale using various process parameters, the desired limits were achieved for critical quality parameters, including main, basic and acidic variants.

Another investment involves the ongoing infrastructure and equipment efforts for mAb production areas. The goal is to complete all facility and equipment installations and initiate Türkiye Ministry of Health Good Manufacturing Practice (GMP) procedures by the end of 2023. Upon activation, production of biosimilars will occur in larger bioreactors, including 500L, 1000L, and 2000L scales. This will mark the establishment of a high-value biotechnological mAb production platform in Türkiye. In parallel, the human resource to be trained and the know-how to be acquired through the biotech products of this platform will make it one of the main stakeholders of a strong biotechnological ecosystem in Türkiye.





MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

HORMONE PRODUCTION FACILITY (ISTANBUL, TÜRKİYE)

620 metrekarelik bir alana sahip olan Hormon Üretim Tesisi, 2018 yılında üretime başladı. Türkiye'de bu yöndeki önemli bir ihtiyacı giderecek kapasitedeki tesis, Avrupa Birliği otoritesinden onay alan ilk hormon üretim tesisi olma özelliğini taşıyor.

STERILE OPHTHALMOLOGY AND STERILE INHALATION PRODUCTION FACILITY (ISTANBUL, TÜRKİYE)

The Sterile Ophthalmology and Sterile Inhalation Facility, spanning 2,500 square meters, began production in 2020. Additional equipment investments were made for the facility, which has an annual production capacity of 600 million BFS and 20 million vials. Developed jointly by Abdi İbrahim and GSK Türkiye and with the support of the Turkish Presidency Investment Office, the Sterile Inhalation Facility was inaugurated on December 8, 2022. The EUR 18 million facility will enable Türkiye to benefit from the advanced nebule technology used in the treatment of respiratory diseases, and also holds the distinction of being the first of its kind in the world that is capable of manufacturing the complete range of GSK's nebule portfolio. With the culmination of the technology, know-how and expertise of the two companies, the facility will contribute to the growth of domestic production of pharmaceuticals in Türkiye and produce 600 million nebules with a total value of TRY 2 billion within the next five years.

ABDI İBRAHIM TECHNOLOGISTICS CENTER (ISTANBUL, TÜRKİYE)

The Abdi İbrahim Technologistics Center, which boasts an indoor area of 22,600 square meters and a total storage capacity of 14,500 Euro-pallets, was launched in 2010 with an investment of USD 35 million. The center, featuring fully automated processes for all material handling, represents the pinnacle of technological advancement in logistics. The center sees an average daily movement of 1,200 pallets, which are stored and handled in an environment where temperature and humidity are controlled 24/7 through a building monitoring system.

In 2022, approximately 7,500 Euro-pallets of pharmaceuticals were exported to 53 countries from the Technologistics Center, and over 38,000 Euro-pallets of pharmaceuticals were shipped to 26 companies receiving production services. The finished goods warehouse handled approximately 87,000 pallet movements during the year.





MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

ABDİ İBRAHİM R&D CENTER (ISTANBUL-TÜRKİYE)

Since its founding, Abdi İbrahim has nurtured a robust R&D culture, which culminated in the establishment of Türkiye's first and largest accredited pharmaceutical R&D center, spanning 13,600 square meters, with an investment of USD 40 million. Equipped with state-of-the-art formulation and analytical method development laboratories, the R&D Center has the ability and infrastructure to develop pharmaceuticals utilizing the inhalation technology and nanotech methods to meet the changing and evolving needs of the national and international pharmaceutical industry.

Specializing innovative product development, achieving high success rates in bioequivalence studies, accelerating reference product development, and preparing Common Technical Document (CTD) files for Türkiye, Europe and other regions, the R&D Center also engages in know-how transfer through collaborative projects with scientific institutions in Türkiye and abroad.

As one of the leading pharmaceutical companies in terms of R&D projects, Abdi İbrahim is committed to maintaining its leadership position through development projects, process improvements, alternative resource initiatives and university-industry collaborations.

The Abdi İbrahim R&D Center is a member of the TÜBİTAK 1004 Centers of Excellence Support Program consortium. Together with ARGEFAR and Ege University, the consortium aims to develop a new antiviral drug.

INTELLECTUAL AND INDUSTRIAL PROPERTY RIGHTS

Boasting a global competence in pharmaceutical production, Abdi İbrahim has 256 patent applications in Türkiye, Europe, and internationally, and holds 29 registered patents in Türkiye and 11 in Europe as of the end of 2022.

Patent applications (2022)
256

Registered patents (2022)
40



3D PRINTING OTC PROJECT

Abdi İbrahim's R&D and innovation efforts are primarily centered around high-value-added products that demand advanced technology. These products are believed to provide the company with a competitive edge in both domestic and international markets. Abdi İbrahim, placing significant emphasis on its R&D vision and its contribution to ongoing work to pioneer distinctive products and business models in the consumer health sector, is actively exploring 3D printing technology. This initiative addresses evolving consumer habits and expectations, aligning with the 21st-century business paradigms of the pharmaceutical industry. This technology enables the precise creation of dosage form structures, facilitating patient-centered treatments, such as personalized dosing. It enhances drug product design to cater to specific disease states or consumer demographics. With an increasing focus on the digitalization of pharmaceutical production processes, Abdi İbrahim has accelerated its efforts through a partnership with Hacettepe University. Should the studies, initially conducted on consumer health products, prove successful, there are plans to scale production based on individualized content and dosage requirements.

UDAYA DUDE
R&D DIRECTOR, ABDİ İBRAHİM



At the core of our R&D and innovation efforts are high-tech, value-added products that we believe will provide our company with a competitive edge in both national and international markets. We are committed to differentiating our products and business models in the field of consumer health and continuously working on producing our biotech pharmaceuticals. Our R&D vision plays a crucial role in these endeavours. The R&D Center has the ability and infrastructure to develop pharmaceuticals utilizing the inhalation technology and nanotech methods to meet the changing and evolving needs of the national and international pharmaceutical industry. In addition to a variety of internal projects, we also collaborate with scientific institutions inside and outside Türkiye on joint projects, contributing to the transfer of know-how. We will continue our R&D activities unabated, guided by our vision of progressing towards the future of our country and our pharmaceutical industry.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

ABDİ İBRAHİM GLOBAL PHARM (AİGP) R&D CENTER AND MANUFACTURING FACILITY (ALMATY, KAZAKHSTAN)

Abdi İbrahim established Abdi İbrahim Global Pharm (AİGP) by acquiring a 60% share of Global Pharm, one of Kazakhstan's leading pharmaceutical manufacturers, in 2012. Serving as Abdi İbrahim's first production facility outside Türkiye, AİGP occupies 12,000 square meters of indoor space and began operations in 2015 with an annual production capacity of 24 million units. Recognized as Kazakhstan's most modern GMP production facility, AİGP boasts a wide product portfolio of approximately 100 pharmaceuticals, including diabetes drugs, antivirals and pharmaceuticals used in the treatment of cardiovascular and central nervous system conditions. By offering innovative pharmaceuticals, AİGP aims to contribute to the pharmaceutical sector in Kazakhstan and become a leader in pharmaceutical exports to the Commonwealth of Independent States (CIS) countries through a multi-dimensional marketing approach.

ABDİ İBRAHİM REMEDE PHARMA (AİRP) R&D CENTER AND MANUFACTURING FACILITY (ALGIERS, ALGERIA)

Having opened its first overseas representation office in Algeria in 1999, Abdi İbrahim joined forces with Remede Pharma in 2014 to create Abdi İbrahim Remede Pharma (AİRP) and undertook the most modern factory investment in the country. The GMP-certified AİRP began operations in 2017 on a site covering an area of 5,678 square meters and boasts an annual production capacity of 51 million units, with a product range that includes cancer and diabetes drugs, antipsychotics, antidepressants and urology, iron, and respiratory products.





MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

INVESTMENTS

Since its founding, Abdi İbrahim has always viewed investments as contributing to "production, employment and exports." The Company sustained its investments during the turbulent years of 2021 and 2022.

With an unwavering passion for investment, Abdi İbrahim took significant steps both in Türkiye and international markets in 2021 and 2022. Among the prominent investments realized by the Company are the following:

ABDİBIO PRODUCT DEVELOPMENT LABORATORY

The Biotechnological Product Development Laboratory was established within the AbdiBio Biotech Pharmaceutical Manufacturing Facility. The 300-square-meter laboratory commenced operations in 2021, facilitating not only product development but also the production of small-batch products.

ADDITIONAL PRODUCTION AND ONCOLOGY FACILITY

The Additional Production and Oncology Facility, situated on an area of 59,500 square meters, commenced operations in 2022. The facility will produce products in various forms (conventional and semi-solid). Investments are being made in production capacity expansion projects, new production equipment and modernization projects featuring state-of-the-art production equipment.

In 2021 and 2022, numerous equipment and revision investments were made for production areas, quality control and R&D departments in Abdi İbrahim's production facilities in Istanbul, Kazakhstan and Algeria.

OM PHARMA (SWITZERLAND)

In a historic move towards becoming a strong international player, Abdi İbrahim acquired OM Pharma, a pharmaceutical company with 83 years of history in Switzerland, in 2020 through a joint venture with a Swiss consortium. After the acquisition, which carried a price tag of Swiss francs 500 million (over TRY 5 billion), Abdi İbrahim, the sole foreign partner in the consortium, now owns 28.5 percent stake in OM Pharma.

With this partnership, some of the chemical pharmaceuticals in OM Pharma's portfolio will be manufactured at Abdi İbrahim's Esenyurt Production Complex for worldwide distribution. This collaboration will also enable Abdi İbrahim to expand its presence in new markets, including Latin America, China and the United States.



Investment*
(USD million)

2020 → **61.4**
2021 → **65.3**
2022 → **53**

* Includes overseas operations and subsidiaries.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

MARKETING AND SALES

Abdi İbrahim serves humanity with 228 brands and 458 products through Türkiye's most competent and extensive marketing-sales team, comprising approximately 3,000 individuals, of which 2,500 are in the field.

As the company with the most extensive brand and product portfolio in the Turkish pharmaceutical sector, Abdi İbrahim contributes to human health in almost every therapeutic area. In addition to improving its existing products, Abdi İbrahim aims to heal more and more lives with each passing year by creating new and strong brands, while taking its services to 120,000 physicians and pharmacists nationwide through its highly organized 2,500-strong field team. In its sales and marketing channels, the Company embraces an effective and efficient approach that aligns with evolving technology and changing industry conditions.

In the years 2021-2022, the period of transitioning back to normal after the pandemic, Abdi İbrahim continued industry leadership by focusing on new launches while returning to its previous dynamics. During this period, 27 product launches were executed. The 2,500-strong field team and the 260-person head office marketing and sales team engaged in various efforts to create more value for the customers. Activities were organized to better understand the needs of healthcare professionals, provide them with accurate information at the right time and offer support. The marketing and sales team, which began using digital channels more extensively (DOZ digital), focused on cross-product projects to benefit healthcare professionals.



MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD


FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

INTERNATIONAL MARKETS



Abdi İbrahim, operating in more than 70 countries with various business models, is taking significant steps to extend its success in the Turkish pharmaceutical sector to international markets.

Abdi İbrahim manages all its international operations with a 624-person International Markets team and aims to consolidate its position in the countries where it operates. With a focus on taking its leadership success in Türkiye to foreign markets, the Company is taking significant steps to license Abdi İbrahim products to foreign firms, establish long-term partnerships and increase its overseas sales revenue and markets.

Abdi İbrahim is also strengthening its collaboration in reference product sales, marketing and production activities across the globe, and it is planning to expand its existing operations in Kazakhstan and Algeria with an innovative product portfolio. Abdi İbrahim's priority markets for portfolio expansion, acquisitions, joint ventures, and other partnerships are the US, Canada, Germany, the UK, Italy, Spain, Switzerland, the United Arab Emirates, Saudi Arabia, Morocco, Uzbekistan and the Balkans.

Number of licensed products in international markets

1,261

Abdi İbrahim's own company, factory, and sales force

- Türkiye
- Algeria
- Kazakhstan
- Iraq
- Azerbaijan
- Georgia
- Germany
- Portugal
- Albania
- Bosnia and Herzegovina
- Kosovo
- North Macedonia
- Tunisia
- Saudi Arabia
- UAE
- Italy
- Uzbekistan

Products sold through distributors/licensing

- Afghanistan
- Australia
- Austria
- Belarus
- Belgium
- Bahrain
- Bulgaria
- Czech Republic
- Denmark
- Estonia
- Morocco
- Philippines
- Finland
- France
- South Africa
- South Korea
- Croatia
- Netherlands
- Hong Kong
- Jordan
- Vietnam
- Yemen
- Greece
- UK
- Ireland
- Spain
- Sweden
- Switzerland
- Italy
- Canada
- Qatar
- TRNC
- Colombia
- Kuwait
- Latvia
- Lithuania
- Libya
- Lebanon
- Hungary
- Norway
- Uzbekistan
- Panama
- Poland
- Romania
- Russia
- Serbia
- Slovakia
- Ukraine

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

SUPPLY CHAIN AND PROCUREMENT

Abdi İbrahim maintains its relationship with domestic and international partners in the supply chain within the framework of ethical values such as honesty, fairness, transparency and integrity, with a focus on establishing sustainable partnerships.

Abdi İbrahim conducts procurement operations in three main areas: direct materials, indirect materials and investments. These operations are planned in line with the company's long- and short-term policies. The selection of suppliers and the improvement of business processes are among the top priorities for Abdi İbrahim in the procurement processes. Abdi İbrahim prefers working with companies that can be relied on for long-term and sustainable cooperation and pays the utmost attention to the compliance of its suppliers with legal regulations and ethical rules in the field of occupational health and safety. Abdi İbrahim also endeavours to enhance the sustainability performance of its suppliers. Abdi İbrahim bases its supplier contracts as well as control processes and procedures on the provisions of the Labor Law No. 4857, and it has more than 2,000 suppliers through which it conducts both direct and indirect procurement.

Abdi İbrahim's procurement and supply activities are based on the universal principles of:

- Quality
- Efficiency
- Safety
- Ethics
- Protection of society and the environment

Suppliers

2021 → **1,886**

2022 → **2,018**

The ratio of local suppliers to all suppliers (%)

2021 → **69.93**

2022 → **72.15**

UFUK GÜLER
PROCUREMENT DIRECTOR, ABDİ İBRAHİM



As a domestic player, local sourcing has always been one of our top priorities. In this context, we had various localization projects in many fields. These were done gradually, as needed. As a company, we had reached the best costs we could achieve with a strong supplier network and standard negotiation processes, and we needed to differentiate ourselves. With the impact of the COVID-19 pandemic, we decided that we needed to focus more on domestic supply. Regarding localization, we focused on six main categories: machinery, spare parts, chemical excipients, chemical reagents, consumables, small devices and equipment. We positioned localization within our procurement strategy. Then, by visiting more than 100 suppliers, we ensured the domestic supply of over 70 critical products and services that we required. As we started to see results from this project, we received positive feedback not only from other pharmaceutical companies but also from suppliers and the public. As the benefits emerged, we decided that we needed to manage the project in a more comprehensive and systematic manner. We also expanded its scope to create a pharmaceutical auxiliary industry in Türkiye. We organized a workshop with all stakeholders and named this project "FOCUS." We introduced our project to various public and private institutions such as the Pharmaceutical Industry Employers' Association, the Istanbul Chamber of Industry, the Machinery and Chemistry Bureau and the Ankara Development Agency. We transformed FOCUS from an internal Abdi İbrahim project into a larger initiative involving the entire pharmaceutical industry in Türkiye. The impact of every department, including blue-collar colleagues and senior management, was essential in bringing our project to fruition.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

FOCUS PROJECT

As part of the HEAL2030 sustainability strategy, Abdi İbrahim has launched a unique project for the localization of the pharmaceutical supply chain. Developed in partnership with the Sustainability Steps Association (SADE), the FOCUS project aims to overcome supply chain issues while also creating direct value for the national economy and the pharmaceutical industry in the form of reduced current account deficit, higher supplier diversity, sustainable drug production, lower national budget outflow, shorter delivery times and international expansion opportunities for suppliers.

The project's advantages include
- Sustainable pharmaceutical production
- Preventing outflow of national budget
- Cost reduction
- Shorter delivery times
- Quick maintenance and technical support
- Accurate product supply
- Support for suppliers to expand internationally

Localization categories in the project
- Pharmaceutical excipients
- Chemicals and reagents
- Machinery and equipment
- Spare parts
- Laboratory equipment
- Consumables

You can find the FOCUS project video here.



LOCALIZATION OF ACETONITRILE

ACN (Acetonitrile), the most commonly used reagent in the laboratories of pharmaceutical factories, is imported from abroad. After long efforts, Abdi İbrahim, which consumes around 35 tonnes of ACN annually, has successfully completed the process of domestic production of the chemical. The joint work of Tekkim Kimya, a chemical company based in Bursa, Türkiye, and Abdi İbrahim's own project team has led to the synthesis of HPLC-quality ACN with a purity of 99.9 percent, which successfully passed all acceptance criteria and laboratory trials within Abdi İbrahim. The project has enabled Abdi İbrahim to produce the reagent for its own usage while also establishing the capacity for domestic production of the reagent in Türkiye. Abdi İbrahim aims to increase the capacity of suppliers to meet the needs of the entire sector in the years ahead.



LOCALIZATION OF ALCOHOL

Alcohol, one of the most important inputs of pharmaceutical production, which Abdi İbrahim uses for both commercial production and cleaning purposes, was produced locally by Omnia. Abdi İbrahim's Esenyurt Production Complex uses around 220,000 liters of alcohol annually, a demand that was met via imports through domestic distributors until recently. Exploring the feasibility of domestic production of the chemical, Abdi İbrahim joined forces with Omnia, an Adana based chemical firm. After the relevant documentation studies and trials were completed, the domestically produced alcohol was approved for use in pharmaceutical production.

MERYEM TOP
COMMERCIAL DIRECTOR, OMNIA



For Omnia, it is a source of pride to be able to contribute to Abdi İbrahim's sustainability goals as a stakeholder. As one of the leading raw material producers in Türkiye, we regard the "FOCUS Project" as our way of repaying our debt to our country. With this project, we have added pharmaceuticals to the list of industries we provide raw materials to inside and outside Türkiye, alongside food, cosmetics, personal care and hygiene and industrial chemicals. In collaboration with Abdi İbrahim, whose mission is to heal lives, we have developed the first pharma-grade ethanol in Türkiye, contributing to the localization efforts.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

MEDICAL

Abdi İbrahim focuses on various treatment areas with its extensive product portfolio and demonstrates an approach that sets it apart in the industry in all business processes, from clinical research to product safety, licensing, market access and promotion.

Medical Directorate, which focuses extensively on product and service quality, conducts its work in a wide range of fields within and outside the company, in accordance with legal and ethical values, forming strategic partnerships.

BUSINESS DEVELOPMENT AND NEW PRODUCTS

The Medical Directorate, actively involved in the development of new products in line with Abdi İbrahim's goals, also contributes to the Business Development Department's evaluation of scientific ideas, new treatment trends and corporate strategies. Throughout 2022, the medical team took part in several key projects and product inquiries from the R&D and Business Development departments, preparing the portfolio content for the field of diabetes. Similar work was conducted for hematology, oncology, CNS, respiratory and ophthalmology, resulting in the creation of new products and portfolios, as well as the formation of advisory boards with input from leading opinion leaders in the respective fields, who provided valuable insights for future portfolio preparations in the Business Development Department. The Medical Directorate also continued to contribute to the assessment of products from an investment perspective in 2021 and 2022.



MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

TRAINING

The Medical Directorate takes responsibility for the basic medical, pharmacovigilance, ethical and compliance, promotion activities and product trainings for new medical representatives and marketing teams at Abdi İbrahim. Each medical representative at Abdi İbrahim receives 60 training sessions per year. The training period, which is typically 3-4 days on average worldwide, amounts to 12-13 hours at Abdi İbrahim, with a total annual training duration of 86 hours.

During the pandemic, the Medical Directorate set an important precedent in the Turkish pharmaceutical sector by digitizing all medical training, launching the digital education platform, Aİ Med Academy, in the first quarter of 2021 as the first step of its digital transformation. In 2022, 88% of the 95,578 hours of training provided to promotion teams were conducted through digital platforms, while the remaining 12% was delivered through face-to-face classroom training.

60 sessions of medical representative training, totaling **86** hours per year

95,578 hours of training for promotion teams in 2022

88% digital, **12%** face-to-face training

Over 1,000 scientific and product demonstration meetings



A bulletin called “Bilimsel Gündem” prepared within the Medical Directorate shares all new developments in the field of popular medicine concisely and effectively. This bulletin, which reaches approximately 22,000 healthcare professionals every 15 days via email, is also shared on Abdi İbrahim’s social media accounts. The bulletin is also shared in a podcast format, increasing its accessibility.

PROMOTION

The Medical Directorate continuously works on making the content and messages of all scientific materials used by Abdi İbrahim’s sales team compatible with digital platforms, ensuring the compliance of such content with regulations on SPC information promotions, and delivering up-to-date and objective disease and treatment data to healthcare professionals. The Directorate, which has approved over 1,000 scientific and product promotion meetings to date, continues to deliver scientific content to these meetings. In addition, as a member of the Pharmaceutical Manufacturers Association of Türkiye (İEİS), the Medical Directorate plays a leading role in proposing regulatory changes to the Turkish Medicines and Medical Devices Agency (TİTCK) as well as in defining the sector’s ethics and rules.

Furthermore, the Medical Directorate participates in congresses and symposiums organized for external stakeholders, especially in digital environments, and supports all scientific and product promotion meetings organized throughout the year by sharing information obtained from online advisory boards and publishing clinical study results. In addition, on public health awareness days, the Medical Directorate contributes to public awareness by sharing informative short articles about the relevant disease and general treatment principles.

ABDİ İBRAHİM SCIENCE AWARDS

In 2022, the Medical Directorate initiated a new program called Abdi İbrahim Science Awards to strengthen Abdi İbrahim’s scientific engagement with young researchers and new-generation physicians. The Abdi İbrahim Science Awards support scientific studies related to Abdi İbrahim’s fields of activity, its products or its treatment areas. To date, nearly 50 researchers from 16 specialties were granted the Abdi İbrahim Science Awards, upon the year-long evaluation of a panel of jurors.

DR. RECEP ERŞAHİN
MEDICAL DIRECTOR, ABDİ İBRAHİM



Following the digital transformation, we gave priority to improving our systemic infrastructure in 2022. We are expanding the coverage areas of the pharmacovigilance and medical information services within the Medical Directorate in parallel with our company’s ongoing global growth and goals. For the first time in our company’s history, on a global scale we commenced infrastructure work to centralize data for pharmacovigilance and medical information, and we plan to complete this process by the end of 2023. As a result, data related to products from the geographies where we operate worldwide will be collected in a single center and will be reportable to all country authorities at the push of a button. With all these preparations coming to life, we are meeting an essential infrastructure requirement for our global journey and becoming ready for inspections by public authorities.

MESSAGE FROM THE CHAIRMAN

CEO’S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

CLINICAL TRIALS

Abdi İbrahim continues to conduct clinical trials on a regular basis, aiming to develop new treatment methods, and improve or compare existing ones.

Abdi İbrahim increases its budget for clinical trials every year and ensures that all trials are in line with relevant legal regulations, such as Good Clinical Practices (GCP) and, primarily, the Clinical Research Regulation published by the Republic of Türkiye Ministry of Health. In parallel with international regulations, Abdi İbrahim obtains Ethics Committee and Authority approvals, prerequisites for global recognition, before commencing clinical trials. In 2021 and 2022, the Company conducted retrospective and observational clinical trials, which were divided into four stages based on the type of trial. The results of these studies were presented on national and international scientific platforms and were also published as articles in medical journals. In 2021 and 2022, the Company continued to design and submit applications for clinical trials for new drug combinations, new indications and international licensing, while also granting partial support to physician requests for investigator-initiated clinical trials.

PRODUCT SAFETY

PHARMACOVIGILANCE

Product safety is one of the essential principles of Abdi İbrahim, whose pharmacovigilance system was successfully audited by the Turkish Ministry of Health, the Ministry of Health of Kazakhstan and two foreign auditors in 2021-2022.

Abdi İbrahim records all safety information for products in its portfolio and continually evaluates the risks and benefits of the products it is responsible for, while also providing this information to the relevant authorities. The Company's Pharmacovigilance Department, which can be reached 24/7, operates in accordance with the "Regulation on the Safety of Medicines" published by the Turkish Ministry of Health and its current guidelines. On an international scale, Abdi İbrahim puts considerable effort into complying with pharmacovigilance laws and regulations in the respective countries.

Abdi İbrahim considers monitoring and reporting adverse effects of its products in line with patient privacy principles as an ethical responsibility and prepares periodic benefit/risk assessment reports and other safety reports, which are then submitted to the Turkish Ministry of Health. Within the framework of the principle of continuous improvement, the Company shapes its in-house training activities, providing comprehensive training in the field of product safety to both its employees and third-party company personnel.

PUBLIC AUTHORITY AND COMPANY AUDITS

Abdi İbrahim's pharmacovigilance system is subject to audits by the Turkish Ministry of Health and operates in accordance with the relevant regulations based on the principles of Good Pharmacovigilance Practices. As stipulated in the company procedures, the system undergoes regular internal audits, and in 2021-2022, it was successfully audited by the Turkish Ministry of Health's institution TİTCK, the Ministry of Health of Kazakhstan and two foreign companies. These audits have significantly contributed to the improvement of the system. The audit conducted by the Ministry of Health of Kazakhstan in 2021 is particularly important as it was the first audit conducted by a foreign Health Authority on Abdi İbrahim's Pharmacovigilance Department.

Firm audits conducted by Abdi İbrahim: Abdi İbrahim also collaborates with service providers for pharmacovigilance activities in the EU and the UK, with the Abdi İbrahim Pharmacovigilance Department providing oversight and control. To ensure qualification in this process, the service provider was audited in 2022, and the qualification process was completed.

Pharmacovigilance System in Germany: In 2021, Abdi İbrahim started establishing a pharmacovigilance system for Abdi Farma GmbH, its overseas subsidiary in Germany, that meets local requirements. The system became operational in 2022. The pharmacovigilance system established in Germany is monitored and controlled by the Abdi İbrahim Pharmacovigilance Department.

Pharmacovigilance System in Azerbaijan: With the publication of new pharmacovigilance guidelines in Azerbaijan, pharmacovigilance activities became mandatory. Accordingly, a pharmacovigilance officer and deputy were appointed in Azerbaijan by the Abdi İbrahim Pharmacovigilance Department, and collaboration began with a third-party company that meets the system requirements. The pharmacovigilance system established in Azerbaijan is monitored and controlled by the Abdi İbrahim Pharmacovigilance Department.

Number of cases violating the Pharmaceutical Marketing Legislation: **0**

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

LICENSING AND MARKET ACCESS

Abdi İbrahim conducts all its business processes within the framework of the legislation in force in Türkiye, while closely following the regulations and guides published by international health institutions. The Licensing Department is responsible for preparing the licensing files of medicinal products for human use containing chemical and biological active substances,

Managing the registration processes, as well as preparing the application file for products in the herbal medicinal products, homeopathic medicinal product, cosmetics, medical devices and dietary supplement categories, obtaining approvals and supporting the procedures of placing the products on the market.

Revisions in the regulations in force in Türkiye and adhered to by Abdi İbrahim were updated by the Turkish Ministry of Health's TİTCK in 2021 and 2022. The World Health Organization's visits to the TİTCK and relevant activities contributed to the transparency of working principles by publishing new regulations and guidelines. Abdi İbrahim conducts follow-ups and internal briefings to ensure that these regulatory changes are fully implemented within its organization.

The Market Access Department is responsible for tracking the reference prices of existing products and making all necessary updates, monitoring the price and reimbursement activities of competitor products and providing necessary guidance, and determining the prices and discount rates that can be used in the selection of new projects.

In 2021;
- Price increases were applied to 86 products.
- 23 products were included in reimbursement plan.
- Distribution permits were obtained, and SSI processes were completed for 19 products.
- 20 products were added to the e-prescription list.
- 4 products that underwent name/ownership changes were included in the SSI list.

In 2022;
- Price increases were applied to 92 products.
- 13 products were included in reimbursement plan.
- Distribution permits were obtained, and SSI processes were completed for 19 products.
- 12 products were added to the e-prescription list.
- 16 products that underwent name/ownership changes were included in the SSI list.

In 2021-2022;
- Applications for the registration of 44 brand names were made in 8 countries.
- In Türkiye, 59 brand name registration applications were submitted, and 53 brand names were registered.
- In Türkiye, 66 human medicinal product licenses were obtained, including 6 transfer licenses, 11 dietary supplements and 1 medical device; 201 licenses were obtained in 29 countries on international markets.
- Exceptional licenses for a product used in COVID-19 treatment were obtained, and the product was delivered to patients through the authorized units of the Turkish Ministry of Health during the pandemic.
- In Algeria, local production approvals were obtained for 9 products in 2019 and 14 products in 2020.
- In Kazakhstan and Bosnia-Herzegovina, the first cosmetic product approvals were obtained with Hametol.
- License applications were submitted on behalf of Abdi Farma in various European countries for two products developed by Abdi İbrahim, and the product launches were planned following approval.
- Manufacturing licenses for 2 imported products were obtained as part of the strategic localization project in Türkiye.
- As part of the GMP (Good Manufacturing Practices) inspection requirement introduced by the Ministry of Health in 2009 for import license applications, document inspections were conducted in three production facilities abroad in lieu of on-site inspections due to COVID-19 restrictions. GMP renewal applications were made for 13 facilities and 15 products.
- After the acquisition of Inoliva İlaç ve Gıda San. Tic. A.Ş., a company operating in the field of consumer health in Türkiye, Abdi İbrahim submitted 27 update applications and successfully completed implementation processes for these products in 2022.

COMBATTING COUNTERFEIT, ILLEGAL, OR DIVERTED MEDICINES

Abdi İbrahim, in line with its quality policy, takes responsibility for combating counterfeit, illegal or diverted medicines that could threaten patient health, alongside its continuous dedication to ensuring full compliance with laws and regulations in its pharmaceutical production, promotion and sales activities. Abdi İbrahim's preventive and control activities in this context are specified in the procedure for Combating Counterfeit, Smuggled and Illegal Pharmaceuticals.

ÇİĞDEM AKYÜREK
LICENSING AND MARKET ACCESS DIRECTOR, ABDİ İBRAHİM



As Abdi İbrahim moves towards its ambitious goals in line with the VISION 2025 strategy with a bold, responsible and passionate approach, we, as the Licensing and Market Access Directorate, work with dedication, dynamism and enthusiasm to contribute to these goals. Our primary responsibilities include planning and monitoring every project process from the R&D stage, determining licensing and prioritization strategies, improving communication with internal stakeholders according to the strategies, ensuring the timely release of products in line with company objectives, keeping track of regulatory changes both in Türkiye and abroad and maintaining communication with health authorities. In fact, we can summarize our entire operation as the sum of processes that ensure the delivery of a product to all patients at the optimal price, quickly and in a sustainable manner.

You can access Abdi İbrahim's Counterfeit, Illegal, or Diverted Medicines Control Policy from here.

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

ANNEX 1: MEMBERSHIPS AND SUPPORTED INITIATIVES

Foreign Economic Relations Board	Union of Chambers and Commodity Exchanges of Türkiye	GS1 Organization for the Global Language of Business	Pharmaceutical Industry Employers Association	Istanbul Exporters' Associations General Secretariat	Türkiye Exporters Assembly	Istanbul Chemicals and Chemical Products Exporters Association	Istanbul Minerals and Metals Exporters' Association
Istanbul Chamber of Industry	Istanbul Commodity Exchange	Istanbul Chamber of Commerce	People Management Association of Türkiye	Turkish Industry and Business Association	Türkiye Training and Development Platform	Corporate Governance Association of Türkiye	Public Communication and Corporate Relations Management Association
ISPE, The International Society for Pharmaceutical Engineering	Environmental Protection and Packaging Waste Recovery & Recycling Foundation	Corporate Communicators Association	All Food Foreign Trade Association	Cosmetics and Cleaning Products Manufacturers Association	Marmara Medical Device Manufacturers and Suppliers Association	Swiss Chamber of Commerce	German-Turkish Chamber of Commerce and Industry
Italian Chamber of Commerce and Industry in Türkiye	The Institute for Internal Auditing Türkiye	UN Global Compact (UNGC)	UNGC CEO Water Mandate	Global Reporting Initiative (GRI)	Women's Empowerment Principles (WEPs)	Business Council for Sustainable Development Türkiye	Business Plastic Initiative
Carbon Disclosure Project (CDP)	Science Based Targets Initiative (SBTi)	Recover Better	We Mean Business Platform	WWF Green Office Program	Türkiye Circular Economy Platform	Impact2030	

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

ANNEX 2: ENVIRONMENTAL PERFORMANCE INDICATORS

Data covers Abdi İbrahim's Esenyurt Production Complex in Türkiye.

Environmental protection expenditures			
Expenditure amount (TRY)	**2020**	**2021**	**2022**
Waste collection, transportation, and disposal	329,401	495,108	1,812,481
Wastewater analyses	39,150	17,500	5,171
Domestic and industrial wastewater treatment plant	73,375	1,493,650	261,500
Activities related to environmental permits, e.g., discharge, emission, EIA	-	-	415,550
Emission measurements	33,920	89,756	45,496
Environmental cleaning tax payments were TRY 257,400 in 2021 and TRY 411,888 in 2022.			

Preventive measures and environmental management investments			
Expenditure amount (TRY)	**2020**	**2021**	**2022**
ISO 14001 Environmental Management System and ISO 45001 Occupational Health and Safety Certifications audits	57,675	30,803	50,538

Packaging materials and raw materials used in production			
(tonnes)	**2020**	**2021**	**2022**
Plastic	344	676	1,111
Cardboard box	2,046	2,606	3,015
Metal	424	414	556
Glass	802	858	1,801
Raw material	5,394	5,592	9,943

Wastewater analyses (tonnes/year)			
	2020	**2021**	**2022**
BOI5 discharge	2	3	3
KOI discharge	17	24	31
The plant's performance is monitored daily through a laboratory established within the wastewater treatment facility. Indicates certain parameters analysed at the plant's inlet and outlet.			

Water consumption			
Water intake (ML)	**2020**	**2021**	**2022**
Surface water	-	-	-
Groundwater	126	129	103
Sea water	-	-	-
Water obtained from third-party suppliers	92	130	173
Total water intake	218	259	276
Discharged water (ML)	101	120	157
Water consumption (ML)	117	139	119

Amount of waste and recycling			
	2020	**2021**	**2022**
Hazardous waste (tonnes)			
Incineration (with energy recovery)	-	229.0	443.3
Incineration (without energy recovery)	559.5	135.4	271.7
Storage	0.2	0.3	-
Recycling	-	114.4	-
Other disposal methods	7.5	3.9	-
Total hazardous waste	567.2	482.9	715.0
Non-hazardous waste (tonnes)			
Incineration (with energy recovery)	-	-	-
Incineration (without energy recovery)	-	-	-
Storage	339.4	477.9	474.6
Other disposal methods	-	-	-
Recycling	956.1	1,067.9	1,255.1
Total non-hazardous waste	1,295.6	1,545.7	1,729.7
Total waste (tonnes)	**1,862.8**	**2,028.7**	**2,444.7**

Energy consumption by energy source			
	2020	**2021**	**2022**
Natural gas (GJ)	162,692	189,424	212,349
Diesel (GJ)	1,709	1,379	1,612
Renewable energy (GJ)	159,155	178,604	200,721
Non-renewable energy (GJ)	-	-	18,380
Company vehicles - Gasoline (liters)	-	-	18,690
Company vehicles - Diesel (liters)	-	-	213,203
The data for 2020 and 2021 only includes operations in Türkiye, while the data for 2022 includes Türkiye, Kazakhstan, Algeria, and Switzerland operations.			

Production quantity			
	2020	**2021**	**2022**
Actual production quantity (units)	283,195,104	326,767,639	391,232,473

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

ANNEX 3: SOCIAL PERFORMANCE INDICATORS

Data covers Abdi İbrahim's operations in Türkiye.

Employees			
	2020	2021	2022
Türkiye	3,918	3,930	4,734
Overseas	534	668	649
Total	**4,452**	**4,598**	**5,383**

Education
79% of Abdi İbrahim employees hold a bachelor's degree or higher.

	2020	2021	2022
Master's and above	350	354	426
Bachelor's and associate degree	2,695	2,719	3,300
Primary and high school	873	857	1,008

Age Group			
	2020	2021	2022
30 and under	1,154	1,159	1,369
30-50	2,624	2,638	3,128
50 and above	140	133	237

Gender			
	2020	2021	2022
Female	1,193	1,274	1,590
Male	2,725	2,656	3,144

Abdi İbrahim Tower (Head Office)			
	2020	2021	2022
Female	192	294	328
Male	156	221	251

Field			
	2020	2021	2022
Female	578	550	714
Male	1,644	1,492	1,710

Countries			
	2020	2021	2022
Female	257	324	309
Male	277	344	340

R&D Center			
	2020	2021	2022
Female	79	86	97
Male	48	53	72

Technical Head Office (Factory)			
	2020	2021	2022
Female	358	344	451
Male	863	890	1,111

	2020	2021	2022
Marital Status			
Single	1,306	1,319	1,762
Married	2,612	2,611	2,965
Maternity Leave			
On maternity leave	54	67	64
Returning from maternity leave	45	68	64
Breakdown by Working Area			
White-collar	3,115	3,065	3,630
Blue-collar	803	865	1,104
Employee Breakdown			
Head Office	245	266	316
Marketing	230	249	263
Medical Sales Representative	2,017	1,842	2,238
Regional Manager	205	200	186
Factory	1,094	1,234	1,562
R&D	127	139	169
Performance Management			
Employees included in the performance system* (Including overseas)	4,452	4,598	4,911

*The performance and career development of all employees are regularly monitored.

Gender Distribution In Senior Management

2021	Factory		Head Office		Field		Total	
	Male	Female	Male	Female	Male	Female	Male	Female
Assistant Director and above	5	3	24	10	-	-	29	13
Manager	13	8	40	37	176	24	229	69
Executive	39	42	66	115	-	-	105	157
Total	57	53	130	162	176	24	363	239

2022	Factory		Head Office		Field		Total	
	Male	Female	Male	Female	Male	Female	Male	Female
Assistant Director and above	5	2	49	14			54	16
Manager	16	12	56	30	160	26	232	68
Executive	45	50	64	125			109	175
Total	66	64	169	169	160	26	395	259

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

ANNEX 4: OHS TRAINING

Trainings in 2021

Abdi İbrahim Tower Head Office and Field

Training topic	Training reason	Training duration (minutes)	Groups	Total training duration (minutes)
OHS orientation training	Orientation	480	7	3.360
General OHS topics and legal regulations	Periodic	60	0	0
Technical topics	Periodic	150	0	0
General health topics	Periodic	240	0	0
Emergency situations and evacuation rules	Periodic	30	7	210
First aid training	Periodic	480	1	480
Third-party company trainings	Orientation	60	20	1,200

Esenyurt Production Complex

Training topic	Training reason	Training duration (minutes)	Groups	Total training duration (minutes)
General OHS rules	Periodic	60	59	3,540
Safety in technical and production operations	Periodic	120	51	6,120
Laboratory safety	Periodic	120	4	480
Warehouse safety	Periodic	120	4	480
Electrical safety	Periodic	30	59	1,770
Emergency information	Periodic	30	59	1,770
General health practices	Periodic	120	59	7,080
OHS orientation training	Orientation	240	40	9,600
Third-party company trainings	Orientation	60	12	720

Trainings in 2022

Abdi İbrahim Tower Head Office and Field

Training topic	Training reason	Training duration (minutes)	Groups	Total training duration (minutes)
OHS orientation training	Orientation	480	12	5,760
General OHS topics and legal regulations	Periodic	60	16	960
Technical topics	Periodic	150	16	2,400
General health topics	Periodic	240	16	3,840
Emergency situations and evacuation rules	Periodic	30	16	480
First aid training	Periodic	480	2	960
First aid training	Renewal	960	2	1,920
Third-party company trainings	Orientation	60	20	1,200

Esenyurt Production Complex

Training topic	Training reason	Training duration (minutes)	Groups	Total training duration (minutes)
Occupational Safety Training	Periodic	240	99	23,760
Occupational Health Training	Periodic	120	99	11,880
Environmental Management System Training	Periodic	120	99	11,880
EHS Orientation Training	Orientation	480	40	19,200
Third-Party Company EHS Orientation Training	Orientation	480	8	3,840

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

ANNEX 5: COMPANY POLICIES

Quality Policy

Abdi İbrahim fully complies with local and international quality standards, cGMP requirements and all relevant legal obligations in its pharmaceutical production and all other activities, offering services that are always safe for human health by ensuring product quality. The Company works with determination, responsibility and passion to continuously remain customer-focused in its services, developing risk-based approaches and trainings to ensure that its quality system is sustainable and adopted by its entire workforce.

Environmental Policy

Abdi İbrahim has made the protection of the environment, continuous improvement, effective use of natural resources, full compliance with the law, prevention of pollution, reduction and separation of waste at the source and recycling and disposal of waste with the best methods available, the basis of its environmental policy. Abdi İbrahim holds all necessary legal permits, as well as the ISO 14001 Environmental Management System certification.

Human Resources Policy

Abdi İbrahim designs processes for its employees to reveal their potential, creating opportunities and an environment conducive to their continuous development. The priorities of the Company's human resources strategy, which adopts the principles of reliability and transparency, are as follows:

- Fostering an environment and atmosphere of passionate dedication to work
- Excelling in talent management and succession planning
- Cultivating a performance-oriented culture tied to strategic priorities
- Developing the technical competencies and leadership skills essential to the strategy
- Establishing the systems and sustainable processes requisite to the HR infrastructure

Occupational Health and Safety Policy

For Abdi İbrahim, ensuring full compliance with the applicable law, international regulations and customer requirements, continuous improvement and establishing a safe working environment in collaboration with employee representatives are at the core of its Occupational Health and Safety Policy. Within this framework, the Company is committed to:

- Eliminating the hazards associated with its activities, and mitigating health and safety risks by identifying and implementing accurate preventative parameters,
- Organizing training activities to ensure that its employees, third-party contractors and relevant stakeholders effectively fulfil their occupational health and safety obligations,
- Setting and working towards quantifiable targets for continuous development.

Abdi İbrahim holds all necessary legal permits, as well as the ISO45001 Occupational Health and Safety Management System certification.

Information Security Policy

Abdi İbrahim knows that effectively protecting information in a timely, accurate and appropriate manner is what allows the Company to maintain its reputation and the continuity of its services. The main responsibilities of the Company with regards to the protection of information assets are as follows:

- Defining the information assets of the organization
- Protecting the information of employees and all stakeholders
- Ensuring the confidentiality, integrity and accessibility of information assets
- Using information assets only for the purposes determined by the management
- Upholding the organization's security policies and rules
- Keeping information security standards and processes up to date
- Ensuring information security awareness among employees through trainings
- Regularly reviewing the internal and external risks related to information security and taking necessary measures by conducting risk analyses

Business Continuity Policy

Abdi İbrahim aims to ensure business continuity by identifying possible risks that may cause business interruptions and taking precautions against these risks. In this context, the Company is committed to:

- Developing a Business Continuity Management System (BCMS), designing necessary operational processes and keeping them up to date,
- Ensuring the continuity of activities at predefined acceptable levels in the event of an incident or a significant business interruption,
- Centrally coordinating crisis and emergency management activities,
- Improve business continuity plans through regular training, awareness-raising activities and practices/drills.

Counterfeit, Illegal, or Diverted Medicines Control Policy

Abdi İbrahim, in line with its quality policy, takes responsibility for combating counterfeit, illegal or diverted medicines that could threaten patient health, alongside its continuous dedication to ensuring full compliance with laws and regulations in its pharmaceutical production, promotion and sales activities. Abdi İbrahim's preventive and control activities in this context are specified in the procedure for Combating Counterfeit, Smuggled and Illegal Pharmaceuticals. Based on this policy, the Company is committed to:

- Collaborating with national and international authorities in the efforts against the aforementioned medicines
- Recording and investigating all reports and complaints related to these medicines and relaying these to national/international authorities
- Taking measures to prevent counterfeiting in the production processes to ensure easy identification of counterfeit products
- Conducting regular investigations to detect such products
- Informing and advising relevant business partners, particularly pharmacy warehouses that the Company works with
- Informing all employees and stakeholders about the issue

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

ANNEX 6: AUDITS

In 2021, Abdi İbrahim successfully passed 3 audits by public authorities (Ukraine MoH, Turkish MoH, and EAEU), 3 certification audits (ISO 13485 and ISO 9001), and 13 customer audits. In 2022, the Company successfully passed 6 audits from public authorities (Turkish MoH, Yemen Authority, and EUGMP), 3 certification audits (ISO 13485 and ISO 9001) and 22 customer audits.

2021

- Maxpharma
- Ukraine MoH
- ISO 13485
- Ministry of Health (Sterile)
- Sun Pharma
- ISO 9001 (Documentation)
- Acino-Takeda
- GSK Pharma + GSK Consumer
- ISO 9001 (General)
- MSD
- Allergan
- Stada
- Welding
- Menarini
- Pfizer
- EAEU audit
  (Kazakhstan, Armenia, Kyrgyzstan, Russia, Belarus)
- Novartis
- Servier
- Acino

2022

- Ministry of Health Audit (General)
- ISO 13485+CE (Dermalix)
- GSK Mock Up Audit
- Onko Koçsel
- Eczacıbaşı
- Helm
- GE Pharma
- Daichi
- GSK Mock Up Audit
- GSK Nebule
- Ministry of Health Audit (Abdi Bio)
- ISO 9001
- GSK GEMBA
- Intertek (on behalf of BAUSCH HEALTH)
- Boehringer Ingelheim
- Welding
- Yemen Authority
- Leo Pharma
- HRA Pharma (Zigzag Associates)
- EU GMP
- Ministry of Health Audit (Annex Phase 1)
- Vifor Pharma (Abdi & Abdi Bio)
- Ministry of Health Additional Activity Audit
- Certipharm (on behalf of Evolupharm)
- GSK GEMBA
- Janssen
- Zentiva
- Astra Zeneca
- ISO 9001 (Second Follow-Up Audit)
- GSK GEMBA (Data Integrity)
- Pfizer Visit

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

GRI CONTENT INDEX

GRI Standards	Disclosure	Page, resource and/or explanation
GRI 1: Universal 2021	Abdi İbrahim has reported the period of 1 January 2021 - 31 December 2022 according to GRI Standards.	
GRI 2: General Disclosures 2021	2-1 Organizational details	11-14
	2-2 Entities included in the organization's sustainability reporting	5
	2-3 Reporting period, frequency and contact point	Two years, surdurulebilirlik@abdiibrahim.com.tr
	2-4 Restatements of information	There is no restated statement regarding the previous period report.
	2-5 External assurance	There is limited external assurance.
	2-6 Activities, value chain and other business relationships	11-14, 20, 83
	2-7 Employees	47-50
	2-8 Workers who are not employees	47-50
	2-9 Governance structure and composition	68, 71
	2-10 Nomination and selection of the highest governance body	68-71
	2-11 Chair of the highest governance body	68
	2-12 Role of the highest governance body in overseeing the management of impacts	68-71
	2-13 Delegation of responsibility for managing impacts	21, 68
	2-14 Role of the highest governance body in sustainability reporting	21
	2-15 Conflicts of interest	72
	2-16 Communication of critical concerns	21, 68-72
	2-19 Remuneration policies	47-50
	2-22 Statement on sustainable development strategy	18-19
	2-23 Policy commitments	18-19, 26-27
	2-24 Embedding policy commitments	18-19, 26-27
	2-25 Processes to remediate negative impacts	37
	2-26 Mechanisms for seeking advice and raising concerns	72
	2-27 Compliance with laws and regulations	72
	2-28 Membership associations	89
	2-29 Approach to stakeholder engagement	24
	2-30 Collective bargaining agreements	48

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

GRI CONTENT INDEX

GRI Standards	Disclosure	Page, resource and/or explanation
GRI 3: Material Topics		
GRI 3: Material Topics 2021	3-1 Process to determine material topics	23
	3-2 List of material topics	23
	3-3 Management of material topics	23-24
GRI 201: Economic Performance 2016	201-1 Direct economic value generated and distributed	74
GRI 204: Procurement Practices 2016	204-1 Proportion of spending on local suppliers	83
GRI 205: Anti-corruption 2016	205-1 Operations assessed for risks related to corruption	72
	205-2 Communication and training about anti-corruption policies and procedures	72
	205-3 Confirmed incidents of corruption and actions taken	72
GRI 206: Anti-competitive Behavior 2016	206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices	72
GRI 301: Materials 2016	301-1 Materials used by weight or volume	90
	301-2 Recycled input materials used	90
	301-3 Reclaimed products and their packaging materials	90
GRI 302: Energy 2016	302-1 Energy consumption within the organization	90
	302-2 Energy consumption outside of the organization	90
	302-3 Energy intensity	90
	302-4 Reduction of energy consumption	40-41, 90
	302-5 Reductions in energy requirements of products and services	No data is reported on energy consumption of sold products.
GRI 303: Water and Effluents 2018	303-1 Interactions with water as a shared resource	38
	303-2 Management of water discharge-related impacts	38
	303-3 Water withdrawal	90
	303-4 Water discharge	90
	303-5 Water consumption	90
GRI 304: Biodiversity 2016	304-1 Operational sites owned, leased, managed in, or adjacent to, protected areas and areas of high biodiversity value outside protected areas	Abdi İbrahim does not have operations in high biodiversity areas.
	304-2 Significant impacts of activities, products and services on biodiversity	
	304-3 Habitats protected or restored	
	304-4 IUCN Red List species and national conservation list species with habitats in areas affected by operations	Abdi İbrahim has no activities in the habitats included in the IUCN Red List.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

GRI CONTENT INDEX

GRI Standards	Disclosure	Page, resource and/or explanation
GRI 305: Emissions 2016	305-1 Direct (Scope 1) GHG emissions	35-36
	305-2 Energy indirect (Scope 2) GHG emissions	35-36
	305-3 Other indirect (Scope 3) GHG emissions	35-36
	305-4 GHG emissions intensity	35-36
	305-5 Reduction of GHG emissions	35-37
GRI 306: Waste 2020	306-1 Waste generation and significant waste-related impacts	39-43
	306-2 Management of significant waste-related impacts	39-43
	306-3 Waste generated	39-43
	306-4 Waste diverted from disposal	39-43, 90
	306-5 Waste directed to disposal	39-43, 90
GRI 308: Supplier Environmental Assessment 2016	308-1 New suppliers that were screened using environmental criteria	21, 25, 26, 83
	308-2 Negative environmental impacts in the supply chain and actions taken	21, 25, 26, 83
GRI 401: Employment 2016	401-1 New employee hires and employee turnover	50, 91
	401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees	48-49
	401-3 Parental leave	91
GRI 402: Labor/Management Relations 2016	402-1 Minimum notice periods regarding operational changes	Minimum notice periods due to operational changes are in full compliance with laws and regulations.
GRI 403: Occupational Health and Safety 2018	403-1 Occupational health and safety management system	51-52
	403-2 Hazard identification, risk assessment, and incident investigation	During the reporting period, there have been no work-related accidents that have caused death or serious injury.
	403-3 Occupational health services	Abdi İbrahim does not have any work procedures that could ex-pose its employees to high-risk diseases.
	403-4 Worker participation, consultation, and communication on occupational health and safety	51-52
	403-5 Worker training on occupational health and safety	92
	403-6 Promotion of worker health	51-52
	403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	51-52
	403-8 Workers covered by an occupational health and safety management system	51-52
	403-9 Work-related injuries	52
	403-10 Work-related ill health	52
GRI 404: Training and Education 2016	404-1 Average hours of training per year per employee	49
	404-2 Programs for upgrading employee skills and transition assistance programs	49-50
	404-3 Percentage of employees receiving regular performance and career development reviews	91

MESSAGE FROM THE CHAIRMAN
CEO'S MESSAGE
THE HEALING FORCE IN A CHANGING WORLD
FOCUSING ON CREATING LONG-TERM VALUE
HEALING THE FUTURE OF ECOSYSTEM
HEALING THE FUTURE OF PEOPLE
HEALING THE FUTURE OF BUSINESS

GRI CONTENT INDEX

GRI Standards	Disclosure	Page, resource and/or explanation
GRI 405: Diversity and Equal Opportunity 2016	405-1 Diversity of governance bodies and employees	48, 91
GRI 406: Non-discrimination 2016	406-1 Incidents of discrimination and corrective actions taken	There were no cases of discrimination in the reporting period.
GRI 408: Child Labor 2016	408-1 Operations and suppliers at significant risk for incidents of child labor	There were no child labor in the reporting period.
GRI 409: Forced or Compulsory Labor 2016	409-1 Operations and suppliers at significant risk for incidents of forced or compulsory labor	There were no forced or compulsary labor in the reporting period.
GRI 411: Rights of Indigenous Peoples 2016	411-1 Incidents of violations involving rights of indigenous peoples	There were no incidents of violations involving rights of indigenous peoples in the reporting year.
GRI 413: Local Communities 2016	413-1 Operations with local community engagement, impact assessments, and development programs	53-64
	413-2 Operations with significant actual and potential negative impacts on local communities	There were no operations with significant actual and potential negative impacts on local communities in the reporting year.
GRI 414: Supplier Social Assessment 2016	414-1 New suppliers that were screened using social criteria	21, 25, 26, 83
	414-2 Negative social impacts in the supply chain and actions taken	21, 25, 26, 83
GRI 416: Customer Health and Safety 2016	416-1 Assessment of the health and safety impacts of product and service categories	85-88
	416-2 Incidents of non-compliance concerning the health and safety impacts of products and services	There were no incidents of non-compliance concerning the health and safety impacts of products and servicesin the reporting period.
GRI 417: Marketing and Labeling 2016	417-1 Requirements for product and service information and labeling	85-88
	417-2 Incidents of non-compliance concerning product and service information and labeling	There were no incidents of non-compliance concerning product and service information and labeling in the reporting period.
	417-3 Incidents of non-compliance concerning marketing communications	There were no incidents of non-compliance concerning marketing communications in the reporting period.
GRI 418: Customer Privacy 2016	418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data	There were no substantiated complaints concerning breaches of customer privacy and losses of customer data in the reporting period.

MESSAGE FROM THE CHAIRMAN

CEO'S MESSAGE

THE HEALING FORCE IN A CHANGING WORLD

FOCUSING ON CREATING LONG-TERM VALUE

HEALING THE FUTURE OF ECOSYSTEM

HEALING THE FUTURE OF PEOPLE

HEALING THE FUTURE OF BUSINESS

ABDİİBRAHİM

Abdi İbrahim Tower
Address: Reşitpaşa Mahallesi
Eski Büyükdere Caddesi, No: 4
Maslak-Sarıyer 34467 İstanbul, Türkiye
Phone: 0212 366 84 00
Fax: 0212 276 20 20

Abdi İbrahim Esenyurt Production Complex
Address: Orhan Gazi Mahallesi
Tunç Caddesi, No: 3
Esenyurt 34555 İstanbul, Türkiye
Phone: 0212 622 66 00
Fax: 0212 623 19 52

info@abdiibrahim.com.tr
www.abdiibrahim.com.tr
facebook.com/abdiibrahimilac
twitter.com/abdiibrahimilac
youtube.com/abdiibrahimilac
instagram/abdiibrahimilac
tr.linkedin.com/company/abdi-ibrahim-pharmaceuticals
www.threads.net/@abdiibrahimilac

For more detailed information about the Abdi İbrahim Sustainability Report, as well as your comments and suggestions, please contact:

Sustainability Committee
surdurulebilirlik@abdiibrahim.com.tr

Dr. M. Oğuzcan Bülbül
Corporate Relations, Sustainability and Communications Director
oguzcan.bulbul@abdiibrahim.com.tr

Megi Erpardo
Sustainability Manager
megi.erpardo@abdiibrahim.com.tr

Buket Koral
Corporate Communications Manager
buket.koral@abdiibrahim.com.tr

Disclaimer
The 6th Sustainability Report (Report) of Abdi İbrahim has been prepared in accordance with the Global Reporting Initiative (GRI) Reporting Principles, the Women's Empowerment Principles (WEPs) and UNGC CEO Water Mandate Progress Communications. This report has been prepared with the sole purpose of informing Abdi İbrahim İlaç San. ve Tic. A.Ş. Stakeholders, and the content and information contained within have been created based on resources and information that were considered accurate and reliable at the time of writing. The information and content contained in the Report cannot be interpreted as any declaration, warranty and/or commitment, and it is not guaranteed that the information and content are complete and unchangeable. All rights of the report belong to Abdi İbrahim İlaç San. ve Tic. A.Ş.

Content and Design
Editoryal
editoryal@editoryal.com.tr
www.editoryal.com.tr